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Abstract
Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, is a
devastating fatal neurodegenerative condition. Mutations in CCNF, the gene
encoding the E3 ubiquitin ligase cyclin F, have been recently identified to cause
ALS.

To examine the effects of the CCNFS621G mutation, three new induced

pluripotent stem cell (iPSC) lines from two siblings with the same CCNFS621G
mutation, and a healthy control, were generated through the employment of mRNA
reprogramming. Characterisation of these stem cells indicated expression of
pluripotency

factors

NANOG,

and

Oct4

(encoded

by

POU5F1)

using

immunocytochemistry and/or qRT-PCR. Karyotyping of the reprogrammed stem
cells revealed no chromosomal abnormalities, and comparison to other established
stem cell lines via bioinformatics assay (the PluriTest) indicated cells with typical
iPSC characteristics. The stem cells used in this study were all capable of
differentiating to cell types from each of the three germ layers, as characterised by
morphology and marker expression. Using these stem cell lines, as well as three
established iPSC lines, a robust motor neuron differentiation protocol was generated
to produce a high yield of patient derived motor neurons to model ALS ‘in a dish’.
These differentiated neuronal cultures had high expression of motor neuron markers,
which were on average 88±1.4% Islet 1 positive, 90.5±1.4% neurofilament heavy
(SMI32) positive, and 83.87 ± 2.48% HB9 positive. Using these motor neuron
models, it was possible to detect and quantify endogenous ALS relevant proteins
including cyclin F, and the hallmark protein TAR DNA-Binding Protein-43 (TDP43). These proteins both localised in the nucleus, in aggregate structures consistent
3

with nuclear bodies. Quantification of both these proteins indicated a relative
decrease in abundance in ALS patient derived motor neurons compared to those
derived from healthy donors. An additional TDP-43 species was also detected in the
motor neurons differentiated from CCNFS621G patient iPSCs. These findings,
combined with an increased retention of proteins tagged for degradations in the ALS
patient derived motor neurons as determined by an UPS function assay, are
consistent with a dysfunction in the UPS in CCNFS621G cells. In further support of
this proposed disease mechanism, proteomic analysis of ubiquitinated proteins
revealed an increase in the proteins uniquely ubiquitinated in fibroblasts, iPSCs and
motor neurons derived from a symptomatic CCNFS621G patient. Together, these data
are in agreement with the proposition that cyclin F substrate recognition is altered by
the S621G mutation.

Ubiquitinomics analysis of motor neurons suggests that

disruption to the normal activity of cyclin F likley causes downstream dysfunction to
a number of downstream pathways including mitochondrial processes, the
spliceosome, autophagy, heat shock, vesicles, extracellular matrix, and the UPS
itself. Comparison of the motor neuron ubiquitome to iPSCs and fibroblasts from
which the neurons derive, serves to highlight the central nature of the UPS in
regulating cellular processes such as the extracellular matrix and RNA processing.
Examing the different cell types in this study, it is clear that ubiquitin also regulates
cell type specific processes such as the cell cycle in iPSCs, and axogenesis in motor
neurons reiterating the dynamic nature of the UPS. Together, the findings of these
studies strongly implicate the UPS as a strong candidate for therapeutic target in
ALS.
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Ubiquitin Proteasome System
Dysfunction in Amyotrophic
Lateral Sclerosis
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1. UBIQUITIN PROTEASOME SYSTEM DYSFUNCTION IN
AMYOTROPHIC LATERAL SCLEROSIS

1.1Amyotrophic lateral sclerosis is a severe neurodegenerative
disease
Amyotrophic lateral sclerosis (ALS) is the most common of the devastating motor
neurone diseases. ALS is characterised by the death of upper and lower motor
neurons, which leads to an eventual loss of control over muscles responsible for
voluntary movements, causing the muscles to harden and/or atrophy (Turner and
Talbot, 2013). Clinical presentation of ALS occurs in one of two manners; 75% of
patients will first experience loss of motor control in their hands or feet, and muscle
weakening advances through their arms or legs – referred to as limb onset. One
quarter of patients experience bulbar onset, wherein speech and swallowing difficulty
are the first symptoms experienced, caused by muscle weakness in the tongue,
pharynx, and larynx.

In both circumstances motor neuron death and subsequent

muscle paresis spreads sequentially throughout the body; people living with ALS are
rendered unable to utilise their hands, walk, speak, and will eventually experience
difficulty breathing (Vucic et al., 2007). In most cases of ALS, cause of death is
usually the result of this respiratory failure, which can lead to broncho pneumonia
(Corcia et al., 2008). On average ALS is fatal within 27 months from the first
clinical symptom presentation. There are 1,900 Australians currently suffering from
ALS, though due to the speed of progression of the disease, the lifetime risk of
having ALS has been estimated as high as 1:400 in Europeans (Shaw, 2010).
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Currently no truly effective therapeutics are available (Parker et al., 2019). The first
FDA approved therapeutic, Riluzole, will only extend patient life span by two to
three months (Miller et al., 1996). Edaravone, which was more recently approved for
use, has been reported to cause a 33% reduced decline in patient physical ability
(Abe et al., 2017; Parker et al., 2019; Rothstein, 2017). Accordingly, therapeutic
development for ALS patients is greatly needed.

A confounding factor in drug development for ALS is the variability of rate of
progression and severity of symptom onset. The average age for diagnosis of ALS is
55 years old, however patients with juvenile forms of ALS have been reported as
young as eight years old. Patients have been known to rapidly decline, dying within
months of diagnosis or conversely, living over 20 years with ALS (Cleveland and
Rothstein, 2001). The affected biochemical pathways known to cause familial ALS
dictate neither the speed of disease progression, nor age of onset. For example, a
mutation in the vesicle trafficking protein gene VABP has been documented to elicit
disease onset in patients of the same family with the same mutation at a range of ages
between 25 and 44 years old (Nishimura et al., 2004). This variability strongly
suggests that a combination of genetic and environmental factors play a role in
pathogenesis (Robberecht and Philips, 2013). Approximately 90-95% of ALS cases
are sporadic, with no family history of the disease. The remaining 10-5% of ALS
cases are hereditary, referred to as familial ALS. The majority of these patients will
remain cognitively normal throughout the course of the disease, however, a subset of
both sporadic and familial ALS patients has been identified with overlapping disease
phenotypes between frontotemporal dementia (FTD) and ALS (Cleveland and
Rothstein, 2001).

Patients experiencing behavioural and personality changes,
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impairment in language comprehension and speech, and memory loss, as well as the
degeneration of muscle, are now considered to be a part of the FTD-ALS spectrum
(Neumann et al., 2006).

1.2 ALS is a disease of proteostasis dysfunction

The mutations in genes already known to cause ALS serve as our best clue in
understanding the cellular mechanisms that lead to neurodegeneration. A diverse
array of gene mutations are known to cause ALS. Genetic mutations in at least 33
genes have been identified to cause ALS (Chen et al., 2013). The normal functional
roles of the affected proteins span a range of cellular mechanisms, including RNA
binding and processing, mitochondrial function, cytoskeletal regulation, intracellular
transport and protein homeostasis (Robberecht and Philips, 2013). Mutations in
these genes will, for some proteins, have indirect effects (via non-protein related
mechanisms), or direclty affect the protein via a gain of toxic function or a loss of
function in these proteins linked to motor neuron death in ALS (Ciechanover and
Brundin, 2003).

There is a recurring theme of protein homeostasis (proteostasis) dysfunction in ALS.
Broadly, the healthy functioning of proteostasis mechanisms are particularly
important as correctly folded proteins are required for all the aforementioned cellular
mechanisms affected in ALS (Ciechanover and Brundin, 2003; Robberecht and
Philips, 2013). More specifically, all genes with mutations that cause ALS are linked
to proteostasis either through inclusion of the proteins in aggregates or through the
35

involvement of the gene product in proteostasis pathways (discussed later in this
chapter). Mutant proteins arising from these genes are either incorporated, or
increase the formation of, cellular aggregates. Many of these mutations affect
proteins that are directly involved in proteostasis pathways. In both scenarios,
disruption to the proteostasis machinery affects cellular viability. Understanding
cellular proteostasis is therefore crucial in delineating the events of ALS to establish
viable therapeutic targets (Tanaka and Matsuda, 2014).

Under normal conditions, an array of cellular proteostasis machinery prevents the
accumulation and subsequent aggregation of misfolded and abnormal proteins.
These undesirable proteins are removed via the ubiquitin proteasome system (UPS),
the primary selective labelling and degrading mechanism of the cell, or via
autophagy in the lysosome system. In some instances, proteins may be refolded into
the correct conformation by cellular chaperones circumventing the need for protein
degradation (Powers et al., 2009). Failure of the proteostasis machinery results in a
build-up of abnormal proteins, which form aggregates within the cell.

In ALS, protein aggregates form inclusions with a glassy (hyaline) or thread-like
(skein) appearance in the spinal cord and brain stem (Mizusawa, 1993). Inclusions
are described in histology as eosinophilic or basophilic- staining positive with an
acidic or basic dye, respectively. Inclusions including eosinophilic intraneuronal
Bunina bodies, and Lewy-body-like inclusions are typical in ALS post mortem
studies (Kato, et al., 1989; Okamoto et al., 2008). These inclusions form via multiple
cellular mechanisms (for review of the role of these proteostasis mechanisms in
neurodegeneration see Yerbury et al. 2016), though are overwhelmingly positive for
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ubiquitin, an essential posttranslational modification. Molecular investigations
consistently identify ubiquitin-positive aggregates in ALS tissues, strongly
implicating the UPS dysfunction in ALS (Arai et al., 2006).

It is still not understood if these aggregates are protective or pathogenic.

The

accumulation of aggregates can serve as a protective mechanism: aggregates
minimise the exposure of the intracellular environment to misfolded proteins.
Cellular mechanisms sequester these misfolded proteins/aggregates into cellular
compartments to reduce inappropriate interactions such as the initiation of further
aggregation. The presence of compartmentalized aggregates therefore serves as a
protection to the intracellular environment. Conversely, an increased presence of the
aggregate prone species (reaching towards supersaturation) in the cell increases
cellular aggregation (Ciryam et al., 2015). The presence of these aggregates
contribute to intracellular crowding, which can affect proper protein structure and
stability, protein activity, including protein-nucleic acid interactions, and also
increases the likelihood of more protein misfolding events (Kuznetsova et al., 2014).
Together, these features represent a likely pathogenic element to the presence of
aggregates. It has been suggested that a healthy threshold of protein misfolding
would exist within the cell to maintain proteostasis, however when proteostasis
systems are overwhelmed, have deleterious effects.

(Hartl et al., 2011)

Understanding the proteostasis mechanisms that maintain these levels, particularly
the UPS, will be important for therapeutic intervention targeted at aggregate
reduction in ALS (Webster et al., 2017).
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1.3 The UPS is a central component of proteostasis, among other
functions

The UPS is the principal selective degradation pathway, involved in the degradation
of up to 90% of intracellular proteins (Jansen et al., 2014; Lee and Goldberg, 1998).
The UPS is comprised of both a labelling component: the ubiquitination system, and
a degrading component: the proteasome system. In the ubiquitination system, the
addition of ubiquitin, a highly conserved 8.5 kDa protein, acts as a posttranslational
modification (Hershko and Ciechanover, 1998). When attached, the ubiquitin label
signals proteins for specific relocation within the cell. The addition of an ubiquitin
molecule was previously thought to act only as a protein degradation signal for the
UPS, however ubiquitin signaling is now regarded as a much more complex cellular
language (Ciechanover, 1994; Komander and Rape, 2012). The addition of specific
ubiquitin chains can affect protein function in proteasome-independent processes,
referred to as the ubiquitin signaling system, thus this first component of the UPS is
critical in ensuring the correct ubiquitin message is attached to the appropriate
substrate protein (Atkin and Paulson, 2014; Komander and Rape, 2012).

Proteins are subjected to a three-step process to label a target protein with ubiquitin:
(1) the ubiquitin molecules are activated via binding to an ATP-dependent E1
ubiquitin-activating enzyme, converting the C-terminal glycine residue to a highenergy thiol ester intermediate; (2) the now active ubiquitin molecule is transferred
to an E2 conjugating enzyme; (3) the E2-ubiquitin complex binds to a specific E3
ubiquitin ligase, which also binds the protein of interest, attaching ubiquitin to the
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target protein via the activated C-terminal glycine and a NH2 of the lysine on the
substrate (Figure 1.1) (Ciechanover and Brundin, 2003; Hershko and Ciechanover,
1998; Komander and Rape, 2012).

A single E3 ubiquitin ligase is capable of

recognizing multiple target proteins, and conversely a single target protein may be
ubiquitinated by more than one of the approximately 600 identified E3 ubiquitin
ligases.

In recent years, commercial availability of ubiquitin immunoaffinity

products combined with proteomic analysis techniques mean proteins ubiquitinated
by the ubiquitin system can be qualified and quantified in a technique termed
ubiquitinomics (Nagarajan et al., 2017).
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Figure 1.1 Ubiquitin proteasome system schematic
The addition of an ubiquitin (Ub) tag onto a protein substrate occurs through a threestep process: Free ubiquitin is bound to an E1 enzyme, which delivers the ubiquitin
to an E2 enzyme. The protein substrate is recognised by an E3 ubiquitin ligase.
Binding of the E2-E3 complex permits the binding of ubiquitin to the protein
substrate. This final step is repeated in the formation of a polyubiquitin chain. The
type of ubiquitination (mono- or poly-ubiquitination) and the chain conformation
indicates if a protein substrate is to be degraded by the proteasome, or is to serve
another purpose in the cell. Ubiquitin is recycled following degradation or via
deubiquitinating enzymes, back to the free pool. Figure adapted from Ciechanover
and Brundin, 2003; Tai and Schuman 2008.
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The redundancies in the UPS reiterate the importance of the system, particularly the
final step (Hjerpe et al., 2016). In the final rate-limiting step, the ubiquitin tag is
covalently bound to an ubiquitin binding-domain on the protein substrate. If only a
single ubiquitin tag is to be added to the protein (mono-ubiquitination) the protein
will exit the cycle following this step (Hicke, 2001). Mono-ubiquitination usually
acts as a localization signal, or a protein confirmation alteration for complex
formation or activity modifying purposes, particularly as a histone modification for
example for DNA transcription (Meas and Mao, 2015; Yau and Rape, 2016).
Proteins requiring the addition of multiple ubiquitin molecules (multi-ubiquitination)
or a chain of ubiquitin (poly-ubiquitination) will repeat this final step (Strieter and
Korasick, 2012). Poly-ubiquitin chains are formed via a covalent isopeptide bond
between a lysine residues or the N-terminal ubiquitin methionine (M1), and usually
the C-terminal glycine of the following ubiquitin in the chain in an ATP-dependent
manner (Lindquist and Kelly, 2011). There is added complexity in the manner by
which the poly-ubiquitin chains are linked, which affects the signaling properties of
this post-translational modification (Figure 1.2). The ubiquitin molecule contains
seven lysine residues which act as linking points, including K6, K11, K27, K29,
K33, K48, and K63 (Alfano et al., 2016). Poly-ubiquitin chains may be linked
repeatedly through the same lysine residues in a homologous chain, or can be linked
by a combination of any of the seven lysine residues, or M1 in a heterologous chain
(Meyer and Rape, 2014). These heterologous chains are either single straight chains,
or branched chains, diverging from a single ubiquitin molecule into two or more
chains (Alfano et al., 2016; Kim et al., 2007; Peng et al., 2003). The diversity of
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possible ubiquitin tags adds significant complexity to ubiquitin signaling (Yau and
Rape, 2016).

Figure 1.2 Ubiquitin post-translational modifications
Ubiquitin can be bound to protein substrates in many forms - as a single ubiquitin
tag, in multiple locations on a protein, and as complex chain structures. Chains form
as ubiquitin binds to one another on one of the ubiquitin lysine (K) residues (K6,
K11, K27, K29, K33, K48, K63) or on methionine 1 (M1). Chains may be
consistently bound to the same lysine residues I.e. all K48 bound, or may bind to
different residues; branching of the chains can also occur. These different types of
ubiquitin chains (or mono ubiquitin) binding encode different signals. Figure adapted
from Yau and Rape 2016.

The idiosyncrasies of the different ubiquitin chain codes are currently not fully
understood (Alfano et al., 2016). Some specific signals have been identified – for
example, if a protein is destined for degradation, the final step is typically repeated to
produce a poly-ubiquitin chain of four ubiquitin tags, joined by all K48 or all K11
links, to signal degradation by the proteasome; this is the most common signal for
ubiquitin chains (Yau and Rape, 2016). Different chain codes are also responsible
for signaling a range of fundamental cellular functions including cell cycling, DNA
damage control, transcriptional regulation, cellular transport (including axonal
transport) and cellular survival, in addition to protein degradation (Ciechanover and
Brundin, 2003). However, most of the ubiquitin ‘code’ combinations have not been
characterized (Alfano et al., 2016; Di Lello and Hymowitz, 2016; Komander and
Rape, 2012).
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Ubiquitin chains are typically formed from the pool of free ubiquitin in the cell
(Groothuis et al., 2006). Ubiquitin chain lengths can however be modified following
synthesis. Deubiquitinating enzymes (DUB) are able to reduce chain length, and
remove ubiquitin chains/monoubiquitin (Hershko and Ciechanover, 1998; Hicke,
2001). In some cases, ubiquitin acts as an inhibitory post-translational modification,
so the removal of ubiquitin by a DUB serves to alter enzyme activities (Groothuis et
al., 2006). This ubiquitin removal by DUB recycles the ubiquitin back to the free
ubiquitin pool for reuse (Park and Ryu, 2014). Interestingly, this reserve of ubiquitin
is affected by cellular homeostasis. Ubiquitin is redistributed in proteotoxic stress
due to competition for the limited pool of free ubiquitin. Quantification of human
frontal cortex by affinity chromatography and protein standard absolute
quantification mass spectrometry indicated that 82% of ubiquitin in the brain is free
ubiquitin (Dantuma et al., 2006). It is therefore unsurprising that depletions to this
ubiquitin pool would exacerbate cellular stress, and that free ubiquitin is considered
neuroprotective (Farrawell et al., 2017; McKinnon and Tabrizi, 2014; Yerbury et al.,
2016; Ryu et al., 2014).

It has been speculated that as aggregates commonly

sequester ubiquitin, that aggregate formation in neurons would lead to a reduction in
free ubiquitin reserves, decreasing ubiquitin availability for other cellular functions,
leading to an increase in cellular stress (Hallengren et al., 2013).

Proteins fated for proteolysis by the UPS are degraded by the proteasome. The
predominant proteasome in mammals is the 26S proteasome, a cytosolic complex
that is composed of two caps, and a central degradation unit. The two caps (19S) are
regulatory units, which recognize the ubiquitinated protein, which in turn is
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internalized and undergoes proteolysis in the degradation unit (20S) (D. Voges et al.,
1999). The 26S proteasome has been detected in three main conformations, which
are hypothesized to correspond to a three-step process to selectively degrade
proteins: (1) the substrate accepting state, wherein ubiquitin is recognized and
recruited, along with the bound protein destined for degradation; (2) the intermediate
state, which corresponds to point of no return for the proteolysis; (3) the
translocating step, in which the protein is processed by the proteasome, degrading it
to small peptides (Pickart and Eddins, 2004).

1.4 Neurons are susceptible to proteostasis dysfunction

Although every cell in the body must carry out selective protein degradation to
maintain proteostasis, neurons appear more sensitive to cellular stress (including
proteostasis dysfunction) than other cell types (Yerbury et al., 2016). Neurons are
some of the most metabolically and structurally complex cells in the human body.
Neurons have a high metabolic demand, owing to the complex structure and
requirement for constant activity in the cell type. Neuronal morphology is very
distinct; neurons, particularly motor neurons, have an incredibly large surface areato-volume ratio relative to other cell types, owing to the specialist structures such as
dendrites and the axon, some of which extend great distances throughout the body to
innervate muscles (Holzbaur, 2009; Tai and Schuman, 2008). This high surface
area-to-volume ratio is taxing not only regarding the transport requirements of the
cell, which alone is energetically taxing, but also causes an overwhelming
requirement for the cell in terms of protein synthesis, including the needs for
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membrane and scaffolding proteins. In addition to these cellular needs, the primary
function of neurons is reliant on the ability of the cell to compartmentalize. Vesicle
formation is essential for the primary role of communication in the neuron, and
requires a plethora of proteins to function (Tai and Schuman, 2008). As protein
synthesis must be balanced by protein degradation in the cells, these high demands
on the synthesis equally place high demands on the protein degradation system of
neurons (McKinnon and Tabrizi, 2014). Unlike many other cell types of the body,
neurons are generally post-mitotic; most neurons must therefore endure a lifetime of
stress upon these systems, with very limited capacity for turnover, unlike most other
cell types (Tai and Schuman, 2008).

Neurons are more susceptible to changes in UPS efficiency when compared to other
neural cell types (Hallengren et al., 2013). In a report by Ding et al. (2004) primary
rat neurons from the cerebral cortex displayed a higher increase in nucleic acid
oxidation than primary rat cerebral cortex astrocytes when treated with the same
concentration of the proteasome inhibitor MG262 for 24 h.

The group used

immunocytochemistry to assess the hydroxyl species 8-hydroxyguanosine and 8hydroxy-2’deoxyguanosine to indicate nucleic acid stress, and observed that neurons
expressed higher levels of these hydroxyl species compared to other neural cells
(Ding et al., 2004). The authors noted differences in the level of immunoreactivity to
the hydroxyl species in the different cell types based on general morphology,
although unfortunately they did not quantify the differences between neurons and
astrocytes, nor did they identify the types of neurons and astrocytes in the mixed
culture other than by morphological observation. Despite these flaws, the overall
observation that neuronal cells elicits an increased stress response to proteasomal
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inhibition is pertinent given the selective neuronal cell death in neurodegenerative
diseases such as ALS.

1.4.1

Motor neurons are particularly sensitive to UPS stresses

Sensitivity of motor neurons to UPS stress has previously been indicated. Ocular
motor neurons, which remain relatively free from degeneration during the course of
ALS pathogenesis, were compared to spinal motor neurons in a study by
Brockington et al. (2013). A comparison of human ocular motor neurons and spinal
motor neurons by microarray analysis indicated differences in expression of genes
relating to ubiquitination, as well as mitochondrial function and RNA metabolism.
The group detected an increase in the expression of 119 genes related to proteostasis
in ocular motor neurons compared to the spinal motor neurons, including 25 genes
deemed to belonged to the UPS (Brockington et al., 2013). The group suggested that
it may be this increased expression of UPS genes that allows the ocular motor
neurons to withstand the effects of ALS progression, compared to spinal motor
neurons.

Dysfunction of the UPS is already known to contribute to ALS, with a number of
UPS gene mutations identified as causing the disease. Ubiquitin is required as an
essential protein for healthy neuronal function and survival (Park & Ryu 2014).
Decreased function of the UPS leads to an increase in aggregated proteins and an
increase in ubiquitin tagged proteins or “UPS substrates” (Bence et al., 2001).
Deficits in the ubiquitin system in particular are detrimental to multiple facets of
neuronal function (McKinnon and Tabrizi, 2014). Cell membrane proteins, proteins
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involved in vesicle formation, including pre- and post-synaptic terminal proteins, and
microtubule proteins all require ubiquitin signaling to function (Tai and Schuman,
2008). Glycine receptors, for example, are thought to be degraded via internalization
and cleavage by the lysosome following ubiquitination (Manuel and Sorkin, 2007).
Disruption to these pathways would have dire consequences to general cellular
functions, as well as neuron specific functional pathways (Tanaka and Matsuda,
2014).

1.5 Proteostasis genes that cause ALS provide valuable information
for all forms of ALS

A number of genes with ALS causing mutations code for proteins of the UPS (Chen
et al., 2013; Table 1.1). The effects of these mutations are varying, however, that
these UPS associated gene mutations are amongst the ALS causing genes indicates
that defects in the UPS system cause ALS. Examination of these identified genetic
causes and subsequent gene products provides insight into both the patient subsets
with these mutations, while also providing a greater understanding of the general
mechanisms that cause ALS. Such information is of undeniable benefit to the
majority of ALS sufferers who have no genetic history to draw from (Robberecht and
Philips, 2013).

1.5.1

Network analysis reveals UPS genes dysregulated in ALS

Recent gene co-expression analysis by Ferrari et al. (2016) identified proteostasis as
a key pathway in the FTD spectrum. In an effort to understand the systems
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implicated in the FTD spectrum, which includes ALS, a gene co-expression network
analysis of 101 healthy individuals was performed. Clustering of co-expression
patterns in the frontal cortex, temporal cortex, putamen, thalamus, hippocampus,
white matter, cerebellum and medulla obtained by microarray indicated that
C9ORF72, VCP, UBQLN2, and OPTN, genes already associated with ALS, were
central players in FTD. The group also identified a panel of potential novel genes
that are likely to be associated with ALS/FTD, including nine proteins from the UPS
pathway (Ferrari et al., 2016). These include proteins that form the E3 ubiquitin
ligase complexes: CAND1, which codes for cullin associated neddylation dissociated
1, a protein that assembles SKP1-CUL1-F-box complexes (Zheng et al., 2002),
MYCBP2, which codes for an E3 ubiquitin ligase (Holland, 2011), CUL2, which
codes for cullin 2, a component of an E3 ubiquitin ligase complex (Brower et al.,
2002), BTRC, which codes for F-box/WD repeat-containing protein 1A, an F-box
protein (Mudhasani et al., 2016), COPS3, which codes for a component of a complex
that deneddylates cullin in SCF-Cul1-F-box ligases and other SCF ligases (Lydeard
et al., 2013). Other identified UPS associated genes include PLAA, the gene for
phospholipase A-2-activating protein, which maintains ubiquitin levels (Fu et al.,
2009), UBQLN1, which codes for ubiquilin 1, a ubiquitin-like protein that associates
with the proteasome and ubiquitin ligases (Kim et al., 2009), USP9X which codes for
probable

ubiquitin

carboxyl-terminal

hydrolase

FAF-X,

which

serves

to

deubiquitinating proteins (Dupont et al., 2009), and PSMD12, which codes for a
proteasome subunit (Küry et al., 2017). Interestingly, the authors noted gene coexpression network analysis did not strongly implicate a hallmark ALS protein,
TDP-43 in the ubiquitin proteasome pathways, however they did find an increase in
RNA regulation which is associated with TDP-43 (Strong et al., 2007). This network
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analyses further implicated the ubiquitin proteasome system in ALS (Ferrari et al.,
2016).

1.5.2

ALS causing mutations in UPS associated genes

Mutations in UPS machinery-coding genes have been identified to cause ALS.
Mutations in the genes for UPS proteins ubiquitin-like protein ubiquilin 2,
(UBQLN2), valosin containing protein (VCP), sequestesome 1 (SQSTM1),
optineuron (OPTN), TANK-binding kinase 1 (TBK1) and more recently, cyclin F
(CCNF) have all been identified to cause ALS (Abel et al., 2012; Williams et al.,
2016). These proteins normally serve a range of function in the UPS. Ubiquilin 2
associates with ubiquitin ligases, poly-ubiquitin chains, and proteasome subunits and
is thought to assist in transitioning proteins between the labelling and degradation
systems of the UPS, including protein clearance mechanisms (Hjerpe et al., 2016;
Schuberth and Buchberger, 2008).

VCP regulates ubiquitination via facilitating

ubiquitination of proteins by bind directly to E3 ubiquitin ligases, and facilitates
ubiquitin removal by binding to DUBs (Meyer et al., 2012). (Moscat et al., 2006;
Sowa et al., 2009; Wang et al., 2006). Sequestosome 1 is a ubiquitin binding protein
which indirectly activate Nuclear Factor Kappa-Light-Chain-Enhancer of Activated
B Cells (NF-κB) through ubiquitination of an E3 ubiquitin ligase (Moscat et al.,
2006). Dorfin is an E3 ubiquitin ligase - which interestingly ubiquitinates SOD1 for
degradation (linking SOD1 accumulation and UPS dysfunction) (Niwa et al., 2002;
Sone et al., 2010). These UPS proteins act on a wide range of proteins, implicating
the downstream effects of these mutations are vast, and due to UPS redundancies, are
still largely unknown.

Importantly, this in turn also suggests that targeting
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proteostasis proteins is a valid path for therapeutics in ALS caused by mutations
other than those directly linked to the UPS (Ishigaki et al., 2004).
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Table 1.1 ALS associated mutations and proteostasis dysfunction
Gene
SOD1
ALS2
SETX
SPG11
FUS

VAPB

ANG

TARDBP

FIG4

OPTN

Protein

Normal Function

ALS Proteostasis dysfunction

Reference

Superoxide dismutase 1

Destroying free superoxide radicals

Ubiquitin positive JUNQ inclusion formation

Farrawell et al., 2017; Valentine et
al., 2005; Wong et al., 1995

Alsin

Guanine Nucleotide Exchange Factor (Rab5
and Rac1)

Loss of function increases aggregate formation.

Hadano et al., 2001; Li et al., 2011

Senataxin

DNA/RNA helicase, RNA transcription and
DNA repair

Present in ubiquitin positive inclusions, including in
axonal spheroids

Rabin et al., 1999; Suraweera et
al., 2009

Spatacsin

Axonal maintenance and cargo trafficking

Hyaline inclusions present in a patient post mortem
study.

Orlacchio et al., 2010; PérezBrangulí et al., 2014

Fused in sarcoma

RNA transcription and processing

Ubiquitin positive aggregate formation and
increased rate of aggregate formation.

Kwiatkowski et al., 2009; Zinszner
et al., 1997

VAMP- associated
protein B

Protein transport; Implicated in the unfolded
protein response

Altered unfolded protein response and increase
aggregate formation.

Nishimura et al., 2004; Tokutake et
al., 2015

Angiogenin

Blood vessel stimulator

Involved in stress granule formation.

Dewey et al., 2012; Gao and Xu,
2008; Greenway et al., 2006

TAR DNA binding
protein-43 (TDP-43)

DNA and RNA binding protein to regulate
transcription and splicing.

Present in aggregates, including ubiquitin positive
aggregates. Wild type TDP-43 is ubiquitinated.

Johnson et al., 2009; Sephton et
al., 2010; Strong et al., 2007

Phosphoionositide5phosphatase (via factor
induced gene 4)

Hydrolyzes D5-phosphorylated
polyphosphoinositide substrates; biogenesis of
vesicular bodies

Impairs protein trafficking. Increases protein
aggregation when mutations accompanied by
Vac14 mutation.

Chow et al., 2009; Michell and
Dove, 2009; Sbrissa et al., 2007

Optineurin

Golgi complex maintenance, membrane
trafficking and exocytosis. Links myosin VI to
the golgi complex.

Found in inclusion bodies, and mutant forms impair
protein trafficking including to the lysosome.
Ubiquitin positive aggregates.

Maruyama et al., 2010; Sahlender
et al., 2005
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ATXN2

VCP

UBQLN2

Ataxin-2

Stress granule and P body formation.

Modifies TDP-43 toxicity, mutation increases
formation of TDP-43 positive aggregates.

Elden et al., 2010; Nonhoff et al.,
2007

Valosin containing
protein

Part of a complex that binds ubiquitinated
proteins and exports misfolded proteins from
the ER to the cytoplasm.

Impairs the unfolded protein response, which leads
to protein aggregation and the UPS. Found in
ubiquitin positive inclusions.

Ishigaki et al., 2004; Johnson et al.,
2010; Weihl et al., 2008

Protein degradation impairment and increase in
misfolded proteins leading to increase in
aggregates.

Deng et al., 2011; Hjerpe et al.,
2016

Ubiquitin-like protein-2

UBQLN2 recognizes aggregated and
misfolded proteins for delivery to the
proteasome for degradation.

Aggregates in vitro. TDP-43 and FUS positive
cytoplasmic inclusions in detected in ALS patient
tissue.

SIGMAR1

Sigma non-opioid
intracellular receptor 1

CHMP2B

Charged multivesicular
body protein 2b

Subunit of endosomal sorting complexes
required for transport (ESCRTs), which
regulate protein trafficking in lysosomal
degradation.

Mutation in CHMP2B results in ubiquitin positive
inclusion body formation. Protein trafficking
disrupted.

Cox and Mann, 2008

Profilin 1

Regulates the assembly of actin monomers to
filaments.

Formation of ubiquitin positive inclusions and
cytoskeletal dysfunction.

Poggetto et al., 2015; Wu et al.,
2012; Yang et al., 2013

C9ORF72

Regulates endosomal trafficking.

p62/ubiquitin- and TDP-43 positive inclusions form
in C9ORF72 patients.

Farg et al., 2014; Mori et al., 2013

Coiled-coil helix-coiledcoil-helix domain
containing 10

Unconfirmed. Predicted to be involved in
oxidative phosphorylation. Localised in the
mitochondria.

Not yet detected.

Bannwarth et al., 2014

Dynactin

Retrograde transport of vesicles and
organelles along microtubules

Axonal protein trafficking dysfunction. Included in
ubiquitin positive aggregates with SOD1 in
SOD1G93A mouse model.

Ayloo et al., 2014; Puls et al.,
2003; Teuling et al., 2008

Tubulin Alpha 4a

Cytoskeletal protein

Forms inclusions in primary motor neurons;
ubiquitin positive aggregates detected in Cos7cells
expressing mutant TUBa4a.

Elden et al., 2010, Smith et al.,
2014; Rademakers & Blitterswijk,
2014

PFN1
C9orf72

CHCHD10

DCNT1

TUBa4a

Inter-organelle signaling modulator at ER
2+

including Ca Reduces aggregation formation
- via chaperone activity

Al-Saif et al., 2011; Gregianin et
al., 2016; Miki et al., 2018; Su et
al., 2010
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DAO
CCNF
NEFH

PRPH
SQSTM1
GLE1

hnRNPA2B1/A1

NEK1

TBK1

MATR3

D-amino acid oxidase

Oxidative deamination of neutral and polar
amino acids (D-isomers)

Increases ubiquitinated aggregates

Mitchell et al., 2010; Pollegeioni

Cyclin F

An E3 Ubiquitin ligase

Aggregate formation, UPS dysfunction

Williams et al., 2016

Neurofilament, heavy
200kDa, heavy chain

Neuronal cytoskeletal filament protein

Neurofilamentous swellings

Figlewicz et al., 1994; lees et al.
1988

Peripherin

Neuronal intermediate filament protein in cells
connected to the periphery

Ubiquitinated skein-like inclusions

Leung et al. 2004

Sequestosome 1

A ubiquitin-binding protein, activates NF- κB

Included in ubiquitin positive inclusions, increases
aggregate formation.

Fecto et al. 2011; Moscat 2006;
Mizuno et al. 2006

GLE1

Transcription control, and nuclear RNA export
as a nuclear pore factor.

Cytoplasmic aggregates in overexpression cellular
systems.

Kaneb et al. 2015; Kutay & Panse,
2008, Aditi et al., 2016

Heterogeneous nuclear
ribonucleoproteins
A2/B1

RNA binding protein. Forms heterogeneous
nuclear RNA complex.

Prone to self-aggregation. Reduced hnRNPA2B1
has been detected in conjunction with TDP-43
aggregates in ALS patient spinal cords.

Calini et al., 2013; Honda et al.,
2015, Kim et al., 2013

NIMA related kinase 1

Phosphorylation of an E3 ubiquitin ligase Von
Hippel-Lindau protein, and voltage dependent
anion channel 1 (VDAC1)

No cellular ALS studies have been performed to
date following the recent identification of mutation.
Known to associate with ALS associated proteins
at endogenous levels including VAPB, VAPA,
Alsin, C21orf2.

Kenna et al. 2016; Patil et al.,
2013; Chen et al., 2009

TANK-binding kinase 1

Mediates degradation by UPS and
inflammatory response; Complexes to mediate
NF- ΚB activation,

Matrin-3

RNA/DNA binding protein

TDP-43, and p62 positive inclusion detected in
patients.
Aggregates with TDP-43 and MATR3 detected in
tissue of ALS patients. MATR3 aggregates
detected in C9ORF72 patients.

Pomerantz & Baltimore 1999;
Freischmidt et al., 2015

Johnson et al., 2014; Zeitz et al.,
2009
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1.5.3

Proteostasis dysfunction evident in sporadic ALS

Understanding the dysfunction caused by the mutations to the UPS system is
essential in treatment of ALS in patients who have proteostasis dysfunction. A
proteostasis dysfunction phenotype is common not only amongst FALS, but is also
described in SALS post mortem investigations. Transcriptome analysis of 148 post
mortem cortex samples, the majority of which were SALS patients, has recently
indicated that 61% exhibited an oxidative and proteotoxic phenotype, as clustered by
an unsupervised machine learning algorithm (Tam et al., 2019). Both Lewy-bodies
and Bunina bodies are reported in SALS post mortem tissue (Kato et al., 1989;
Okamoto et al., 2008). In a study of 102 SALS patient post mortem tissue, 86% were
positive for Bunina aggregate structures (Piao et al., 2006). The majority of SAL
studies describe TDP-43 post mortem pathology, including cytoplasmic and nuclear
inclusions (as described in the following section) (Van Deerlin et al., 2008; Webster
et al., 2017). In some cases, all three - Lewy-bodies, Bunina bodies, and TDP-43
inclusions have been detected in the same tissue (Miki et al., 2018). Given that the
majority of ALS is SALS, identifying commonalities between SALS and FALS is an
important step in therapeutic development.

The presence of these common

aggregates, a result of proteostasis dysfunction, clearly indicates proteostasis as a
critical target in ALS therapeutics (Webster et al., 2017).

1.5.4

TDP-43 pathology implicates proteostasis dysfunction

ALS is widely regarded as a TDP-43 proteinopathy, due to the detectable TDP-43
positive aggregate phenotype common to post mortem investigations. TDP-43
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positive inclusions are reported in over 90% of ALS pathology, representing the most
prevalent hallmark of ALS pathology (Scotter et al., 2015). Pathological TDP-43 has
been detected in many altered forms, including ubiquitinated, hyper-phosphorylated,
and cleaved (C-terminal fragment) (Mackenzie et al., 2010). Why this protein is so
widely included in aggregates in ALS is not clear. Normally, soluble TDP-43 is
degraded by the UPS, and under conditions of aggregation, TDP-43 will be degraded
by autophagy (Scotter et al., 2014). Disturbance to these proteostasis systems would
therefore yield a retention of TDP-43, as seen in ALS pathology (Mackenzie et al.,
2010).

Despite the presence of TDP-43 in a wide range of neurodegenerative disease
pathology, the functional roles of this protein are still yet to be fully understood.
TDP-43 has been detected to have both cytosolic and nuclear functions (Ederle and
Dormann, 2017). Cytosolic localisation of TDP-43 is widely regarded as an ALS
phenotype, alongside the presence of TDP-43 in aggregate/inclusion structures. This
mislocalisation prevents proper function of TDP-43 in mRNA splicing, as well as
transcription, gene regulation and non-coding RNA processing (Ederle and
Dormann, 2017). Ubiquitously expressed, TDP-43 is also essential in embryonic
development (Sephton et al., 2010). Fortunately, this early expression of TDP-43
facilitates the examination of the role of this protein in models such as patient
derived stem cell and as well as stem cell derived motor neuron models which are
increasingly commonly engaged for ALS research (Lee and Huang, 2017).
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1.6 Mutations in CCNF can cause ALS

Recent identification of a novel ALS associated gene has reiterated the links between
the UPS and ALS. Mutations in CCNF, a gene encoding cyclin F, an E3 ubiquitin
ligase were implicated in a genetic study using genome-wide linkage analysis
coupled with next generation sequencing (Williams et al., 2016). Genetic analysis of
two patients revealed the mutation CCNFS621G was shared in the cyclin F gene.
Genetic analysis revealed a further nine novel FTD/ALS causing mutations in the
CCNF gene in families from Australia, Italy, Spain, Canada, Japan, the United States
of America, and the United Kingdom.

Since this initial population study, the

prevalence of cyclin F mutation in ALS and FTD in mainland China has been
detected at 0.6% (Pan et al., 2017) in one cohort study, and 2.56% in FALS patients
and 1.03% in SALS in another cohort (Tian et al., 2018). One patient with a
mutation in a 207 ALS patient cohort was identified in Taiwan (Y.-C. Lee et al.,
2017).

1.6.1

The role of cyclin F must differ between mitotic and non-mitotic cells

Prior to this identification of cyclin F as an ALS associated protein, the focus of
cyclin F investigation was in cancer research. Accordingly, the function of the
protein has been predominantly investigated in mitotic cells (Table 1.2). Cyclin F is
one of the eight conserved cyclin proteins that regulate the cell cycle (D’Angiolella
et al., 2013). First identified in 1994, cyclin F shares the common features of a
cyclin - cyclin F levels fluctuate throughout the cell cycle, and crucially, changes in
concentrations of cyclin F affect the cell cycle (Kraus et al., 1994). Control of the
cell cycle is believed to be through degradation of cyclin F substrates. The conserved
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sequence rich in proline, glutamic acid, serine, and threonine (PEST) determines
ubiquitin dependent degradation, as is the mechanism for many cyclins (Bai et al.,
1994). The effect of cyclin F on the cell cycle has been demonstrated by increased
expression of cyclin F in C33A cells. Increased expression significantly increased
the proportion of cells that expressed CD20, indicating the cells were in G2/M phase
as measured by flow cytometry (Bai et al., 1994). Cyclin F oscillates through the
cell cycle in a pattern similar to cyclins A and B, though it peaks in G2 (Bai et al.,
1994; Murray, 2004).

Cyclin F, also known as the F Box Only Protein 1, contains two motifs fundamental
to its function in the UPS as an E3 ubiquitin ligase. The PEST region is found in
many cyclins; unlike other cyclins, cyclin F is the only cyclin that is kinase
independent, thereby earning it the name ‘The Orphan Protein’ (Bai et al., 1994).
Cyclin F was the first identified member of the F box protein family; these proteins
contain an F box motif, which is an approximately 55 amino acid sequence that
mediates protein-protein interactions (Bai et al., 1996; Kraus et al., 1994). The F box
motif is crucial to the activity of cyclin F as this motif binds to S-phase kinaseassociated protein 1 (SKP1) (Craig and Tyers, 1999); the binding of these two
protein subunits allows cullin 1 (CUL1) to bind and form the SKP1-CUL1-F-box
protein, an E3 ubiquitin ligase complex (Xie et al., 2013).
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Table 1.2 Summary of cyclin F research
Author

Year

Findings

Kraus et al

1994

First Identification of cyclin F - described as a cyclin

Bai et al

1994

Sequencing of CCNF indicated presence of conserved proline
glutamic acid serine threonine rich (PEST) sequence that
determines ubiquitin dependent degradation of other cyclins

Bai et al

1996

Skp1 identified as interactors with cyclin F, proposed as a
component of an E3 ubiquitin ligase complex

Movsesyan et
al

1996

Nerve growth factor and fibroblasts growth factor reduced cyclin
F expression in PC12EY cells

Ng et al

1998

Indicates Skp1 interact with Skp1 binding of Skp2 and cyclin F
similar (noted as unpublished)

Kong et al

2000

Nuclear localisation signals of cyclin F are functional and
independent; thought to co-localise with cyclin B to transport to
nucleus (as cyclin B has no NLS)

Fung et al

2002

Cyclin F is degraded when the spindle-assembly checkpoint.
Accumulates upon DNA damage checkpoint activation

2004

Heterozygous CCNF KO no obvious effects in mice; CCNF KO
or non-functional cyclin f had developmental anomalies - lethal
by day E10.5. Cyclin F deletion yields no obvious phenotypes in
certain tissues (gut, bone, bladder, cornea, lens) fibroblast cell
cycle progression affected

Tetzlaff et al

D’Angiolella et
2010
al

Cyclin F (as the substrate recognition unit) ubiquitinates
centrosome duplication protein CP110; suggests cyclin F
expression influences γ-tubulin and centrin 2 expression;
Proposes cyclin F has the opposite role to cyclin E (limiting
centrosome duplication via degradation of CP110)

Emanuele et al 2011

NUSAP1 is a cyclin F substrate; cyclin F substrates may also
be acted on by other ligases (as would be expected)

Buganim et al

Cyclin F expressed in mouse iPSCs during reprogramming
(referenced as a cell cycle regulator marker)

2012

D’Angiolella et
2012
al

Cyclin F ubiquitinates RRM2 for degradation when accumulated
in the nucleus. Binding of RRM2 different to binding of CP110.
Cyclin F downregulation required for efficient DNA repair.
Cyclin F keeps dNTPs in balance

Klein et al

2015

Cyclin F active in G2 DNA damage checkpoint checkpoint
control via B-Myb (and cyclin A pathway) suppression

Elia et al

2015

Nuclease EXO1 ubiquitinated (and subsequently degraded) by
cyclin F following UV radiation

Choudhury et
al

2016

There is a reciprocal feedback loop between SCF
anaphase promoting complex/cyclosome (APC/C
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cyclin F

Cdh1

and

) resulting

in the degradation of cyclin F signalled by APC/C
phase and the reverse in S phase
Walter et al

2016

Choudhury et
al

2017

Williams et al

2016

Cdh1

in G1

Cell division cycle 6 (CDC6) is a cyclin F substrate; degradation
of CDC6 following ubiquitination via cyclin F is required to
prevent more than one DNA replications occurring
Cyclin F phosphorylated by protein kinase B (AKT), stablising
cyclin F and increasing formation of SCF

cyclinF

First study identifying mutations in the CCNF gene causes ALS.
Nine mutations identified globally. Phenotype included
increased abundance of ubiquitinated TDP-43 ,ubiquitinated
RRM2 and ubiquitin proteasome system dysfunction
S621G

Examined effects of CCNF
in zebrafish - found reduced
response to light stimulus, and reduced response distance in
Hogan et al

Lee et al

Pan et al

Lee et al

2017

S621G

positive responders. Examined expression of CCNF
in
Neuro-2a cells resulted in upregulation of caspase 3 activity
compared to WT

2017

Identified 7 phosphorylation sites on Cyclin F
transfected/expressed in HEK293 cells - 5 novel including
Ser621. Mutation at S621G prevents phosphorylation,
increasing ubiquitination activity. Phosphorylation decreases
activity of cyclin F

2017

The prevalence of CCNF mutation in ALS and FTD patients in
mainland China was detected at 0.6%

2017

One patient in a 207 ALS patient cohort was identified in
Taiwanese population study
S621G

Lee et al

2018

Tian et al

2018

Expression of CCNF
increased Lys48-specific
(proteasomal) ubiquitination in transfected in Neuro-2A and SHSY5Y cells. Immunoprecipitation pull down of Lys48
S621G

ubiquitinated proteins in CCNF
found these proteins to be
involved in autophagy, heat shock, chaperonin and
sequestesome-1
Identified 8 likely pathogenic variants of CCNF, and prevalence
in the examined population was 2.56% in FALS and 1.03% in
SALS
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Figure 1.3 Structure of cyclin F protein
Cyclin F structure includes two nuclear localization signals (NLS), an F Box motif
(region binds to Skp1 and core components of E3 ligase), cyclin box (100 amino acid
region conserved in cyclins) and PEST (proline, glutamic acid, serine and threonine)
enriched region for ubiquitin dependent degradation (Adapted from Kong et al
2000).

These previous studies have indicated varying cyclin F localisation in different cell
types, though has been predominantly detected to localise in the nucleus, and
contains two nuclear localisation signals (Xie et al., 2013). Perinuclear cyclin F was
detected via immunofluorescence in COS-1 cells transfected with a CCNF encoding
plasmid, which was used to detect cyclin F localization due to the naturally low
expression of cyclin F in these cells.

Between 10 – 30 % of cells exhibited

perinuclear staining positive for cyclin F. This change in localization could indicate
that: 1. Cyclin F localization changes throughout the cell cycle, reflecting another
role in the cell (Bai et al., 1994). Alternate roles of cyclin F beyond DNA
maintenance was described by Kong et al (2000) who found cyclin F acted to shuttle
cyclin B to the nucleus. Similarly, D’Angiolella noted cyclin F co-localized with
centrosomal

protein

110

(CP110)

at

the

centrosome

as

indicated

by

immunocytochemical analysis of synchronized U2OS osteosarcoma cells (2013); 2.
Subcellular localisation is altered by forced overexpression of cyclin F; and/or 3.
That the protein can mislocalise under cellular stress.
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A small number of substrates have been identified to interact with cyclin F,
predominantly in regulating DNA maintenance roles in mitotic cells. These
substrates of cyclin F include: nucleolar spindle associated protein (NuSAP) which is
associated with spindle formation of microtubules (Emanuele et al., 2011;
Raemaekers et al., 2003); the aforementioned CP110, which regulates centrosome
production during S phase (Chen et al., 2002; D’Angiolella et al., 2013).
Ribonucleotide reductase family member 2, (RRM2) which catalyses ribonucleotide
conversion to dNTPs - during G2, SKP1-CUL1-F-box-1 is the only ubiquitin ligase
that controls the degradation of RRM2, making its activity crucial for maintaining
DNA synthesis and repair (D’Angiolella et al., 2012); Myb-related protein B (BMyB), which is a transcription factor - found to be suppressed by cyclin F binding
(which inhibited phosphorylation) following UV damage; and exonuclease-1 EXO1
which is a 5’-3’ exonuclease (Elia et al., 2015; Klein et al., 2015).

The functional role of cyclin F is not yet fully understood in the context of ALS. To
date, seven studies have been published concerning CCNF mutations in ALS; no
studies have yet examined cyclin F in viable patient derived motor neurons.
Preliminary cellular mechanistic studies by Williams and colleagues (2016), have
indicated that mutant cyclin F may cause ALS through UPS dysfunction, and finding
an increase in ubiquitinated TDP-43, indicating it as a likely substrate. The cellular
role of cyclin F as a cell cycle regulator/DNA maintenance protein would logically
differ in a post-mitotic motor neuron. As cyclin F is an ubiquitin ligase, Williams et
al (2016) examined the potential role of cyclin F in the UPS. To determine protein
clearance, a protein clearance assay was performed. The group found that Neuro2As
had an increased propensity to retain proteins following the over -expression of eight
61

of the different mutant cyclin F forms, compared to wild type cyclin F. Investigation
into the proteasome activity indicated mutant cyclin F had no effect on proteasomal
activity, implicating the ubiquitin system of the UPS.

Immunoblotting of co-

immunoprecipitated ubiquitin in Neuro2A cells with overexpressed wild type, or
mutant CCNFS621G, indicated an increase in ubiquitinated TDP-43, as well as a cyclin
F substrate, RRM2. Together these findings indicate that these forms of mutant
cyclin F can cause ubiquitin system dysfunction (Williams et al., 2016).

The disease mechanism of CCNFS621G has since been followed up by members of this
same group: expression of human CCNFS621G in zebrafish was found to elicit more
aberrant neurite branching and reduce photomotor responses (response to light
stimulus as a nervous system activity indicator) compared to the WT (Kokel and
Peterson, 2011). Measurement of the positive responders also indicated a decreased
response in the CCNFS621G in zebrafish compared to the WT (Hogan et al., 2017).
Cyclin F expressed in HEK293 cells indicated seven phosphorylation sites in cyclin
F including at S621, which had previously been suggested by Kong et al., (2000).
This study indicated that the mutation S621G prevented phosphorylation, thereby
leading to an increase in ubiquitination activity. Examination of the expression of
CCNFS621G in Neuro2As and SH-SY5Y cells indicated increase in degradation
signaling ubiquitination (Lys48); further examination of the proteins that were K48
ubiquitin

tagged following

CCNFS621G expression indicated an

increased

ubiquitination of proteins associated with autophagy and the heat shock response
(Lee et al., 2018).
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To date, studies into CCNFS621G have relied on the overexpression of proteins. More
studies are required, however, to ascertain the function of the protein at endogenous
level; this will be important to determine if there is only one mechanism affected by
ALS causing mutations, or if multiple mechanisms may contribute to
neurodegeneration. It is clear is that cyclin F is an important protein in the cell cycle
and is central to proteostasis. Further understanding of the effects of mutations in
CCNF will be critical for elucidating potential therapeutics to provide reprieve. For
ALS research, furthering our understanding of the role of this cyclin F could provide
significant insight into ALS pathogenesis, particularly regarding the ubiquitin
system. Identifying why cyclin F mutations cause ALS is therefore a crucial task.

1.7 Induced pluripotent stem cells in ALS research

1.7.1

Pluripotent stem cells provide access to previously inaccessible cells

In 2006, Takahashi and Yamanaka successfully reprogrammed murine fibroblasts
into a pluripotent state, creating the first induced pluripotent stem cells (iPSC)
(Takahashi and Yamanaka, 2006). These iPSCs have a high rate of proliferation, are
immortal, and most importantly, can differentiate into any cell types (Takahashi and
Yamanaka, 2013). The upregulation of four key pluripotency factors (Oct3/4, Sox2,
Klf4 and c‐Myc also known as OSKM factors) via lentiviral transduction altered
cellular phenotype via genome insertion, directing the cells into a state of
pluripotency(Takahashi et al., 2007). Nine years later this general principle is still
applied, though reprogramming is often carried out without the use of lenti viruses or
sendai viruses. Instead, techniques such as multiple synthetic mRNA transfections of
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the OSKM factors are used to generate pluripotent stem cells (Warren et al., 2010;
Yakubov et al., 2010) free from viral contaminants. For neurodegenerative research
these cells provide the tools to recapitulate neurodegenerative diseases such as ALS
‘in a dish’ (Takahashi and Yamanaka, 2013).

The ability to generate stem cells from a non-embryonic source eliminated the ethical
controversy that had previously plagued embryonic stem cell research. The concept
of iPSCs generated opportunities for patient specific medicines, and excited the
possibility for genetically identical models (Ooi et al., 2013). Today, iPSC research
divides into four fundamental areas: 1. Cellular replacement therapies research,
wherein cells are generated with the aim to be placed back into the in vivo
environment (including as entire organs); 2. Drug development research; 3. Cellular
modelling for mechanistic studies, to better understand disease; 4. Stem cell research,
which focuses on development and improvement of the generation of iPSCs through
reprogramming (Ebert et al., 2012).

1.7.2

Patient derived neurons are drastically changing ALS research

Patient derived iPSCs are a compelling research tool for investigating ALS. Indeed
ALS was the first neurodegenerative disease to be modelled using iPSCs. In 2008,
Dimos et al. successfully differentiated motor neurons from an ALS patient using the
cells to generate embryoid bodies, then generated spinal motor neurons and glial
cells. The group demonstrated the generation of neurons that expressed the motor
neuron specific markers homeobox protein 9 (HB9), and islet 1 and 2 (ISL1 and
ISL2). While this group did not demonstrate whether the neuron electrophysiology
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was similar to in vivo motor neurons, nor examine disease phenotype, this research
introduced the idea of iPSC modelling into ALS research (Dimos et al., 2008).

1.7.3

Disease phenotypes are displayed in ALS iPSC derived neurons

Proteostasis dysfunction has been identified repeatedly in independent ALS iPSC
research. Almost every iPSC derived motor neuron study of TDP-43 has observed
an increase in TDP-43 levels compared to controls (Bilican et al., 2012; Burkhardt et
al., 2013; Egawa et al., 2012; Nishimura et al., 2014; Serio et al., 2013; Zhang et al.,
2013). Many have reported TDP-43 mislocalisation (Burkhardt et al., 2013; Serio et
al., 2013; Zhang et al., 2013), decreased neuronal survival, (Bilican et al., 2012;
Serio et al., 2013) and increases in TDP-43 associated with aggregates (Egawa et al.,
2012), matching post mortem findings. Interestingly, Burkhardt et al. (2013) saw
TDP-43 inclusions in SALS patient iPSC derived motor neurons, which matched the
same patient post mortem, pathology. The only study that has reported no difference
in TDP-43 concentration and aggregate formation in ALS derived cells compared to
controls was by Liu-Yesucevitz et al. (2014) The group compared an iPSC line
derived from a patient with a TDP-43G298S mutation to a healthy control line, finding
no significant difference in TDP-43 concentrations or aggregates as measured by
western blot quantification and immunocytochemistry respectively (Liu-Yesucevitz
et al., 2014). These findings are contrary to previous reports, though could be due to
alternate differentiation protocols, and incomplete characterisation: The group failed
to characterise the type of neuron examined, determining only that the cells
expressed neuronal markers βIII tubulin (βIII TUB), microtubule associated protein 2
(MAP2) and choline acetyltransferase (ChAT), omitting motor neuron specific
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markers HB9, ISL1, and ISL2. This omission is disappointing considering the
fundamental involvement of motor neurons in ALS, particularly in early stage
disease.

The authors’ suggestion that TDP-43 aggregation could increase with

culture time in these neurons is inconsequential for identifying early stage events that
translate to clinical ALS if they remain unwilling to determine the neuronal subtype
of their cells. Overall, the TDP-43 models have shown agreement between patient
derived samples analysed by different groups, a positive step towards confirming the
use of iPSC derived motor neuron models and suggests that iPSC derived neurons
are an excellent model for investigating proteostasis in ALS (Lee and Huang, 2017).

Patient iPSC derived neuron models have been used to examine early stage events in
ALS pathogenesis (Kiskinis et al., 2014; Wainger et al., 2014). Throughout the
differentiation and maturation of iPSCs into motor neurons, it has been possible to
examine disease progression, modelling disease mechanisms that can occur in vivo
(Han et al., 2011). This is perhaps the most potent feature of the iPSC derived
neurons, as it is possible to monitor patient specific changes in cellular metabolism
prior to the clinical presentation stage of the disease (Ooi et al., 2013). Already, this
ability to examine early stage events by iPSC derived motor neurons has yielded
important findings in ALS research. In early 2014, neurofilament aggregates were
found to form in early stage disease in iPSC–derived motor neurons (Chen et al.,
2014). The formation of neurofilament aggregates in motor neurons differentiated
from SOD1D90A patient iPSCs was investigated; the concentration of the aggregates
formed in the cells were similar to those seen in patients and significantly, the
formation of neurofilament aggregates preceded neurite swelling and degeneration.
Devlin et al. (2015) recently used iPSC derived motor neurons to address the changes
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in electrophysiology that occur in early stage ALS (Devlin et al., 2015). Previous
reports on electrophysiological properties of motor neurons had been conflicting in
the field; Wainger et al. (2014) had reported that SODA4V patient iPSC derived motor
neurons had exhibited hyperexcitability following 28 days of culture. Seemingly
contradictorily, Sareen et al. (2013) had previously reported that C9orf72 repeat
expansion patient derived motor neurons exhibited a reduced action potential output
(hypoexcitability) following 56 days of culture (Sareen et al., 2013). Devlin et al.
(2015) suggested that in fact, these cellular phenotypes could be sequential events in
disease progression; in a longitudinal electrophysiology study of TDP-43 and
C9orf72 repeat expansion patient derived motor neurons, the group found that both
ALS affected cell lines had initial repetitive firing in the first six weeks of culture,
corroborating with the Wainger et al. (2014) findings. This hyperexcitability then
significantly decreased in the following four weeks of culture, as cells exhibited a
progressive decrease in action potential output when measured at a similar culture
time to Sareen et al. (2013), highlighting the impact of differences in differentiation
protocols - particularly time. This phenotype change from hyperexcitability to
hypoexcitabilty reflects that seen in patients, reiterating the strength of these models
(Devlin 2017). Importantly, these cells provide the opportunity to examine early
stage events in ALS patient derived model.
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1.8 Summary and directions of this study
Using iPSC-technology it is possible to investigate the role of the UPS, not only in
the context of ALS, but in the development of motor neurons - from the implications
of the system in reprogramming fibroblasts to iPSCs, in maintaining these stem cells,
and in the differentiation of the cells to the final motor neuron models. Here, in this
study iPSCs have been successfully generated from both healthy donor and from
CCNFS621G patient (pre-symptomatic and symptomatic for ALS) fibroblasts.

A

robust protocol to generate motor neurons was established for the first time in the
Ooi laboratory, yielding neuronal cells positive for motor neuron markers at a high
purity. ALS patient iPSC derived motor neurons exhibited distinct phenotypes from
those derived from the healthy controls; In some cases these ALS motor neurons
were different from previously established sporadic Alzheimer’s disease patient iPSC
derived motor neurons (Balez et al., 2016). This study highlights the strength of
these models in expressing a disease relevant phenotype, as detectable via both bias
and unbiased approaches, in a patient derived model. These studies move towards
establishing potential screening models for diagnostic biomarkers, which is crucial
for effective therapeutic intervention. Moreover, these cells represent an important
addition to the therapeutic development pipeline; these cells will likely prove an
important tool in validating the effects of novel drugs on a human neuronal model
unhindered by protein overexpression, and broadly serve to improve our
understanding of the UPS.

68

1.9 Hypotheses of this study
1. Fibroblasts derived from symptomatic and pre-symptomatic CCNFS621G
patients, as well as healthy donor derived fibroblasts can be reprogrammed to
iPSCs, and differentiated to iPSC derived motor neurons.

2. Disease relevant phenotypes can be modelled using iPSC derived motor
neurons from CCNFS621G and SOD1E101G ALS patients.

3. The ubiquitomes of iPSC derived motor neurons are different from derivative
cell types (fibroblasts and pluripotent stem cells), and within individuals in
motor neurons.

1.10 Aims of this study
1. Generate motor neurons using iPSCs from fibroblasts derived from patients
with ALS, and healthy donors, including CCNFS621G ALS patients.

2. Quantify ALS-relevant proteins TDP-43 and Cyclin F, and UPS dysfunction
in iPSC derived motor neurons from ALS patients compared to healthy donor
derived cell lines.

3. Compare the ubiquitomes of iPSC derived motor neurons to derivative cell
types (fibroblasts and pluripotent stem cells) and between different cell lines
in motor neurons.
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Chapter Two:

Methods and Materials
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2 . METHODS AND MATERIALS

Experiments in this study were carried out as described in this methods section (2.1
Methods). All equipment and reagents referred to in the Methods section are
described in detail in the Materials section (2.2 Materials). Experiments were
carried out using cell lines described in Table 2.1, using media and solution
compositions described in Table 2.2, with reagents described in Table 2.3, and
equipment described in Table 2.4. Software used in these experiments are described
in Table 2.5. Plasmids, primers and antibodies utilised in this study are described in
Table 2.6, 2.7, and 2.8 respectively. Consumables used are described in
Supplementary Table 7.1.

2.1 Methods

2.1.1

General cell culture

The range of different cell lines and cell types of this study (Table 2.1) were used in
accordance with Human Research Ethics application (HE13/272), in conjunction
with a Materials Transfer Agreement (MTA; Ethics HREC/11/CRGH/179). Patient
and healthy donor derived fibroblasts, generously donated to the Macquarie
University Motor Neuron Disease Centre, were supplied by A/Prof Ian Blair, and
prepared by Dr Shu Yang (Macquarie University, Australia). The fibroblasts were
attained by skin punch from low UV exposed tissue, to minimise the potential
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collection of cells with genetic abnormalities caused by UV damaged. NSC34 cells
were kindly donated by Neil Cashman (University of Toronto, Canada) and a stock
was prepared by Natalie Farrawell (University of Wollongong), HEPG2 cells were
previously cultured by Natalie Farrawell, and were kindly supplied by the Prof Mark
Wilson (University of Wollongong) from stocks. C2C12 cell stocks, prepared by Dr
Rodrigo Lozano (University of Wollongong), were kindly gifted by the Dr Elise
Stewart (University of Wollongong). Snuff cells were purchased from StemGent.
The iPSC lines SAD (derived from a sporadic Alzheimer’s disease patient), and HC2
(derived from an age- and sex-matched healthy donor) were kindly gifted from the
laboratory of A/Prof Kuldip Sidhu (University of New South Wales, Australia)
(Chung et al., 2012). Fibroblasts from the SOD1 cell line (derived from ALS patient
MQ130054 with SOD1E101G mutation) were provided under the MTA by the
Macquarie University Motor Neuron Disease Centre; these fibroblasts were
reprogrammed using mRNA reprogramming by Rachelle Balez.

Cells were cultured at 37°C in 5% CO2, and maintained as described in General cell
culture, unless otherwise stated. All cells centrifugation was carried out in a 15 mL
centrifuge tube at 300 x g for 5 minutes unless otherwise stated. Cell passage
number, as well as general morphology was monitored to ensure cells did not reach a
high passage (relative to each cell type). Routine mycoplasma testing of cell lines
was carried via supernatant samples of each cell line provided to technical officers
(at the Illawarra Health and Medical Research Institute). Short tandem repeat (STR)
analysis was performed as described in this chapter.

72

Cells were cultured in tissue culture flasks in General Culture Media, which was
changed three times a week. Cells were passaged upon reaching 80% confluency;
Cells were washed with phosphate buffered saline (PBS) treated with 0.05% Trypsin/
ethylenediaminetetraacetic acid (EDTA) for 2 mins to detach cells. Cells were
dislodged by tapping the flask, and trypsin was inactivated by the addition of serum
containing General Culture Media. Cells were collected and centrifuged at 800 x g,
for 5 mins. The supernatant was aspirated and the cells were resuspended in General
Culture Media. Cells were seeded at a density of 1.25 x 103 cell/cm2. For long-term
storage, cell stocks were generated. Cells were detached and pelleted as per
passaging method.

The cell pellet was resuspended in General Culture Media

containing 10% dimethyl sulfoxide (DMSO). Resuspended cells were stored in
cryovials and cooled to -80oC in a Mr Frosty freezing container overnight. Cells
were moved to long-term storage in liquid nitrogen vapour cryotank. Cells were
thawed as required; Cells were quickly reheated to 37oC in a water bath. Once the
cells had defrosted, cells were aspirated and placed into 5 mL of warm General
Culture Media in a 15 mL centrifuge tube. The cryovial was then washed with 5 mL
of pre-warmed Dulbecco’s modified eagle medium with F12 supplement
(DMEM/F12) to ensure all cells were collected, and the media was gently added to
the cells. Cells were pelleted via centrifugation, the supernatant was removed and
cells were gently resuspended in General Culture media, and plated in a tissue
culture flask.
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2.1.2

Reprogramming fibroblasts to iPSCs

Three fibroblast cell lines were reprogrammed for the purpose of this study. Cell
lines from a healthy female, a pre-symptomatic CCNFS21G female (who became
symptomatic during the course of this study), and a symptomatic CCNFS21G male
were reprogrammed using a microRNA enhanced mRNA reprogramming kit. The
reprogramming was carried out as per the manufacturer’s recommendations; Prior to
reprogramming, pluriton media was conditioned using NuFF cells as described by
the StemGent Generating NuFF-Conditioned Pluriton Medium Protocol; NuFF cells
were thawed and cells were seeded at a density of 26.6 x 103 cells/cm2 in a T75 flask.
NuFF cells were incubated overnight. Cells were washed with PBS to remove the
General Culture Media, and the cells were cultured in 20 mL pluriton media
supplemented with basic fibroblast growth factor (bFGF; 4 ng/mL) overnight. The
conditioned media was collected and replaced daily for 10 days. The conditioned
pluriton was filtered and frozen until required. Conditioned pluriton was
supplemented with recombinant protein B18R and pluriton supplement immediately
prior use in culture.

Fibroblasts were plated in Matrigel coated 6 well plates at a density of 5 x 103
cells/cm2, 1 x 104 cells/cm2 and 2.5 x 104 cells/cm2 as described in General cell
culture. On day 0 of the reprogramming protocol, fibroblasts were washed with PBS
to remove the fibroblast media, and cultured in pre-warmed conditioned pluriton
media for 2 h. A microRNA transfection complex solution was prepared in a low
binding microtube by adding Stemfect Buffer (64.5 µL) to a prepared microRNA
cocktail (10.5 µL) and mixing gently. In a separate low binding microtube, RNA
74

transfection reagent (12 µL) and Stemfect Buffer (63 µL) was also gently mixed and
left to incubate for 5 min at room temperature. The transfection reagent-buffer
solution was gently mixed with the microRNA solution, and left to incubate at room
temperature for 15 minutes. The microRNA transfection complex (50 µL) was added
dropwise to the 3 reprogramming, without piercing the surface of the media by
holding the plate at a 45 degree angle. The plate was rocked in an X and Y plane, to
minimise the adherence of the transfection complex to the plate.

Cells were

incubated overnight. On day 1, the transfection complex containing media was
removed and replaced with fresh pre-warmed conditioned pluriton as per day 0. A
mRNA transfection complex solution was prepared in a low binding microtube by
adding Stemfect Buffer (45 µL) to a prepared mRNA cocktail (30 µL; mRNA molar
stoichiometry 3:1:1:1:1:1 Oct4:Sox2:Klf4:c-Myc:Lin28:nGFP) and mixed gently. In
a separate low binding microtube, RNA transfection reagent (12 µL) and Stemfect
Buffer (63 µL) was also gently mixed and left to incubate for 5 min at room
temperature. The transfection reagent-buffer solution was gently mixed with the
mRNA solution, and left to incubate at room temperature for 15 minutes. The
mRNA transfection complex (50 µL) was added dropwise to the 3 reprogramming
wells, as per the microRNA transfection complex. Cells were incubated overnight.
The mRNA transfection was repeated on day 2, 3, 5 - 11 of reprogramming. On day
4, cells were co-transfected with both the microRNA and the mRNA transfection
complexes.

On day 12 of reprogramming, the transfection complex containing media was
removed. Cells were cultured in conditioned pluriton media for 4 days, with daily
media changes as iPSC colonies formed. These colonies were gently collected using
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a 1000 µL pipette, and replated into a 24 well Matrigel coated tissue culture plate.
Each colony was plated and cultured separately as different clones. These clones
were expanded upon reaching 80% confluency, or when the colonies appeared to be
growing densely in the middle of the colony. Clones were passaged and expanded to
larger plates until enough cells were present to plate onto a 60 mm tissue culture
plate.

2.1.3

Culturing iPSCs

All iPSC lines used in this study were cultured as follows unless otherwise stated.
The iPSCs were cultured in TeSR E8 supplemented with 10,000 U/mL penicillin and
10 mg/mL streptomycin on 60 mm tissue culture plates coated with Matrigel, diluted
in DMEM/F12. Spontaneously differentiating cells were removed using a 20 µL
pipette tip, prior to the daily media changes. Cells were passaged upon reaching
80% confluence. The iPSC cultures were incubated with 1 mg/mL dispase for 3 min
at 37oC. Dispase was aspirated and cultures washed three times with DMEM/F12.
Colonies were gently detached into DMEM/F12 using a cell scraper, and centrifuged.
Supernatant was aspirated and the cells resuspended in TeSR E8, triturating cells into
even sized cell clumps. A cell clump count was performed and cells were evenly
distributed on a Matrigel coated 60 mm tissue culture plate at 1000 cell clumps per
plate.

In addition to these three reprogrammed lines, a further three lines were utilised for
experiments. The iPSC lines 10.13 (derived from a sporadic Alzheimer’s disease
patient), and 1.4 (derived from an age- and sex-matched healthy donor) were kindly
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gifted from the laboratory of A/Prof Kuldip Sidhu (University of New South Wales,
Australia) (Chung et al., 2012). The iPSC line MQ54.2 (derived from ALS patient
MQ54, who had a mutation at SOD1E101G) was also reprogrammed using mRNA
reprogramming by R. Balez.

For long-term storage iPSC cells stocks were generated. Stem cells cultured for 5-6
days were passaged as aforementioned; the cell pellet was gently resuspended in cool
mFreSR to ensure larger colonies were maintained. Cells were then gently
transferred to a cryovial, and slowly cooled to -80oC in a Mr Frosty freezing
container overnight. Cells were then moved to the -190oC cryotank for long-term
storage. To recommence cell culture, the cryovials were retrieved from cryogenic
storage and quickly thawed in a water bath at 37oC. Cells were gently aspirated to
minimise colony disruption, and placed in a 15 mL centrifuge tube. The cryovial was
then washed with 5 mL of pre-warmed DMEM/F12 and the media was gently added
to the cells. Cells were centrifuged, and the cell pellet was resuspended in TeSR E8
with Rho-associated protein kinase (ROCK) inhibitor (10 µM), and plated onto 60
mm Matrigel coated plates.

2.1.4

Characterising and selecting appropriate iPSC clones

Stem cells clones were selected based on morphology, gene expression and protein
expression. The first stage of pluripotency assessment was based on observations of
morphology. Cells were examined daily for stem cell like morphology; Stem cells
exhibit a round simple morphology, with a large dark nucleus observable under 4X
magnification; iPSCs grow in colonies and are capable of self-renew with quick
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proliferation. Clones that exhibited this morphology were selected for further
examination as a potential clone. Gene expression was determined by quantitative
reverse transcription polymerase chain reaction (qRT-PCR; see Relative gene
expression), and by the PluriTest.

Protein expression was determined by

immunocytochemistry (see Protein expression). Selected clones were verified by
genome analysis, karyotype analysis and by the ability to differentiate into the three
germ layer tissues (endoderm, mesoderm and ectoderm). Cells of each germ layer
tissues were characterised by morphology, relative gene expression and protein
expression (see Relative protein expression and Protein expression).

2.1.5

PluriTest

An iPSC clone from each of the three cell lines was further verified for pluripotency
expression via the PluriTest. RNA samples were purified and concentrations were
calculated as described in Relative Gene Expression. RNA samples (500 ng) were
submitted to Genea (Sydney, NSW, Australia) for testing. The microarray assay
was performed on an Illumina HT12 Chip according to (Müller et al., 2011) as subcontracted by Genea Biotech. Scores including the non-negative matrix factorization
generated novelty score, and logistic regression model pluripotency scores were
generated using microarray data. These scores are determined by comparison of gene
expression to previously characterised stem cell gene expression profiles as well as
the gene expression profiles of other cell types.
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2.1.6

Genomic analysis

2.1.6.1 Short tandem repeat analysis
In order to confirm the cell lines were not subjected to any detectable genetic
abnormalities following reprogramming, ensure cell lines were not misidentified, and
verify that no cross-contamination had occurred, the STR loci of the reprogrammed
iPSC genomes were compared to the fibroblasts from which they originated. Cells
from the respective cell stages were cultured and passaged for collection as
previously described. Once cells were pelleted by centrifugation, the respective pellet
was washed in PBS and transferred to a microtube. The cells were again centrifuged,
and the PBS was removed from the pellet. The cell pellet was stored at -80°C.
Samples were delivered to the Garvan Institute for STR analysis of microsatellite
profiles. Loci of tetra and pentanucleotide repeats from 18 established loci were
amplified via PCR (from DNA extracted from the cell pellets). Resulting STR
profiles were compared to one another, and to the American Type Culture Collection
database, the Deutsche Sammlung von Mikroorganismen und Zellkulturen database
and internal institute database.
2.1.6.2 Gene specific analysis
2.1.6.2.1 Genomic DNA Purification for CCNF Sequencing

To confirm the genotype of the cell lines were as previously reported, a gene specific
analysis was performed via PCR. Genomic DNA was purified using the Invitrogen
PureLink Genomic DNA kit as per manufacturer’s recommendations.

Anterior

neural precursor (aNPC) cells were washed twice with PBS, scraped using a cell
scraper and collected in a 15 microfuge tube. Cells were centrifuged at 800 x g for 5
mins to pellet and PBS was removed. Cells were further separated via trypsin
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incubation for 5 min at room temperature. An equal part trypsin inhibitor was added
to inactivate the trypsin. Cells were transferred to a microtube, centrifuged at 300 x g
for 5 minutes at room temperature; the supernatant was removed. Cell pellet was
resuspended in PBS (200 µL), proteinase K (20 µL) and RNase A (20µL) and
incubated at room temperature for 2 min. Cells were digested by incubating in
PureLinkR Genomic Lysis/binding buffer (200 µL) at 55oC for 10 min. Ethanol
(200µL; 100%) was added to lysate. Unwanted cellular material was removed by
adding the lysate solution to the PureLinkR Spin Column and centrifuging at 10,000
x g at room temperature for 1 min. DNA was washed by adding PureLink Genomic
Wash Buffer 1 (500 µL) to the column and centrifuging at 10,000 x g at room
temperature for 1 minute, followed by the addition of PureLink Genomic Wash
Buffer 2 (500 µL) to the column and centrifuging at 10,000 x g at room temperature
for 3 minutes. DNA was eluted by incubating PurelinkR genomic elution buffer (80
µL) in the column at room temperature for 1 min, and spinning at 3000 x g at room
temperature for 1 min. This step was repeated to increase DNA yield. The
concentration and purity (A260/A280 ratio) of the eluted DNA was measured on the
nanodrop.
2.1.6.2.1

Amplifying CCNF

The Cyclin F genotype was verified with CCNF primers CCNF E16F and CCNFE16R designed by Dr Tracey Berg for the mutated region (bp 621) using Snapgene
software.

To amplify the region of interest in the genomic DNA, PCR was

performed using Primestar reagents. Primestar buffer (diluted in solution to 1X),
dNTPs (2.5 mM), sense and antisense primers CCNF-E16F (2 µM) and CCNF-E16R
(2 µM), polymerase and water were added to the purified genomic DNA. The PCR
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solution was heated to 98oC for 30 s followed by 30 rounds of heating to 98oC for
10s, 58oC for 10 s, 58oC for 10s, 72oC for 10. Samples were cooled to 72oC for 10s
then cooled to 4oC. Sequencing was performed at the University of Wollongong,
School of Biology by Research Technical Officer Margaret Phillips.

2.1.6.2.2

Gene Expression Analysis

PCR product was verified by gel electrophoresis by Dr Tracey Berg. The PCR
product (3µL) was added to bromophenol blue loading dye (1.5 µL) and loaded into
an agarose gel (1%), along with a 100 bp ladder (3 µL; diluted 1:1 in loading buffer).
An 85V current was applied to the gel for 40 min. The gel was stained and imaged.
Bands present in the sample lanes were compared with the 100 bp ladder.

2.1.6.3 Karyotype analysis
To ensure reprogramming had no effect on the chromosomal integrity of the cell
lines, a karyotype analysis was performed. Induced pluripotent stem cells were
cultured in a T25 flask until 25% confluent. Cells were then transported to Stem
Core (University of Queensland, Australia) to be analysed for any chromosomal
anomalies. Cells were arrested at metaphase and chromosomes were G-banded. 1530 cells were assessed at a resolution of 400 bphs.
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2.1.7

Differentiation to three tissue types

2.1.7.1 Endodermal cell type differentiation
Endodermal progenitors were differentiated using an endodermal progenitor
differentiation protocol from Stem Cell Technologies.

Five days following

passaging, iPSC colonies were dissociated using a 5 min accutase (1X) treatment.
Accutase was inhibited with trypsin inhibitor (1 mg/mL), and cells were collected in
DMEM/F12 and centrifuged. Cells were resuspended in TeSR E8 supplemented
with ROCK inhibitor (10 µM), and plated at 2.1 x 105 cells/cm2 on Matrigel coated
plates. On day 1, the media was aspirated and cells were washed with DMEM/F12.
Cells were cultured overnight in STEMdiff definitive endoderm basal media
supplemented with STEMdiff Definitive Endoderm Supplement B (1% v/v) and
STEMdiff Definitive Endoderm Supplement A (1% v/v). On day 2, a full media
change was performed, and cells were cultured in STEMdiff definitive endoderm
basal media supplemented with STEMdiff Definitive Endoderm Supplement B (1%
v/v) for four days, with daily media changes to generate endodermal progenitors. On
day 5 the endodermal progenitors were harvested for characterisation.
2.1.7.2 Mesodermal cell type differentiation
Myoblasts, originating from mesodermal cells, were differentiated using a protocol
adapted from Caron et al., 2014. On day 0, cells were dissociated into single cells by
treating with accutase for 5 minutes. Accutase was inactivated via the addition of
trypsin inhibitor (1 mg/mL), added 1:1 with accutase. 5 mL of DMEM/F12 was then
added, and the cells were pelleted via centrifugation. The cells were resuspended in
skeletal muscle induction media (stage 1) and plated in collagen I coated plates
(coated overnight) at 2,500 cell/cm2. Cells were incubated in hypoxic conditions
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(5% CO2, 5% O2), at 37oC, with three partial media changes a week for 10 days. On
day 11, cells were again passaged with accutase as described for day 0, though were
resuspended in skeletal muscle media (stage 2). Cells were maintained for 1 week.
On day 18, the skeletal muscle media (stage 2) was aspirated, and replaced with
skeletal muscle maturation media. Cells were then incubated in normoxic conditions
for two weeks with three partial media a week. Cell morphology was compared to
C2C12 cell line morphology as a positive control.

2.1.7.3 Ectodermal Cell Type Differentiation: Motor Neuron Differentiation
Ectodermal derived cells were the primary cell type of interest in this study; iPSCs
were differentiated into motor neurons using a protocol adapted for this study from
Qu et al., 2014 and Bilican et al., 2014. The iPSC colonies were washed with PBS
and colonies were collected in neural induction media using a cell scraper (Table
2.1). Cells were plated in a non-tissue culture plate and incubated for three days. A
partial media change was performed on day 2. The floating embryoid bodies formed
by day 4 were collected and plated on a pre-coated laminin (20 µg/mL) tissue culture
plate. Partial media changes were performed three times a week for two weeks,
during which time neural rosettes formed. These rosettes were manually isolated and
plated on 60 mm tissue culture dishes which were pre-coated overnight with collagen
I (10 µg/mL), washed with PBS and coated for 1 h with laminin (10 µg/mL),
fibronectin (10 µg/mL) and collagen in aNPC Media prior to use.

Cells were

maintained in aNPC Media with partial media changes 3 times a week until plates
were 80% confluent.
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To prepare cells for the final differentiation phase, aNPCs were accutase treated and
seeded at 3.125 x 103 cells/cm2 and cultured for seven days. Cells were caudalised
by the addition of increasing retinoic acid over three days (0.3 µM). Cells were
cultured in motor neuron precursor media for seven days with a partial media change
three times a week. Media was gradually changed to Motor Neuron Media through
half media changes, which were performed three times a week. Cells were matured
for six weeks.

2.1.8

Relative gene expression

To evaluate relative gene expression in different cell types, qRT PCR was
performed. Respective cells were thoroughly washed in PBS, then collected in TRI
reagent (800 µL) using a cell scraper in ensure all cells were collected. RNA was
purified using TRI reagent; at this stage samples were stored at -80oC for a maximum
of two months before continuing purification. All mRNA samples were kept on ice at
all times, unless stated to ensure minimal sample degradation. TRI reagent samples
were incubated with chloroform (200 µL; 5 min). RNA was collected from the top
aqueous phase after the solution was centrifuged (5 min; 12,000 x g). Nucleic acids
were precipitated using an incubation with ice-cold isopropanol (500 µL; -20oC for
30 minutes). A nucleic acid pellet was collected via centrifugation at 4oC for 10 min
at 12,000 x g. The pellet was washed in 70% ethanol (v/v) and centrifuged for 5 min
at 12,000 x g. The supernatant was aspirated, and the pellet air-dried before
resuspension in 40 µL tris EDTA pH 8.0. Nucleic acid concentrations and sample
purity concentrations were then calculated using a UV-vis spectrophotometer
(Nanodrop 2000C). The nucleic acid was treated with Ambion TURBO DNA-free
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as per manufacturer’s instructions to remove genomic DNA contamination. Nucleic
acid samples were diluted in nuclease-free water to a concentration of 200 µg/mL, in
a final volume of 50 µL, and mixed with 1X TURBO DNase buffer with 1 µL
TURBO DNase. The DNase solution was incubated for 1 h at 37oC before the
addition of DNase inactivation reagent.

Following incubation (5 min) at room

temperature, the solution was centrifuged at 12,000 x g for 90 s and the supernatant
containing the purified RNA was collected. The RNA concentration was measured
again. To reverse transcribe RNA to complimentary DNA (cDNA), 1 µg total RNA
was annealed with 0.5 g oligo(dT) and 0.5 g random primers at 65oC for 4 mins,
then incubated on ice for 1 min. The RNA reaction was performed with 1X buffer, 2
mM dNTPs, 200U MM-LV RTase, 40U RNasin (per sample) at 37oC for 2 h. To
quantitate cDNA levels, the Express SYBR GreenER qPCR Supermix Universal kit
was used according to the manufacturer’s instructions. Each sample of template
cDNA (2 µL) was reacted with a master mix containing 200 nM of both sense and
antisense primers, with 10 µL EXPRESS SYBR GreenER qPCR supermix made up
to 20 µL with nuclease free water.

Primers designed for coding regions of genes

listed in Table 2.7 were utilised. To quantitate gene expression levels, cDNA was
analysed with the quantitative real time PCR Instrument. Reactions were heated to
95oC for 5 min annealing at manufacturer indicated primer temperature denaturing
for 40 cycles at 95°C for 10 s, annealing at specific primer Tm for 10 s and extension
at 72°C for 10 s. A melt curve was obtained by ramping the temperature from 37oC
to 95oC at a rate of 2oC/min. A final cooling phase of 37oC for 5 min was performed.
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2.1.9

Plasmid amplification

2.1.9.1 Plasmid transformation
In order to carry out plasmid-based assays, the mCherry empty vector and the degron
(µGFP) plasmids were amplified via bacterial amplification. Chemically competent
bacteria (JM109 strain of Escherichia coli) were defrosted on ice. Two aliquots of
bacteria (50 µL) were treated with β-mercaptoethanol (2 µL) and incubated for 10
minutes. The solution was gently mixed by swirling every two minutes during this
incubation. The plasmid (between 10-50 ng) was added to the bacteria in one aliquot.
No plasmid was added to the negative control aliquot. The bacteria cells were then
heat pulsed by incubating at 42oC for 30 s, followed by incubation on ice for 2 min.
Lysogeny broth (LB; 900 µL; 15% agar, 10% NaCl, 10% tryptone, 5% yeast extract
in MilliQ H2O), once heated to 42oC was added to the cells, which were incubated
for 1 h at 37oC on a shaker at 250 rpm. Cells were streaked onto freshly prepared
kanamycin (50 µg/mL) LB agar plates with a cell spreader. Cells were also plated
onto a positive control plate, containing no antibiotic and a negative control plate
containing ampicillin (100 µg/mL; no ampicillin resistance gene was present in the
plasmids amplified). Plates were incubated upside-down for 16 h at 37oC. If no
colonies were growing on the negative control, the plates were placed upside-down
at 4oC for 8 hours.

A colony from the kanamycin plate was collected with an

inoculation loop. The colony was streaked out (16 streak) on agar plates. The plates
were incubated upside-down for 16 h at 37oC. A single colony was then selected
with an inoculation loop and incubated in pre-warmed LB broth (37oC) containing
kanamycin (25 µg/ml) and ampicillin (50 µg/ml) for 4 hours. This bacterial solution
was then further diluted five fold in the antibiotic-containing LB broth and incubated
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at 37oC for 16 hours on the shaker (180 rpm). The bacteria were pelleted via
centrifugation at 4000 x g for 10 min. Supernatant was discarded at cell pellet was
frozen at 20oC.

2.1.9.2 Plasmid purification
Plasmids were purified following bacterial amplification using Qiagen Maxiprep kit
as per the manufacturer’s recommendations. The cells were lysed by incubating the
cell pellet in RNase A containing P1 lysis buffer (10 mL), and the P2 buffer (10 mL)
for 5 minutes at room temperature. LyseBlue solution was used to a homogenous
mixing of the solutions. To remove the bacterial genomic DNA and the bacterial
debris, the P3 buffer was vigorously mixed to the lysis solution and incubated on ice
for 20 min; the plasmid was collected from the supernatant following centrifugation
at 20,000 x g at 4oC for 30 min, and again for 15 minutes. The plasmid containing
supernatant was run through an equilibrated QIAGEN-tip column by gravity flow.
To remove any contaminants the column was washed with the QC buffer (60 mL).
The plasmid DNA was eluted from the column with the elution buffer (15 mL). DNA
was precipitated with isopropanol (10.5 mL) and centrifuged at 15,000 x g at 4oC for
30 min. The DNA pellet was washed with the 70% ethanol and centrifuged at
15,000 x g at room temperature for 10 min. The pellet was air drier for 10 mins and
redissolved in TE buffer.

The purity was assessed via nanodrop as previously

described (see 1.1.6.2.1 Genomic DNA purification for CCNF sequencing)
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2.1.9.3 Plasmid verification via PCR
To ensure the correct plasmid was amplified, the DNA sequence was verified via
PCR. The plasmids were amplified via PCR using the BigDye Terminator v3.1
Cycle Sequencing Kit. Each PCR amplification solution containing the plasmid of
interest (500 ng), BigDye reaction mix (1 uL), BigDye sequencing buffer (5X) and
CMV forward primer (1 uL, 1.6 uM), made up to a total volume of 10 uL with
nuclease free water was amplified using a thermocycler preheated to 96oC. The
amplification was performed over 35 cycles of 10s at 96oC, 5s at 55oC and 4 min at
60oC.

The sequencing PCR product was purified. The PCR sequencing product was diluted
two fold in nuclease free water, and precipitated with 50 uL ethanol (50 uL), 2 uL
EDTA pH 8 (125 mM), 2 uL sodium acetate at room pH 5.2 (3M) temperature
overnight. The DNA was then pelleted via centrifugation at 14,000 rpm for 30 mins
at 4oC. The supernatant was discarded. The DNA pellet was washed with 70% icecold ethanol and centrifuged 14,000 rpm for 30 mins at 4oC. The pellet was airdried.

Sequencing was performed at the University of Wollongong, School of

Biology by Research Technical Officer Margaret Phillips. Snap Gene software was
utilised to analyse the resulting sequence. The resulting sequence was compared to
the known sequence, acquired from the Addgene online plasmid repository.
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2.2 Protein quantification
2.2.1

Relative whole cell protein expression

To determine the expression of specific proteins in different cell types,
immunocytochemical staining was performed. Incubations were carried out at room
temperature unless otherwise stated. Once cells reached the optimal confluence,
media was aspirated and cells were gently washed three times with PBS (pH 7.4).
Cells were fixed with paraformaldehyde (4% w/v). Paraformaldehyde was aspirated
and three PBST washes (5 min) were performed. Fixed cells were permeablised with
TritonX-100 in PBS (0.5% v/v) for 15 min and blocked. Cells were incubated in the
appropriate primary antibody as described in Table 2.8. Cells were washed three
times in tris buffered saline with tween 20 (0.05% v/v; TBST) and were incubated in
an appropriate secondary antibody for 1 h. Cells were incubated in a secondary
antibody conjugated with a fluorescent (488) molecule for the corresponding species
of which the primary antibody was raised (anti-rabbit or anti-mouse), diluted in PBS
(1:1000). Cells were gently washed three times with PBS with tween (PBST).
Coverslips were mounted onto glass slides with 5 µL slowfade reagent with DAPI
and sealed with nail varnish. For nuclear staining at high magnification, RedDot2
staining was performed prior to mounting the slide. Cells were washed three times in
PBST, and incubated in RedDot2 (1:200) in PBST. Cells were washed three times in
PBST prior to mounting.

Imaging was performed on a fluorescent microscope for iPSCs, on a live cell imager
for endodermal cells, and on a confocal microscope for all other cell types, including
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motor neurons. Where appropriate protein expression was compared to positive
controls, the iPSC clones were compared to other established iPSC lines, endodermal
cells were compared to HEPG2 cells. All secondary antibodies were tested for crossreactivity and non-specific immunoreactivity using the appropriate immunoglobulin
G negative control of the relevant species.

Quantification of motor neuron markers was performed using FIJI Is Just Image J
(FIJI) software. Cells lines from six different donors were differentiated in triplicate.
Six -ten images were taken for each of the technical replicates. Analysis was carried
out using PRISM software; following confirmation that the data was normally
distributed, one-way ANOVA, with Tukey’s multiple comparisons post hoc analysis
was performed. Quantification of Cyclin F and TDP-43 was carried out using Cell
Profiler Software (as per Table 2.11).
2.2.2

Protein collection and quantification

To determine the abundance of total protein present in a sample for western blot and
ubiqutinomics analysis, protein samples, once harvested, were quantified by
detergent compatible (DC) protein assay, comparing against a BSA standard curve.
Cells (fibroblasts, iPSCs, aNPCs, and motor neurons) were washed twice in PBS and
lysed in radioimmunoprecipitation assay buffer (RIPA; (50mM Tris-HCl (pH7.4),
1% sodium deoxycholate, 150mM NaCl, 1mM EDTA, 1%TritonX-100, 0.1% SDS
with 1 mM sodium orthovanadate, 10 mM N-Ethylmaleimide (omitted for negative
DUB inhibitor assay), 1X Phosphate Inhibitor cocktail 2)) lysis and extraction buffer.
To ensure a large yield, a cell scraper was used to detach any non-lysed cells, and the
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collected cell lysate solution was vortexed vigorously and stored on ice. The lysate
was centrifuged at maximum speed for 5 minutes at 4oC. For insoluble fraction
examination, the lysate was collected and the insoluble pellet was resuspended in
RIPA buffer 2% sodium dodecyl sulfate (SDS). The lysate solution was vortexed
and centrifuged as per the RIPA soluble lysate. This was the SDS soluble fraction.
The lysate was collected and the insoluble pellet was resuspended in RIPA buffer 8M
Urea. This was the Urea soluble fraction. The lysate solution was vortexed and
centrifuged as per the RIPA soluble lysate

Protein concentration was quantified via a detergent compatible DC protein assay
according to manufacturer’s specifications. A standard curve was produced using
BSA standards at 1000, 500, 250, 125, 62.5, 20.83, 6.94 and 0 µg/mL, in the buffer
the samples were collected in. Standards or samples were plated in triplicate in a 96
well plate (5 µL). Surfactant reagent S was combined with copper tartrate containing
reagent A in a 2:100 ratio; this solution was added to each well (25 µL) and gently
mixed. Folin reagent containing Reagent A was then added to each well (200 uL).
The plate was gently mixed on an orbital plate shaker and incubated for 15 minutes
at room temperature. The absorbance values were detected at 750 nm using a plate
reader. The protein sample concentrations were interpolated from the BSA standard
curve. Samples were stored at -80oC.

To determine the relative abundance of proteins including cyclin F, TDP-43 and
phosphorylated TDP-43, western blot assays were performed. Two techniques were
used to quantify proteins: 1. Quantification with 10% acrylamide gels, normalising to
neuronal marker NSE; 2. Quantification with total protein.
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In both methods,

statistical significance was determined using PRISM software, using a one-way
ANOVA, with Tukey’s post hoc.

2.2.3

Protein quantification via western blot

To separate the proteins by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS PAGE), 10% acrylamide (v/v) resolving hydrogels and 5%
(v/v) acrylamide stacking hydrogels were prepared using the Mini-PROTEAN®
Tetra Handcast System (Bio-Rad) using the 10 well gels (see Table 2.2 Media and
solution compositions) and assembled prior to placement in the gel electrophoresis
tank in SDS-PAGE buffer to ensure no leaking occurred. To minimize protein
degradation, samples were slowly defrosted on ice. XT sample buffer and 25 mM
dithiothreitol (DTT) were added to the defrosted lysate samples (10 µg), and made
up to a total volume of 10 µL with excess RIPA lysis and extraction buffer. Samples
were incubated at 95°C for 5 minutes to denature proteins and stored on ice prior to
loading. Sample (10 µL), pre-stained precision plus protein ladder (6 µL) and a
pooled sample of the six cell lines (10 µL) were loaded in the stacking hydrogel.
Samples were separated at 100 V (constant voltage) for 100 mins. The hydrogels
were then equilibrated in ice-cold transfer buffer for 20 minutes. Gels were
transferred onto a polyvinylidene fluoride (PVDF) membrane using a transfer tank at
100 V (constant voltage) in stirred ice-cold transfer buffer for 42 min. Membranes
were vigorously washed three times in tris buffered saline with TBST for seven
minutes. Membranes were blocked overnight in 5% BSA in TBST (w/v). Membranes
were incubated in TPD-43 antibody raised in mouse (1:1000), or phosphorylated
TDP-43 raised in rabbit (1:1000), or cyclin F antibody raised in rabbit (1:2000)
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diluted in 3% BSA in TBST (w/v) overnight. Membranes washed again in triplicate,
and incubated with the appropriate secondary antibody (anti-mouse-horseradish
peroxide 1:10000 or anti-rabbit-horseradish peroxidase (1:10000) diluted in 3% BSA
in TBST (w/v) for 1 h. Membranes were washed again in triplicate. Membranes
were incubated in chemiluminescent substrate (ECL) for 30 s and sandwiched
between two clear plastic films, ensuring neither bubbles nor debris were present.
The membrane was exposed to film in a dark room. The film was developed using a
film processor and assessed for any saturation by eye. The membrane was washed in
triplicate. The film was scanned with a densitometer, and the density of the bands
was assessed for saturation using Quantity One software. If saturated bands were
present, the ECL was reapplied and the membrane was re-imaged. The non-saturated
developed film image was exported, and the band density was quantified using Licor
software; Bands corresponding to the proteins of interest were identified by
comparison to the known weights of the protein ladder, and from descriptions in the
literature.

To normalised to neuron specific enolase (NSE), membranes were

incubated with the NSE antibody from a different species; Neurons were incubated
in NSE antibody 1:10000 antibody raised in mouse or NSE antibody 1:5000 antibody
raised rabbit) for diluted in 3% BSA in TBST (w/v) for 1 h. Membranes washed
again in triplicate, and incubated with the appropriate secondary antibody (antimouse or anti-rabbit-horseradish peroxide diluted in 3% BSA in TBST (w/v) for 1 h.
Membranes were washed in triplicate and imaged as described above. The density of
the proteins of interest were normalised to the pooled sample within the respective
gel, and normalised to the normalising protein density.
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2.2.3.1 Protein quantification via western blot, normalised to total protein
Separation of proteins was carried out using a 4 – 20% precast Criterion gels (Bio
Rad). Prior to transfer of the protein to PVDF membrane, the gradient gel was
equilibrated in water to reduce any movement of the gel, and imaged in a gel
imaging system. The Criterion gel was then equilibrated in transfer buffer and
proteins were transferred as aforementioned. Prior to incubation in blocking buffer,
the PDVF membrane was imaged again for total protein. The PDVF membrane was
divided according to the protein ladder (following initial investigation into band
sizes), and the respective membranes were incubated as described in the previous
section. Blots were imaged with a gel imager using ECL as previously described.
Exposure time was optimised for each membrane, and normalised to the pooled
control. Protein bands were quantified as previously described using Licor software,
and were normalised to total protein.

2.3 Increasing UPS stress

Two inhibitor compounds were engaged in this study to increase ubiquitin
proteasomal stress. The Z-Leu-Leu-leu-Al peptide, commonly known as MG132,
was used as a proteasomal inhibitor. PYR41, an inhibitor of apex E1 ubiquitin
activating enzyme UBA1 was used to partially inhibit the ubiquitin system. Both
inhibitors were solubilised in DMSO, therefore a vehicle (DMSO) control was
included in each experiment, in which DMSO was added in equal concentration.
Final concentrations used in these assays were as follows: concentration curve assay
concentrations were 0 (DMSO control), 1, 2.5, 10, 100 and 250 μM MG132 and 0
μM (DMSO control) 1 μM, 2.5 μM, 5 μM, and 10 μM PYR41; proceeding MG132
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assays were 10 μM MG132, and PYR41 assays were 1 μM, and 10 μM PYR41. For
cells requiring a partial media change, media was removed from the well, returning
an exact half volume, and adding a second half volume of fresh inhibitor
supplemented media. Cells were treated with MG132 for 16 h, PYR41 for 24 h (or
refreshed every 48 h in the longitudinal study) at the indicated concentration (using
either a concentration curve, or single concentration, as described). Neurite analysis
was performed using the Incucyte Zoom software using the NeuroTrack package.
Cell-body cluster parameters were set for brightness for segementation mode, with
0.9 Segmetnation adjustment. Minimum cell width was set at 10.000 for cleanup.
cell-body cluster filters were set to minimum 200.00 μm2, maximum 1000.0. Neurite
paramters were set to filter: best, neurite sensitivity: 0.6, width: 1.

2.4 Assessing cellular viability

Resazurin based viability assay was performed to indicate cellular health. Cells
(fibroblasts (at 70% confluence), iPSCs (at 40% confluence) and motor neurons (on
day 54 of differentiation)) were treated with proteasomal inhibitor or UBA1
inhibitor, as per 2.1.1.1. The total media was aspirated and replaced with PrestoBlue
reagent diluted 10X in DMEM/F12. Cells were incubated for 2 hours, and the
PrestoBlue solution was transferred to a black 96 well plate. Fluorescence was
measured at 560 nm excitation/590 nm emission. Background fluorescence was
subtracted, and where indicated, florescence was normalised to no treatmeatment
(vehicle) controls. A minimum of three replicates were performed, as indicated.

95

2.5 Assessing the efficacy of the UPS: Degron assay

To assess the efficacy of the ubiquitin proteasome system a degron assay was
performed in motor neuron precursors. Once cells had reached an appropriate
confluence or stage of differentiation, cells were transfected with Lipofectamine
LTX according to the manufacturer’s protocol. All reagents were incubated at room
temperature for 20 min. The pEGFP-C1-GFPµ, and mCherry plasmids were diluted
to 0.5 μg/µL in Opti-MEM. To ensure cells that had taken up the pEGFP-C1-GFPµ
also took up the mCherry plasmid, these were added in a 2:1 ratio, to a total of 100
ng of DNA per 96 well plate well. The LTX PLUS reagent was added to the DNA;
LTX reagent (0.4 µL per 100 ng plasmid) was added to the DNA solution. The LTXplasmid solution was incubated for 25 min at room temperature to allow the
liposomes to form. The LTX-plasmid complexes (100 μL) were added dropwise to
the centre of the well, and gently rocked in an X-Y plane. Cells were imaged
following 16 h of incubation, using the in-incubator microscope (Incucyte Zoom).
Analysis was performed using the Incucyte Zoom Software. The standard analysis
package was used; Green channel images, indicating degron signal retention as an
indicator of proteasomal function were analysed using Top-Hat Parameters with
radius 80.000 μm, 1.3000 GCU threshold no edge split applied. Cells were filtered
for red fluorescence, as an indicator of mCherry expression, indicative of a
transfection success, using Top-Hat Parameters, radius 100.000 μm, 1.0000 RCU
threshold, no edge split applied, minimum area filtered to 20.000 μm2, and minimum
eccentricity of 0.1500.
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2.6 Ubiquitinomic analysis of fibroblasts, iPSCs and motor neurons

2.6.1

Lysate collection

Cells were harvested as per protein quantification, by manually scraping in lysate
buffer containing protease inhibitors and a deubiquitinating enzyme inhibitor.
Samples were quantified by DC Assay, as previously described and delivered dry ice
to the University of New South Wales for ubiquitinomic sample processing by liquid
chromatography tandem mass spectrometry (LC-MS/MS) by Jess McKenna,
Research Assistant (Saunder’s Laboratory) as described in 2.1.1.4 Ubiquitin
immunoprecipitation and LC-MS/MS.

2.6.2

Ubiquitin immunoprecipitation and LC-MS/MS

The following protocol was used by Jess McKenna for purification and subsequent
LC-MS/MS analysis: Mono- and poly-ubiquitinated proteins were immunopurified
using specialized ubiquitin matrix (VIVAbind Ubiquitin Kit, VIVA Bioscience).
After significant washing to remove residual detergent, beads were digested for 30
min at 27°C, then reduced with 1mM DTT and left to digest overnight at room
temperature with sequencing-grade trypsin (5 μg/mL, Promega), as described
previously (Turriziani et al., 2014). Samples were alkylated with iodoacetamide (5
mg/mL), and protease digestion terminated with trifluoroacetic acid (TFA). The
trypsin-treated eluents were collected following brief centrifugation. Eluant was
purified and desalted using self-packed stage tips with 6 layers of C18 Empore disks
(Pacific Laboratory Products), and dried in a SpeedVac. Samples were resuspended
in a formic acid (5%), acetonitrile (2%) solution (12 μL). The purified eluate was
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stored at -80°C prior to mass spectrometry analysis. The digested peptide sample (5
μL) was separated along a self-made C18 column and introduced by nanoelectrospray
into the LTQ Orbitrap Velos Pro coupled to an Easy-nLC HPLC. Tandem mass
spectrometry data was collected for the top 10 most abundant ions per scan over a
140-minute time gradient. The MS/MS raw files were analysed using MaxQuant
(v1.2.7.4) against the Uniprot human database, and exported as a ‘proteinGroups.txt’
from MaxQuant. The file generated by MaxQuant was used for all subsequent
analyses carried out in this study by Monique Bax.

2.6.3

Filtration of LC-MS/MS output

Data filtration and analysis was performed using RStudio (v1.1.423) unless
otherwise specified. The raw MaxQuant output was imported into R Studio where
the data were filtered for contaminants, reverse hits, proteins only identified by site
and number of unique peptides (≥ 2), and all further analysis was performed using
these filtered data. The identified proteins were filtered for contaminants, a label-free
quantitation (LFQ) intensity score > 0 in at least three of the four replicates of each
cell stage.

2.6.4

Verification of data and analysis of change to ubiquitome

To validate these data, a comparison of the samples was carried out. Multiscatter
plots of the data, a heatmap of the Pearson’s Correlation calculated values and a
Principal Component Analysis were used to visualise the comparisons of the
different replicates, within and between cell lines. Venn analysis using InteractiVenn
software was employed to compare the proteins present in each combination of the
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two cell stages. The resulting filtered list used to qualify protein-protein interactions
using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; v10.5;
Szklarczyk et al., 2017). The KEGG enriched protein interactions list was exported,
and a heatmap of these KEGG grouped proteins generated in PRISM v7, ordered by
the most KEGG pathways with highest number of protein interactions.

To quantify and compare the changes of the ubiquitomes at the different cellular
stags, the Pegasus method was utilised to scale and statistically analyse the
differences in LFQ intensity between cellular stages. Briefly, the Perseus
methodology was adjusted with concepts from Benjamini and Hochberg (1995), Cox
et al., (2012), and Hogl et al., (2013); LFQ intensities were transformed to logarithm
(log2) and post-transformation missing values were assigned random numerical
values within the lowest quartile of the resulting normal distribution of each
replicate. To compare two cell stages, the mean of one cell stage was subtracted from
each replicate of the opposite cell stage, and vice versa, scaling these LFQ
intensities.

A two-sided, unequal variance Student’s T-test with a Benjamini-

Hochberg test to reduce Type I errors was performed. The mean abundance from the
scaled LFQ intensity, and a significance threshold was set at an abundance ≥ 2 and
Q-value < 0.01. Significantly different proteins were analysed for significant protein
interactions using the STRING and Cytoscape.

Proteins were analysed for

significantly higher than expected interactions based on the Kyoto Encyclopaedia of
Genes and Genomes (KEGG), Functional and Cellular Component enriched
grouping.
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To determine if these changes were consistently occurring in different cell lines this
analysis was repeated for three other cell lines. Filtering was completed as
aforementioned. Venn analysis using InteractiVenn to was implemented compare the
changes common to all four cell lines at each change of cellular stage, following
export of the STRING enriched protein interactions, following filtering as
aforementioned (Heberle et al., 2015).

To compare the ubiquitomes of the cell lines, data was filtered and normalised as
aforementioned. A principal component analysis was performed comparing 1. The
different cellular stage from the different cell lines; 2. The cell lines at each cellular
stage. The transformed relative abundances of in the motor neurons were analysed
for significant differences via one-way ANOVA, filtering for false discoveries using
BH, using PRISM. The proteins that were significantly different were filtered by
patterns of significance. The resulting list of significant proteins was analysed for
protein interactions in STRING. Protein interactions pathways that were significant
were exported.

Ubiquitinated proteins were also compared to known proteins

associated with ALS as available on the ALSoD website (Abel et al., 2013).

2.7 Assessing cellular nitrite as an indicator of nitrosative stress

To assess nitrosative stress in the ALS affected cell lines compared to controls, a
Griess assay was performed as per Balez et al., 2016. Supernatant samples were
collected from cell cultures prior to harvesting for protein.

Supernatant was

measured using the microplate assay. A nitrite standard was prepared with sodium
100

nitrate 100 µM, 50 µM, 25 µM, 12.5 µM and 0 µM diluted in MN Media. Griess
reagent (20 µL; N-(1-naphthyl)ethylenediamine 0.1% (w/v) Sulfanic acid 1% (w/v)
in 5% phosphoric acid (v/v)), supernatant or nitrite standard (150 µL) and milliQ
water (130 µL) was added to a black well clear bottom 96 well plate under low light
conditions and incubated at room temperature in darkness for 30 min. Absorbance
was detected at 548 nm using a plate reader. A standard curve was generated from
the linear standard absorbance measurements, and the supernatant samples were
calculated from the line of best fit. Analysis was performed using PRISM software,
via one-way ANOVA with Bonferroni post hoc analysis.
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2.8 Materials
Table 2.1 Cell lines utilised in this study
Cell line

Description

Species Sex

Age

Commonly used cell culture lines
NuFF

Newborn human foreskin fibroblasts used
to condition media.

Human

M

0

NSC34

A motor neuron-like cell line from mouse
neuroblastoma x spinal cord hybrid.

Mouse

NA*

NA*

Hep G2
C2C12

Liver cancer cell line.

Human

M

15

Skeletal myoblast from C3H mouse

Mouse

F

2 months

HEK293T

Human Embryonic Kidney 293 cells

Human

F

0

ALS Patient and Control Lines
CCNF1

Fibroblasts from skin punch sibling of
CCNF2 with CCNFS621G, pre-symptomatic
at time of collection. APOE ε3/3

Human

F

62

CCNF2

Fibroblasts from skin punch of patient
with CCNFS216G mutation. APOE ε3/4

Human

M

59

UBQLN2
Control

Healthy donor sibling of an ALS patient
with UBQLN2 mutation. APOE ε3/4

Human

F

Unknown

Human

M

Unknown

Human

M

57

Human

M

65

Human

F

62

Human

M

59

Human

F

Unknown

MQ130054
HDF1
HDF10

Fibroblasts from skin punch from an ALS
patient with SOD1E101G mutation. APOE
ε2/3
Control donor 1; age and sex matched for
SAD patient
Sporadic Alzheimer’s disease patient
number 10

Reprogrammed ALS Patient and Control iPSC lines
CCNF1;
MB1-10
CCNF2;
MB2-1
HC1;
MB3-10

iPSC line generated from CCNF1
fibroblasts; mRNA reprogrammed in this
study
iPSC line generated from CCNF2
fibroblasts; mRNA reprogrammed in this
study
iPSC line generated from UBQLN2
Control fibroblasts; mRNA reprogrammed
in this study

SOD1;
MQ54-2

iPSC line generated from MQ130054, the
SOD1E101G mutation fibroblasts; mRNA
reprogrammed for this study by Rachelle
Balez

Human

M

Unknown

HC2;
1-4

HC2 iPSC line; Healthy control donor 2;
age and sex matched to SAD patient;
previously virally reprogrammed

Human

M

57

SAD;
10-13

SAD iPSC line; previously virally
reprogrammed

Human

M

65
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*NSC34 cells, are a hybrid cell line with abnormal chromosomes, XX and XY
chromosomes, as reported by Neil Cashman.

Table 2.2 Media and solutions composition
Media

Volume

General Culture Media

500 mL Total Volume:

DMEM/F12

440 mL

Foetal Bovine Serum

50 mL

Glutamine

5 mL

Penicillin-Streptomycin (10,000 U/mL)

5 mL

Pluriton Media

500 mL Total Volume:

Pluriton Base Media

494.8

Penicillin-Streptomycin (10,000 U/mL)

5 mL

Pluriton Supplement (2500X)

200 µL

Recombinant B18R

300ng/mL

bFGF

4 ng/mL

TeSR E8

500 mL Total Volume:

TeSR E8 Basal media

474 mL

TeSR E8 20X supplement

25 mL

TeSR E8 500X supplement

1 mL

Neural Induction Media

50 mL Total Volume:

DMEM/F12

47.8 mL

Penicillin-Streptomycin (10,000 U/mL)

500 µL

Glutamax

500 µL

MEM non-essential amino acids

500 µL

N2 Supplement

500 µL

B-27 Supplement

200 µL

Anterior Neural Precursor Media

50 mL Total Volume:

DMEM/F12

47.75 mL

Penicillin-Streptomycin (10,000 U/mL)

500 µL

Glutamax

500 µL

MEM non-essential amino acids

500 µL

B-27 Supplement

250 µL

N2 Supplement

500 µL

bFGF
Motor Neuron Precursor Caudalising
Media
Neurobasal media

500 ng

Penicillin-Streptomycin (10,000 U/mL)

500 µL

Glutamax

500 µL

50 mL Total Volume:
48 mL
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MEM non-essential amino acids

500 µL

N2 Supplement

500 µL

bFGF

250 ng

Retanoic acid

0.3 µM

Motor Neuron Precursor Media

50 mL Total Volume:

Neurobasal media

48 mL

Penicillin-Streptomycin (10,000 U/mL)

500 µL

Glutamax

500 µL

MEM non-essential amino acids

500 µL

N2 Supplement

500 µL

bFGF

250 ng

Retanoic acid

0.1 µM

Purmorphamine

2 µM

Motor Neuron Media

50 mL Total Volume:

Neurobasal media

48.15 mL

Penicillin-Streptomycin (10,000 U/mL)

500 µL

Glutamax

500 µL

MEM non-essential amino acids

500 µL

B-27 Supplement

100 µL

N2 Supplement

250 µL

BDNF

500 ng

GDNF

500 ng

IGF

500 ng

cAMP

500 ng

Polyacrylamide Resolving Gel (10%)

40 mL Total Volume:

Water (MilliQ)

19.87 mL

Acrylamide (40%)

10 mL

Tris-HCl 1.5M pH 8.8.

10.13 mL

SDS (10%)

400 µL

Ammonium persulfate (10%)

400 µL

Tetramethylethylenediamine

32 µL

Polyacrylamide Stacking Gel

12 mL Total Volume

Water (MilliQ)

9 mL

Acrylamide (40%)

1.5 mL

Tris-HCl 1.5M pH 6.8.

1.5 mL

SDS (10%)

120 µL

Ammonium persulfate (10%)

120 µL

Tetramethylethylenediamine

12 µL
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Table 2.3 Reagents used
Concentration Catalogue
Used
Number
(unless stated)

Material/Compound

Company

Accutase

Stemcell
Technologies

1X

07920

Acetonitrile

Sigma Aldrich

2%

271004

Acrylamide/Bis Solution

Bio Rad

Agar
All-Trans Retanoic Acid

Thermo Fisher
Scientific
Stemcell
Technologies

Ambion Turbo DNA-free

Invitrogen

Ammonium Persulfate

Bio Rad

(40% v/v)
1.5%
0.3 µM
0.1 µM

161-0148
BD 244510
72262

As Described

AM1907

10%

161-0700

1:1000

11593027

100X

17504-044

BigDye Terminator v3.1 Cycle
Sequencing Kit

Thermo Fisher
Scientific
Life
Technologies
Thermo Fisher
Scientific

Bovine Serum Albumin

Sigma Aldrich

C18 Empore Disks

Pacific
Laboratory
Products

1X

34-70545218-2

Chemiluminescent Substrate

Thermo Fisher

1X

32106

Chloroform

Sigma Aldrich

100%

C2532500ML

Ampicillin
B-27 Supplement

Collagen I
Corning Matrigel hESCQualified Matrix, LDEV-Free
Criterion 4-20% TGX StainFree Precast Gel
Detergent Compatible Assay
(Reagents A, B, S)
Dibutyryl Cyclic Adenosine
Monophosphate
Dimethyl Sulfoxide
Dispase
Dithiothreitol

Life
Technologies
In Vitro
Technologies

As Described
10%

10 µg/mL

4337455
A7906100G

A1048301
354277

Bio Rad

1X

567-8095

Bio Rad

1X

S36942

Millipore

10 ng/mL

Sigma Aldrich
Stemcell
Technologies
Sigma Aldrich
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10%

28745
472301100ML

1X

7913

4X

101977770

01
DMEM/F12

Invitrogen

Ethanol
Ethylenediaminetetraacetic
acid (EDTA)
Express SYBR GreenER
qPCR Supermix Universal Kit
Fibroblast Growth Factor
Basic (bFGF)
Fibronectin Human Protein
Plasma
Foetal calf Serum (FCS)

1X

12500-096

VWR

100%

AJA214-2

Sigma Aldrich

1 mM

E9884100G

Life
Technologies

As Described

Miltenyi Biotec

5 ng/m

130-104923

10 µg/mL

33016015

Life
Technologies
Bovogen
Biological

11784-01K

10%

SFBS-F
106526

Formic Acid

Sigma Aldrich

5%

Glutamax

Life
Technologies

1:100

35050061

Glycerol (Molecular Biology
Grade)

Sigma Aldrich

1:1

G5516-1L

Griess Reagent

Molecular
Probes

1:14

F-7921

Insulin-Like Growth Factor 1
(IGF)
iPS Brew
Isopropanol
Kanamycin
L-Glutamine
Laminin Mouse Protein,
Natural
Lipofectamine LTX
MEM Non-Essential Amino
Acids
mFreSR

Miltenyi Biotec

10 ng/mL

Miltenyi Biotec
Sigma Aldrich
Thermo Fisher
Scientific
Life
Technologies
Life
Technologies
Thermo Fisher
Scientific
Life
Technologies
Stem Cell
Technologies

1X
100%
1:1000
100X

130-093887
130104258
11815024
25030

2.0 mg/mL

23017-015

As Described

15338-100

0.1 mM

11140050

1X

5854

MM-LV RTase

Promega

200 U

M1708

MMdNTP

Promega

200 U

U1511

mRNA Reprogramming Kit

Stemgent
Life
Technologies
Sigma Aldrich
Life
Technologies
Promega
Promega
Thermo Fisher

N2 Supplement
N-Ethylmaleimide
Neurobasal Media
Nuclease-Free Water
Oligo(dT) 15 Primers
OptiMEM
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As Described

00-0071

1:50

17502-048

10 mM

E3876-5g

1X

21103-049

1X
0.5 μg
1X

7732-18-5
C1101
31985-070

Paraformaldehyde

Sigma Aldrich

4%

Penicillin Streptomycin

Sigma Aldrich

10,000 U/mL &
10 mg/mL

Sigma Aldrich

1X

Phenol-Chloroform-Isoamyl
Alchohol Mixture
Phosphate Inhibitor Cocktail
Pluriton Medium
Pluriton Supplement
Polyvinylidene Fluoride
(PVDF)
Precision Plus Protein Dual
Color Standards
PrestoBlue
Protease Inhibitor Cocktail II

Roche
Stemgent
Stemgent

Purmorphamine

00-0070
01-0016

Merck Millipore

1X

IPVH00010

Bio Rad

1X

1610374

1:100

A13261

1 x tablet

P-1511

Thermo Fisher
Scientific
Astral
Scientific

Proteinase K
PureLinkR Genomic Mini Kit

1X
1X
2500X

158127100G
P4333100ML
77617500ML

20 mg/mL
Life
Technologies
Stem Cell
Technologies

PYR41

Sigma Aldrich

Qiagen Maxiprep Kit
Random Primers
Recombinant Human BrainDerived Neurotrophic Factor
(BDNF)
Recombinant Human Glial
Cell-Derived Neurotrophic
Factor (GDNF)
Recombinant RNasin
Ribonuclease Inhibitor
Rnase A
ROCK Inhibitor
Slowfade Gold Antifade
Mountant with DAPI
Sodium Acetate
Sodium Chloride (NaCl)
Sodium Deoxycholate
Sodium Dodecyl Sulfate
Solution (In H2O; SDS)
Sodium Nitrate
Sodium Orthovanadate
STEMdiff Definitive Endoderm
Kit TeSR E8 Optimised

Qiagen
Promega

1X

K1820-00

2 µM

72204

Conc Gradient

N2915

0.5 μg

12162
C1181

Miltenyi Biotec

10 ng/mL

130-103435

Miltenyi Biotec

10 ng/mL

130-098449

Promega
Sigma Aldrich
Invitrogen

40U

N2515

20 mg/mL
10 μM

SCM075

1X

S36942

Sigma Aldrich
Sigma Aldrich
Sigma Aldrich

7.5 M
150 mM
1%

Sigma Aldrich

10%

Sigma Aldrich
Sigma Aldrich
Stemcell
Technologies

As Described
1 mM

S2889
S5886
D6750-25G
71736500ML
221341
S6508-10G

As Described

5115
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TeS-E8 20X, 500X
Supplement and Basal
Medium

Stemcell
Technologies

1X

5940, 5942,
5943

Tetramethylethylenediamine

Bio Rad

1X

161-0800

Trifluoroacetic Acid (TFA)

Sigma Aldrich

1X

T62200

Trireagent

Molecular
Research
Centre

1X

TR 118

Tris-EDTA

Sigma Aldrich

1.5 M

93302

Tris-HCl

Sigma Aldrich

50 mM

Triton X-100

Sigma Aldrich

1X

Trypsin (Sequencing Grade; 5
μg/mL)

Promega

5 μg/mL

25300054

Trypsin Inhibitor

Sigma Aldrich

1 mg/mL

T9128500MG

Trypsin/EDTA
Tryptone (bacto)
Turbo Dnase

Life
Technologies
BD Bioscience
Life
Technologies

T8787250ML

0.05%

25300054

1.0%

BD211705

As Described

AM1907

UltraPureTM Distilled Water
(DNAse, RNAse free)

GIBCO

1X

10977

Urea

Sigma Aldrich

8M

U48836X25ML

VIVAbind Ubiquitin Kit

Viva
Bioscience

As Described

VB2950

XT Sample Buffer

Bio Rad

1X

1610791

Y-27632 (ROCK inhibitor)

Millipore

10 μM

688000

Yeast Extract
Z-Leu-Leu-Leu-al (HPLC
grade; MG132)

Sigma Alrich

0.5%

Sigma Aldrich

As Described

92144
C22115MG

Sigma Aldrich

1X

β-Mercaptoethanol
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Table 2.4 Equipment utilised
Equipment
Model

Source

Autoclave
Western blot imager
Benchtop centrifuge
Biosafety cabinet
Cell freeze down vessel
Centrifuge

HS 5510EC1
Amersham Imager 600
5415R
S@femate 1.2 ABC
Mr Frosty
Multifuge 1XR
Heraeus Labofuge
400R
DMI6000
GS-800
Pipette Pal controller
CP1000

Getinge
GE
Eppendorf
NATA LAF technologies
ThermoFisher Scientific
ThermoFisher Scientific

FLUOstar OPTIMA

BMG LabTech

Westinghouse
Conditionaire Safe-Tee
Amersham Imager 600
Weber
Haemocytometer
MD-02N-220
HERA Cell 150i CO2
Incubator
IncuCyte ZOOM
LTQ Orbitrap Velos Pro
with Easy-nLC HPLC
SpectraMax

Westinghouse
Conditionaire International
GE Healthcare Life Sciences

Eclipse T5100

Nikon

Timesaver
Autoflow IR direct CO2

Samsung
Nuaire
Edwards Instrument
Company
Eppendorf

Centrifuge (primary)
Confocal microscope
Densitometer
Electric pipette
Film processor
Fluorescence plate
reader
Fridge/freezer
Fumehood
Gel imager
Haemocytometer
Heat block
Hypoxic incubator
In-incubator imager
Mass spectrometer
Microplate reader
Microscope (cell
culture)
Microwave
Normoxic incubator
Orbital shaker

Bioline Orbital Shaker

PCR Thermocycler

Master Cycler Pro
Eppendorf Research
Plus
STR6
Light Cycler 480 II
Nanodrop 2000C

Pipettes
Platform shaker
qRT-PCR
Spectrophotometer
Ultra low freezer (80°C)

ThermoFisher Scientific
Leica
Biorad
Wheaton
AGFA

Weber
Major Science
ThermoFisher Scientific
Essen Bioscience
ThermoFisher
Molecular Devices

Eppendorf
Stuart Scientific
Roche
ThermoFisher Scientific

TSU series

ThermoFisher Scientific

Vortex

250VM

HWAShin mixer technology
company

Waterbath

SWBD

Stuart- Bibby Scientific
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Table 2.5 Software packages utilised
Software

Source

Version

Amersham Software.

GE

1.2.0

CellProfiler

BSD 3-clause

2.1.1

Cytoscape

The Cytoscape Consoritum

3.5.1

Excel

Microsoft, USA

2010

FIJI

W. Rasband, National Institutes
of Health

1.50a

MARS Data

2.30R3

LI-COR Biosciences

4.0.21

Incucyte Zoom

Essen Bioscience

2015A

Inkscape
Leica Application Suite
AF
Leica Application Suite
X
LI-COR

Free Software Foundation

0.91

Leica Microsystems

2.6.0

LI-COR Biosciences

1.9.0.1374
7
5.2

Light Cycler 480

Roche

1.5.0.39

Nanodrop 2000/2000C

Thermo Fisher Scientific

1.4.2

SoftMax pro

Molecular Devices

7.0

Prism

GraphPad Software

5.01 & 7.0c

Quantity One

4.3.0

STRING

Biorad
Foundation for Open Access
Statistics
Creative Commons BY 4.0

InteractiVenn

GPLv3 (InteractiVenn @ GitHub)

1.0

ALSoD

Abel O.

6.0

FLUOstar Optima and
Data Analysis BMG
LABTECH
Image Studio

R Studio

Leica Microsystems
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1.1.423
10.5

Table 2.6 Plasmids utilised
Plasmid
pEGFP-C1-GFPµ
mCherry
eGFP
pHB9-mCMV-GFP
pMD2.G
pRSV-Rev
pMDLg/gRRE

Description
Degron
mCherry Vector
GFP Vector
HB9 Vector
Lentivirus VSV-G envelope
Lentivirus REV packaging
Lentivirus REV Gag and Pol packaging
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Table 2.7 Primers employed in this study
Primer

Sense (S)/
Antisense (A)

CCNF (E16F)

S

CCNF (E16R)

A

CMV

S

CMV

A

NANOG

S

NANOG

A

POU5F1

S

POU5F1

A

U6

S

U6

A

HPRT1

S

HPRT1

A

GDF3

S

GDF3

A

PAX3

S

PAX3

A

PAX7

S

PAX7

A

Protein
Target

Primer Sequence 5’-3’

Cyclin F

GGCTCTCTCCACCTTGC

Cyclin F

GATGTCCCTTCTGGTGCAC

CMV Promoter

CGCAAATGGGGCGGTAGGCGTG

CMV Promoter

CAGGATTCTTACTTGTACAGCTC

NANOG

TGGTGGTAGGAAGAGTAAAG

NANOG

CCAGAACCAGAGAATGAAATC

Oct4

GCTTTGCATATCTCCTGAAG

Oct4

GATCACCCTGGGATATACAC

RNU6B

CTCGCTTCGGCAGCACA

RNU6B

AACGCTTCACGAATTTGCGT

HGPRT

ATAAGCCAGACTTTGTTGG

HGPRT

ATAGGACTCCAGATGTTTCC

GDF3

CCAAGGTTTCTTTCTTTACCC

GDF3

AATGTCAACTGTTCCCTTTC

PAX3

ATCAACTGATGGCTTTCAAC

PAX3

CAGCTTGTGGAATAGATGTG

PAX7

AGGAGTACAAGAGGGAAAAC

PAX7

TAATCGAACTCACTGAGGG
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Table 2.8 Antibodies and parameters optimised and utilised for immunocytochemistry
Antibody

Species

Supplier

Product Code

Time to
Fix/Permeabilise
time (min)

Block

1:500

8/15

1h Gt Ser

1:200

8/15

1h Gt Ser

8/15

1h Gt Ser

10/15

2h 5% BSA

10/15

1h Gt Ser

10/15

1h Gt Ser

10/15

1h Gt Ser

10/15

1h Gt Ser

10/15

1h Gt Ser

10/15

1h Gt Ser

APP

1h Gt Ser

Dilution

Primary Antibodies
OCT4
SSEA4
TRA-1-60
FOXA2
SMI32
Islet 1
HB9
CCNF2
Phos-TDP-43
(409/410)
TDP-43
IgG Control

Mouse

Stemcell T

Mouse

Abcam

Mouse
Mouse
Rabbit
Mouse
Mouse
Rabbit
Rabbit
Mouse
Mouse

01550
ab16287

Stemcell T

AB_2686905

1:200

Abcam

Ab60721

1:200

Abcam

Ab7795

1:800

Abcam

ab20670

1:600

DSHB

81.5C10

1:50

Santa Cruz

santsc-952

PT

22309-1-AP

1:200

Abnova

H00023435-M01

1:600

Thermo Fisher

10400C

APP

1:1000
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IgG Control
NSE
NSE

Rabbit
Mouse
Rabbit

APP

Sigma Aldrich

I5006-10MG

APP

Abcam

ab16808

1:10,000

-

Abcam

ab53025

1:5,000

-

1h Gt Ser
1h Gt Ser
1h Gt Ser

Secondary Antibodies
Alexa Fluor
488 AntiRabbit
Alexa Fluor
488 AntiMouse
Alexa Fluor
633 AntiRabbit

Goat

1:1000

A11001

Thermo FS

A11008

Goat

Thermo FS

A21050

1:1000

-

1h Gt Ser

Mouse HRP

Goat

Merck M

AP308P

1:10,000

-

1h BSA

Rabbit HRP

Goat

Merck M

AP307P

1:10,000

-

1h BSA

Goat

1:1000

-

1h Gt Ser

Thermo FS

-

1h Gt Ser

APP: As per primary; DSHB: Developmental Studies hybridoma bank; Gt Ser: Goat Serum; Merck M: Merck Millipore; Stemcell T:
Stemcell Technologies; Thermo FS:Thermo Fisher Scientific; PT: Proteintech
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Table 2.9 Cell profiler settings
Primary Object
Identification

Nuclei

Dead
Cells/Debris

Nuclear
Speckles

Diameter of nucleus (pixel units)
Minimum

30

5

2

Maximum

100

30

35

On

On

On

Global

Automatic

Per Object

Masking

-

-

Nuclei

Smoothing
Threshold
Scale

5

-

-

Minimum

0.0001

-

0

Maximum

1

-

1

Shape,
propagate

-

Intensity

Automatic
detection

-

Intensity,2

Automatic
detection

-

Size filter,2

On

Off

On

Border
Exclusion
Threshold
Strategy

Threshold

Declumping
Method
Size of
smoothing
filter
Distance
between
maxima
Fill hold after
thresholding
and
declumping
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Chapter Three:
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Pluripotent Stem Cell Derived
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3 GENERATION OF PATIENT INDUCED PLURIPOTENT STEM CELL
DERIVED MOTOR NEURON MODELS

3.1 Introduction
3.1.1

iPSCs in neurodegenerative research

The central premise of developmental biology is that differentiation relies on
epigenetic changes to stem cells to differentiate mature somatic cells. In 2006,
Takahashi and Yamanaka took advantage of this concept, reversing this process in
murine cells to generate the first murine induced pluripotent stem cells (iPSCs).
These adult-cell derived stem cells were immortal, self-renewing and had the
potential to differentiate into any cell type. Following this success, the technique
was quickly applied to human patient cells offering the opportunity to investigate and
model disease in a patient specific context.

3.1.2

mRNA reprogramming overcomes concerns for genetic interference

Initially, reprogrammed iPSCs were reported to have high levels of genetic mutations
and chromosomal deformities, particularly due to lentiviral involvement (Hayden,
2011). The initial method of human fibroblast-to-iPSC reprogramming relied on the
upregulation of four pluripotency factors, Oct4, Klf4, Sox2, and c-Myc, (OKSM
factors) by retroviral transductions.

These transductions caused an increased

expression of the OKSM proteins, which act to upregulate a range of downstream
pluripotent factors, causing the adult somatic cells to revert back to a state of
pluripotency.
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As with all cell culture systems, genetic mutations are an area of concern in cellular
reprogramming; for early iPSC research, viral integration was an obvious issue.
Though very effective, the inclusion of viral genetics in the cell lines impinged on
potential future applications.

New reprogramming methods have since been

developed that ensure the donor genome is not altered by viral integration (Bellin et
al., 2012). Reprogramming via regular mRNA transfections eliminated the need for
viral involvement in the reprogramming process, thus paving the way for disease
modelling, and the potential for cellular replacement therapies.

This mRNA

reprogramming method is thought to reduce cellular mutations (Miyoshi et al.,
2011). Recorded aneuploidy events in mRNA reprogramming have been detected at
rates of 2.3% using mRNA reprogramming products, compared to other nonintegrating systems which are as high as 11.5% (Schlaeger et al., 2015; Warren et al.,
2010). Donated fibroblasts may contain mutations, so it is difficult to determine if
mRNA reprogramming does induce a higher mutation rate than other cellular
experiments (Gore et al., 2011). Nonetheless, methods are available to identify if
genetic mutations have been induced by cellular reprograming; karyotyping and
genome sequencing are widely regarded as essential steps in selecting stem cell lines
for future use (Müller et al., 2008) .

3.1.3

Reprogramming efficiency improved using mRNA transfections

Though mRNA reprogramming overcame the major shortfalls of early iPSCs
reprogramming, the initial efficacy of non-integrating systems still proved to be low
(Bellin et al., 2012; Schlaeger et al., 2015). Integrating retroviral reprogramming,
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had an initial success rate of 0.01% for reprogramming fibroblasts. By the time
mRNA reprogramming was published in 2012, this had increased to 0.04% (Bellin et
al., 2012; Hayden, 2011; Warren et al., 2012). Given this low success rate, there has
been a concerted effort in the field to increase the reprogramming rates. Initially, as
a novel technique, little was understood of the reprogramming process. It is now
evident that cellular reprogramming occurs in what are usually described as three
phases: an early, intermediate, and late stage (Milagre et al., 2017; Wen and Tang,
2015; Zunder et al., 2015). Partial reprogramming is therefore possible, as cells may
not necessarily complete the entire reprogramming process. The selection of the
individual colonies that arise in cultures following successful reprogramming is
therefore an important process. Previous studies have focussed on improving the
reprogramming process, including changing the compounds used to reprogram. In
2007, Yu et al., found that c-Myc could be replaced with Lin-28 to reduce cellular
death and differentiation found to be induced by c-Myc expression in hESC (Yu et
al., 2007). Supplementation of c-Myc with Lin-28 has since been found to assist the
process, and is thus included in mRNA reprogramming cocktails (Feng et al., 2009).

Additional compounds have been found to increase reprogramming rates.

The

introduction of B18R, a Type I interferon vaccinia virus neutralising receptor, saw
significant reduction of cellular death through reprogramming (Mandal and Rossi,
2013). Inclusion of this interferon inhibitor allowed cells to be dosed with a larger
amount of mRNA without causing cellular death, which resulted in a larger final
reprogramming yield (Warren et al., 2012). MicroRNA (miRNA), small non-coding
RNA molecules, were also identified to directly contribute to reprogramming
efficiency, following the known necessity of miRNAs in embryonic stem cell
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maintenance. The addition of miRNAs to reprogramming cocktails has been found to
increase efficiency by up to 14-40 fold (Mallanna and Rizzino, 2010). Together,
these improvements to mRNA reprogramming methods have steadily increased the
success rate mRNA reprogramming up to 0.6-4.4% successful reprogramming – a 36
fold improvement in initial efficacies (Rao and Malik, 2012; Schlaeger et al., 2015;
Warren et al., 2010).

3.1.4 Selection of iPSC clones and pluripotency maintenance is essential
Establishing the pluripotency of the reprogrammed iPSC lines is crucial to ensure a
cell line is a viable tool for any application in stem cell research. Upon successful
reprogramming multiple colonies of stem cells normally arise in the culture (Mandal
and Rossi, 2013). Characterisation of these colonies is crucial to select cell lines that
have fully reprogrammed, and ensure no genetic abnormalities have arisen through
reprogramming. A series of steps should be carried out for optimal characterisation
(Figure 3.1) (Müller, 2014). Initial observations of proliferation, overall colony
shape and cellular morphology provide crude but crucial criteria for early stage
colony characterisation. Prior to the final step of screening for maintained genetic
stability, for example by way of karyogram, determining gene and protein expression
of pluripotency factors via qRT-PCR, and immunocytochemistry, respectively,
serves to narrow iPSC colony choice without the need to generate large sample sizes.

Comparative tools such as the PluriTest are useful in assessing global cellular
profiles compared to already established pluripotent cell lines. Developed in 2012,
the PluriTest was designed as a less expensive, faster, and more ethical alternative to
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the traditional teratoma assay. The PluriTest is a bioinformatics assay used to
determine the pluripotency of a cell line. RNA samples from the reprogrammed cell
lines are submitted to a microarray assay, which detects the global genomic profile of
the cells. The profiles are compared to known profiles of both pluripotent and
somatic cell lines in a standardised non-bias approach. Two scores are produced
from the PluriTest analysis: the pluripotency score and the novelty score. The
pluripotency score is a determined through analysis of metagenes identified by
Mϋller et al. (2011). The data for the pluripotency score is scored using a logistic
regression model which gives a choice between the two classifications (pluripotent
and non-pluripotent). A high pluripotency score indicates the microarray data has a
signature similar to that of known pluripotency signatures. The novelty score is
generated using non-negative matrix factorization, modelling to compare the
microarray data to known pluripotency data in a stem cell model matrix. This score is
used to assess the purity of the pluripotency. A low novelty score indicates that the
microarray data can be reconstructed based on the stem cell model matrix. Nonpluripotent cells such as somatic cells and even abnormal cells would yield a high
novelty score.

Figure 3.1 Experimental workflow of iPSC generation and characterization.
A series of characterisation steps ensure optimal iPSC clone selection, adapted from
Müller et al. 2012. Following reprogramming, and upscaling isolated colonies, stem
cell phenotypes are assessed via morphology, gene and protein expression to shortlist
iPSC clones. Likely clonal candidates should be further investigated via a gene
expression panel assessment, comparing other known stem cell expression profiles
(such as the Pluritest), and be tested for genetic stability.
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3.1.5

Generating motor neurons from iPSCs to model motor neurone diseases

Like all neurodegenerative conditions ALS is a difficult disease to study. Limited
access to the affected cells of the central nervous system make models a necessity
when trying to understand the events that cause the death of motor neurons. For
ALS, animal models and cellular models are available to study living tissue affected
with disease symptoms. Previously, cellular models were not able to account for the
unique genetics of ALS patients. When Takahashi and Yamanaka first described the
reprogramming of somatic human cells into induced pluripotent stem cells, the
possibility to create patient specific models for neurodegenerative disease was made
a reality.

Since the commencement of the first motor neuron differentiation study by Dimos et
al., many advances have been made in motor neuron differentiation protocols.
Claims of motor neuron culture purities have increased from 18% to up to 70%
(Dimos et al., 2008; Qu et al., 2014). These significant increases in purity can be
credited to an improved understanding of motor neuron development, quality, and
affordability of compounds. The improvement of morphogen consistency through
higher quality control from suppliers, inclusion of small molecule inhibitors and
improved extra cellular matrices are notable features of the many protocols since the
first iPSC derived motor neuron differentiation protocol was published.

To mimic the in vivo environment, a number of steps are common in all motor
neuron protocols. Generation of neural rosettes, to replicate the neural tube
development stage, and embryoid bodies are common steps (See Table 3.1).
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Caudalisation of the neural precursors is increasingly used, meaning that most motor
neuron protocols would likely generate spinal motor-neuron like cells, though little
has been done in the field to verify motor neuron subtypes in iPSC derived motor
neuron cultures.

Morphogens including basic fibroblast growth factor (bFGF), retinoic acid (RA), and
brain derived neurotrophic factor (BDNF), and glial derived neurotrophic factor
(GDNF) are motor neuron differentiation staples. The addition of growth factors
such as insulin-like growth factor (IGF) and cyclic adenosine monophosphate
(cAMP), as well as the use of small molecule purmorphamine are more recent
additions to protocols. Collectively, these advancements in both fibroblast-to-iPSC
reprogramming, and motor neuron differentiation provide viable methods to generate
novel models to study the mechanisms of motor neurone diseases (Figure 3.2)

Figure 3.2 Overview of patient iPSC derived motor neurons generation
Workflow of reprogramming fibroblasts to iPSCs, and the use of these cells to
differentiate motor neurons. Characterisation at each step is essential to ensure
success of the previous step and establish population.
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Table 3.1 Motor neuron differentiaiton protocols published prior to the commencement of this study
Reference

Repro
gram
metho
d

Major findings

Mutation of
concern in
iPSC lines

MN

G85S

MN

P56S

MN

First patient
model.

derived

RV

2 (1 ALS
line):
2

SOD1

Boulting et
al., 2011

No indication of differences in
phenotype of ALS-iPSC MNs
compared to healthy iPSC
motor
neurons
during
differentiation.
Implied
differences at maturation,
although
no
significance
noted.
Decrease level of VABP in
ALS-iPSC motor neurons.
First VABP iPSC derived
motor neuron model

RV

11:
7

SOD1
L744F
SOD1

RV

7 (4
ALS):7

VAPB

Reduced
neurite
length,
increase in TDP-43 mRNA
expression and increased
TDP-43 levels in aggregates in
ALS iPSC- derived motor
neurons.
Decrease in neuronal survival
337V
in TDP
patient iPSC motor
neurons. Increase in TDP-43
protein (soluble and detergent
resistant) expression in the
motor neurons.

RV
EV

16 (3
ALS):
8

TDP-43
M337V
TDP-43
G298S
TDP-43

RV

4 (1ALS):
3

TDP-43

Egawa et
al., 2012

Bilican et
al., 2012

Cell
type

L144F

Dimos et
al., 2008

Mitne-Neto
et al., 2011

iPSC

iPSC
lines:
patients

Q343R

Spina
l MN

M337V

MN

MN
markers

Electro
physiology

Maturation
from EB
formation

ECM

HB9,
BIIITUB,
ISL1, ISL2
ChAT
Olig2 Pax6
HB9,
BIIITUB,
ChAT,
CHT1, ISL
(1/2)

-

RA,AA,SHH
agonist, GDNF,
BDNF CTNF

Whole cell
patch clamp
& calcium
imaging

RA, AA, SHH,
agonist, β-merc,
LDN193189,
SmoA,
SB431542,
GDNF, BDNF,
CTNF

HB9, Chat,
MAP2,
ISL1, αbungarotox
in
HB9,
ChAT,
SMI-32,
ISL (1),
MAP2,
GFAP
HB9,
BIIITUB,
ChAT,
SMI32

-

bFGF, Dorso,
RA, AA, SHH,
BDNF, GDNF*
cAMP

Laminin
polyornithine

21 - 56
days

Dors, bFGF,
SB431542,
BDNF, GDNF,
NT3, RA, SHH

Matrigel

35 days

SB431542,
Dorsomorphin,
Nacetylcysteine,
RA,
Puramorphine,
Bfgf', Bdnf,
Gdnf, Forskolin,
EGF, DAPT

Laminin
Fibronectin
Matrigel

21 - 42
days
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Whole patch
clamp,
current
clamp,
voltage
clamp

Laminin,
and/or
primary
murine glia
monolayer

Maturatio
n time
from EB

Other

7-15 days

11 days

Cocultured
with
C2C12

Yao et al.,
2013

Decreased neurite length in
murine
ALS-iPSC
motor
neurons..

RV

Sareen et
al., 2013

Decreased
ability
to
continuously
fire
action
potentials in iPSC C9ORF72
RE patient derived neurons

EV

Zhang et
al. 2013

Higher levels of TDP-43
localized in cytoplasm in TDPA90V
43
mutation
lines.
Decreased
levels
of
microRNA-9 in the motor
neurons.
Increased levels of mutant
TDP-43, and mislocalisation in
iPSC astrocytes. Decrease in
neuronal survival in iPSC
astrocytes. TDP-43 not noncell autonomous.
Majority of sporadic ALS lines
had
TDP-43
pathology
including
TDP-43
mislocalisation,
hyperphosphorylation, TDP-43
positive
aggregates,
and
Ubiquitin aggregates.
.
Cellular models corresponded
to post mortem findings in
same patient. Only sporadic
ALS models published to date.
Human-iPSC derived neural
progenitors
can
be
differentiated to motor neuronlike cells when transplanted in
G93A
SOD1
murine models.
Neurons derived from patients
iPSCs with a repeat expansion
in C9ORF72 express toxic

Serio et al.
2013

Burkhardt
et al. 2013

Popescu et
al., 2013

Donnelly et
al., 2013

G93A

6 (3
mouse
ALS):
6
8 (4 ALS):
8

SOD1

MN

HB9,
BIIITUB,
ChAT,

Whole-cell
patch clamp

SHH, RA,
GDBF, BDNF,
IGF, CNTF,

Laminin

SNS

C9ORF72 RE

Spina
l MN

Patch clamp

RA, Pur, cAMP,
AA, BDNF,
GDNF

Polyornithine,
laminin

14 – 49
days

RV

5 (2 ALS):
4

TDP-43
A90V
TDP-43

HB9,
BIIITUB
ChAT,
SMI-32,
GFAP
BIIITUB,

Whole cell
perforated
patch clamp

bFGF, BDNF,
GDNF

PL-ornithine
laminin
Matrigel

8 or 14
days

LV

4 (2 ALS):
3

RV

M337V

Neuro
ns

TDP-43

M337V

MN
and
astroc
ytes

GFAP

Calcium
imaging

RA, BDNF,
GDNF, CNTF

Matrigel

SNS

34 (24
ALS):
34

Sporadic
N139K
SOD1
A4V
SOD1
A315T
TDP-43
G1566A
FUS
FUS not
specified

MN –
Upper
and
lower
MNlike,
and
CN.

HB9, ISL1,
L1CAM
MAP,
SMI31

Whole cell
patch clamp
& calcium
imaging

Dihydrochloride,
FGF, AA, CNTF,
BDNF, GDNF,
SmoA, DAPT

PL-Lysine
Laminin

14 – 86
days

RV

1:1

-

Neuro
ns –
MN
like

MAP2

-

-

Collagen

14 days
In vivo

RV

13 (8
ALS):
13

C9ORF72 RE
D90A
SOD1

MN

HB9,
BIIITUB

-

BDNF, GDNF,
CTNF NT3

Poly-DLysine and
laminin,or

33 – 38
days
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Cocultured
with
murine
primary
astrocyte
s and MN
Cocultured
with
primary
human
astrocyte
s and MN

A4V

GGGGCC RNA foci,
LiuYesucevitz
et al, 2014

Presence of TDP-43 positive
aggregates increased with
culture time.

Kiskinis et
al. 2014

The
SOD1
exhibited
oxidative and ER stress,
reduced
mitochondrial
function, subcellular transport
and proteostasis. Correction of
A4V
SOD1
alleviated
dysfunctions. Cell lines with
the C9ORF72 RE share some
transcriptional changes with
1A4V
the SOD
iPSC-ALS MN
lines. MN can integrate with
chick embryo spinal cord.

Chen et al.
2014

Insertion of the SOD1
expression in ESC can cause
cells
to
exhibit
disease
phenotype. Correction of the
D90A
SOD1
alleviates
neurofibillary aggregation and
cellular
degeneration.
Neurofibrillary
aggregate
formation is an early ALS
event.
Gene correction for SOD1
mutation
rescinded
hyperexcitability.
Retigabine
increased survival of ALSIPSC motor neurons.

Wainger et
al. 2014

laminin or
collagen.

SOD1
D91A
SOD1

A4V

D90A

G298S

LV

4 (1 ALS):
2

TDP-43

RV

10 (4 ALS)
9

SOD1
C9ORF72 RE

RV
and
SV

5 (2 ALS):
3

SOD1
D90A
SOD1

RV

13 (8
ALS):
13

SOD
H517Q
FUS
M511Nfs*6
FUS
C9orf72 RE

Laminin
Fibronectin
Matrigel
Poly-LLysine
Laminin
lysine

>21 – 28
days, SNS

SB431542,
LDN193189,
CHIR99021, RA,
Pur

Laminin

11 days

BDNF, GDNF
CNTF, AA

Poly-Dlysine
Laminin
Primary
cortical
murine glia
Monolayer

15-30
days

MN

BIIITUB,
MAP,
CHaT

-

SNS - two
methods
referenced.

A4V

Spina
l MN

HB9, ISL1
BIIITUB,
MAP

Whole cell
voltage and
current
clamp

BDNF, GDNF
CNTF, AA

A4V

Spina
l MN

BIIITUB,
HB9,
CHaT

-

Motor
Neuro
ns

HB9

Whole-cellpatch, multi
electrode

A4V
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3-30 days

Correctio
n of
SOD1
mutation
via Zinc
finger
nuclease
and Coculutred
with
murine
glia,
chick
embryo
spinal
cord
Used
TALEN
and Cocultured
with
C2C12
myocytes
and MN

Used the
Correcte
d cells
from
Kiskinis
et al.
2014

Chestkov
et al., 2014

Possible to develop an ALSiPSC motor neuron model
from
a
SOD1-assocated
patient line.

SV
and
LV

2:
2

SOD1-SNS

Nishimura
et al. 2014

RNAi has potential as a
selective target for a TDP-43
M337V
to reduce disease
phenotypes.
Motor neurons with C9ORF72
M337V
RE and TDP-43
exhibit
hyperexcitability
prior
to
reduction of action potential
output.

RV

2 (1 ALS):
2

TDP-43

SV
and
RV

8 (4 ALS):
6

TDP-43
C9ORF72 RE

Devlin et
al., 2015

MN

HB9,
BIIITUB,
CHaT,
GFAP

-

SB431542,
RA,SHH, bFGF,
BDNF, GDNF,

Matrigel
Gelatin

14 days

M33V7

MN

BIIITUB

-

32

32

24 days

M337V

MN

BIIITUB,
GFAP
SMI32

Whole patch
clamp,
current
clamp,
voltage
clamp

N-acetyl
cysteine, bFGF,
RA, Pur, BDNF,
GDNF, CTNF,
SmoA, CTNF,
Forskolin

Polyornithine,
Laminin,
Fibronectin,
Matrigel

80 -150
days

Cocultured
with
iPSC
derived
Astrocyte
s

Ascorbic acid, AA; β-III tubulin, BIIITUB, β- mercaptoethanol; β-merc; Brain –derived neurotrophic factor, BDNF; cortical neurons, CN; cyclic adenosine
monophosphate; dorsomorphin, DORS; extracellular matrix, ECM; endoplasmic reticulum, ER; episomal vector system, EV; glial derived neurotrophic
factor, GDNF; Glial fibrillary acidic protein, GFAP; induced pluripotent stem cell, iPSC; islet 1, ISL1; lentiviral, LV; microtubule associated protein 2,
MAP2; poly-L, PL; purmorphamine, Pur; retinoic acid, RA; repeat expansion, RE; retroviral, RV; neurofilament H, SMI32; smoothened agonist, SmoA;
sonic hedgehog, SHH; specifics not specified, SNS; sendai virus, SV; Transcription activator-like effector nuclease system, TALEN; *Listed as growth
derived-neurotrophic factor.
.
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3.2 Hypotheses
1. Fibroblasts derived from ALS patients with a cyclin F mutation (CCNFS621G) can
be reprogrammed to induced pluripotent stem cells.

2. Induced pluripotent stem cells reprogrammed from fibroblasts from ALS patients
and control lines can be differentiated to motor neurons.

3.3 Aims

1. To reprogram, fibroblasts derived from ALS patients with a cyclin F mutation
(CCNFS621G), as well as an additional healthy donor to iPSC and complete
subsequent characterisation.

2. To differentiate motor neurons from ALS patient derived iPSCs, and healthy
donor derived iPSCs, and complete subsequent characterisation.

128

3.4 Successful reprogramming of patient derived fibroblasts to
iPSCs.

3.4.1

Fibroblasts from motor neurone disease patients and control lines are
capable of reprogramming to iPSCs.

To generate iPSCs, fibroblasts were reprogrammed using daily transfections of
pluripotency mRNA transcripts for 12 days; GFP mRNA transcripts were also
included in the transfection to monitor successful transfection (efficiency was not
calculated). By day 6, fibroblasts from a healthy donor and two CCNFS621G patients
exhibited fluorescence indicating transfection was occurring (Figure 3.3). Following
four days of culture, upon the completion of reprogramming, (day 16) stem cell-like
colonies appeared in culture, amongst cells that had retained fibroblast morphology
(Table 3.2). Colonies exhibited a round morphology of densely packed cells. High
magnification indicated cells with large nuclei and round morphology growing in
very close proximity (Figure 3.4).

Following collection and separation of the

individual colonies, single colonies were expanded and monitored for growth, and
for any changes to morphology.

Colonies with difficulties attaching following

passage, and cells with slow rates of proliferation were discarded; clones that were
successfully expanded to a 60 mm dish were catalogued and cryogenically stored.
Each independent reprogramming experiment generated a minimum of eight clones
that were likely candidates for future use.
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Table 3.2 Successful isolation and expansion of iPSC clones following
reprogramming
Cell line

Cell line abbreviation

Number of
clones

HC1

HC1- (Clone number)

15

CCNF1

CCNF1- (clone number)

10

CCNF2

CCNF2- (clone number)

8
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Figure 3.3 Representative images of fibroblast to iPSC reprogramming by transient
mRNA transfections
Images are representation of cells through the stage of reprogramming including
fibroblasts prior to reprogramming, cells positive for GFP due to the internalisation
and translation of GFP mRNA, as part of the mRNA reprogramming cocktail during
reprogramming, and the colonies arising from reprogramming. Images were taken
during reprogramming of three cell lines derived from a healthy female donor (HC1),
a female ALS patient with CCNFS621G mutation (CCNF1), and a male ALS patient
with CCNFS621G mutation (CCNF2). Brightfield images of fibroblasts were taken one
day following passage, prior to transient mRNA reprogramming (day -2). Scale bar =
200 µm. Fluorescent images of GFP expression were taken on day 10 of
reprogramming. Scale bars = 100 µm. Brightfield images of induced pluripotent stem
cell colonies on day 16 amongst fibroblast-like cells that were not fully
reprogrammed. Scale bars = 100 µm.
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3.5 Cells reprogrammed from ALS patient and healthy donor
fibroblasts have stem cell-like morphology.
To narrow the selection of iPSC clones for use in further experiments, clones were
first assessed for stem cell-like morphology. Clones were short-listed based on stem
cell-like qualities, including rounded cell shape, large nuclei, smooth colonies, self renewal ability and speed of proliferation. Clones 2, 7 and 10 reprogrammed from
fibroblasts from healthy female donor 1 (HC1; HC1-2, HC1-7, HC1-10), clones 2, 5,
7, 8 and 10 from a female pre-symptomatic ALS patient with CCNFS621G mutation
(CCNF1; CCNF1-2, CCNF1-5, CCNF1-7, CCNF1-8 and CCNF1-10), and clones 1,
7 and 8 from a male symptomatic ALS patient with CCNFS621G mutation CCNF2
(CCNF2-1, CCNF2-7 CCNF2-8) all displayed these stem cell-like qualities (Figure
3.4). Cell morphology and proliferation in these clones was similar to previously
characterised iPSC cell lines including the iPSC line derived from an ALS patient
with a SOD1E101G mutation (SOD1), the iPSC line derived from a healthy donor
(HC2), and iPSC line derived from a patient with sporadic Alzheimer’s disease
(SAD), age- and sex-matched to the HC2 line.

132

Figure 3.4 Induced pluripotent stem cell morphology following transient mRNA
reprogramming
Brightfield images of iPSC colonies following passage from cell lines derived from a
healthy donor (HC1), a pre-symptomatic CCNFS621G ALS donor (CCNF1), a
symptomatic CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G
mutation (SOD1), an additional healthy donor (HC2) and a sporadic Alzheimer’s
disease patient (SAD) as a neurodegenerative control. Cells were grown in TeSR E8,
and showed typical rounded cells, with rapidly expanding spiky colony borders
typical of pluripotent stem cell culture in TeSR E8. Asterisk (*) indicates
spontaneously differentiating cells that are routinely removed from cultures. Image
was taken at 10X magnification on an Incucyte imager; scale bars = 100 µm.
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3.5.1

Reprogrammed clones had variable pluripotency gene expression.

To select an appropriate stem cell clone for further experiments, relative gene
expression was measured in the clones that exhibited stem cell-like qualities. RNA
samples were measured for expression of the pluripotency factor Oct-4 encoded by
POU5F1, and Nanog, encoded by NANOG in comparison with levels expressed in
fibroblasts.

The relative mRNA expression of these pluripotency genes in the

shortlisted clones was normalised to housekeeper genes U6 and HPRT.

Clones reprogrammed from the healthy control female fibroblasts (HC1) exhibited a
higher relative pluripotent gene expression compared to fibroblasts, with an over
3,400 fold increase in NANOG in clone 10, and a near 27,000 fold in POU5F1. As
expression of both mRNAs was highest in clone 10 (HC1-10), this clone was
selected for further characterisation as the representative HC1 cell line (Figure 3.5).

The clones reprogrammed from the pre-symptomatic CCNFS621G patient fibroblasts
(CCNF1) were the first fibroblasts to be reprogrammed and characterised via qRTPCR for this study. All the iPSC clones characterised, including CCNF1-3, CCNF15, CCNF1-7, CCNF1-8 and CCNF1-10, showed significantly higher levels of both
POU5F1 mRNA and NANOG mRNA compared to fibroblasts; this included an over
3,000 fold increase in NANOG in clone 10 (F (5, 14) = 22.56. P<0.0001) and an over
2,800 fold increase in POU5F1 in clone 10 (F (5, 24) = 775.5. P<0.0001). Clone 10
showed a higher expression of NANOG compared to clone 2, and had a higher
expression of POU5F1 compared to three other clones. This clone 10 (CCNF1-10)
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was therefore selected for further iPSC characterisation as the representative CCNF1
cell line (Figure 3.6).

Clones reprogrammed from symptomatic CCNFS621G patient (CCNF2) all expressed
higher levels of POU5F1 compared to the fibroblasts (a 700 fold increase in NANOG
in clone 1 compared to fibroblasts; and an over 9000 fold increase in POU5F1 in all
clones. Clone 1 (CCNF2-1) showed higher POU5F1 expression than clone 7, and
expression of NANOG was also higher in clone 1 compared to both other clones
measured, as well as the fibroblasts sample. Clone 1 (CCNF2-1) was consequently
selected for further characterisation (Figure 3.7).
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A

B

Figure 3.5 Relative gene expression of pluripotency factors in HC1 clones.
Relative mRNA expression of pluripotency factor genes NANOG and POU5F1 in
clones generated from mRNA reprogramming of fibroblasts from a healthy donor.
Lysate was collected from cultures with ~80% confluency, five days following
passage. Relative gene expression was determined by quantitative real time PCR, and
normalised to two house keepers U6 and HPRT. Expression of pluripotency factors
was compared to fibroblasts collected prior to reprogramming. N=2 independent
samples.
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A

B

Figure 3.6 Relative gene expression of pluripotency factors in CCNF1 clones.
Relative mRNA expression of pluripotency factor genes NANOG and POU5F1 in
clones generated from mRNA reprogramming of fibroblasts from an ALS patient
donor with a pre-symptomatic CCNFS621G mutation. Lysate was collected from
cultures with ~80% confluency, five days following passage. Relative gene
expression was determined by qRT-PCR, and normalised to two housekeepers U6
and HPRT. Expression of pluripotency factors was compared to fibroblasts collected
prior to reprogramming. N=3 independent samples. **P>0.01, ***P>0.001.
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A

B

Figure 3.7 Relative gene expression of pluripotency factors in CCNF2 clones.
Relative mRNA expression of pluripotency genes NANOG and POU5F1 in clones
generated from mRNA reprogramming of fibroblasts from an ALS patient with a
symptomatic CCNFS621G mutation. Lysate was collected from cultures with ~80%
confluency, five days following passage. Relative gene expression was determined
by qRT- PCR, and normalised to two housekeepers U6 and HPRT. Expression of
pluripotency factors was compared to fibroblasts collected prior to reprogramming.
N=2 independent samples.
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3.5.1

Cells reprogrammed from ALS patients and healthy donor fibroblasts express
pluripotency factors.

To further validate that the reprogrammed cells were pluripotent, pluripotent protein
expression was evaluated by immunocytochemistry.

Protein expression for

pluripotency factors Oct-4 (Figure 3.8) were confirmed using fluorescent-labelled
secondary antibodies. Expression levels were comparable to previously characterised
iPSC cell lines in the Ooi lab, including the SOD1 iPSC line derived from an ALS
patient with a SOD1E101G mutation, the HC2 iPSC line derived from a healthy donor,
and the age- and sex-matched SAD iPSC line, derived from a patient with sporadic
Alzheimer’s disease.

Clone 10, clone 1, and clone 10 from the reprogrammed fibroblasts of a symptomatic
CCNFS621G patient, the pre-symptomatic CCNFS621G donor and a healthy donor
respectively, showed ubiquitous expression of the pluripotent protein Oct-4 in the
iPSC colonies two days following passage. Pluripotent protein levels were
comparable to other established pluripotent cell lines.
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Figure 3.8 Reprogrammed cells from ALS patients and a healthy donor express
pluripotency factor Oct4
Representative fluorescent images of iPSCs on day two following passage, stained
with an antibody for Oct4, with secondary Alexa Fluor 488, nuclear stain for DAPI,
and corresponding overlay images. The iPSC clones were derived from cell lines
derived from a healthy donor (HC1), a pre-symptomatic ALS patient with
CCNFS621G mutation (CCNF1), a symptomatic ALS patient with CCNFS621G mutation
(CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an additional healthy
donor (HC2) and a sporadic Alzheimer’s disease male patient (SAD) as a
neurodegenerative control. N=2 independent samples.
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3.5.1

All selected iPSC lines generated from mRNA reprogramming exhibited
pluripotent bioinformatics profiles

To further confirm pluripotency of the cells, the PluriTest was performed by Genea
Biocells. RNA samples from the three aforementioned clones (HC1-10, CCNF1-10
and CCNF2-1) as well as the SOD1 cell line, derived from a male ALS patient donor
with a SOD1E101G were analysed for a range of pluripotency markers using a
microarray assay. Microarray data was analysed for pluripotency and novelty.
Pluripotency scores, determined by Genea Biocells, ranged from 18.19 – 22.04 au.
Novelty scores ranged from 1.53 – 1.68 au. All cell lines submitted for the PluriTest
were deemed be normal pluripotent cells, and passed the PluriTest (Figure 3.9).
These clones were therefore submitted to the final stages of characterisation.
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Figure 3.9 PluriTest score output
Non-negative matrix factorization generated novelty score and logistic regression
model pluripotency scores were generated using microarray data by Genea Biotech
from supplied RNA samples of clones from reprogrammed iPSC cultures from (A) a
healthy donor (HC1; green), (B) a pre-symptomatic CCNFS21G ALS patient (CCNF1;
pink), (C) a symptomatic ALS CCNFS621G patient (CCNF2; red), and (D) an ALS
patient with a SOD1E101G mutation (SOD1; SOD1). N=1 independent sample.
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3.5.1

Gene specific analyses verified genetic profile, including CCNF genotype,
was unchanged by reprogramming

Previous reports have indicated genetic mutations can arise during cellular
reprogramming. To ensure no genetic mutations were induced by the reprogramming
process, genomic analyses were performed. Genomic DNA from fibroblasts and the
respective reprogrammed iPSCs from each cell line (HC1, CCNF1, CCNF2 and
SOD1) was sequenced STR analysis by the Garvan Medical Research Institute.
Sequences were then compared to fibroblasts of origins. No genetic variations were
detected. To verify specifically that the CCNF genotype was as originally reported
upon collection, specific gene analysis was performed by Dr Tracey Berg.
Genotypes for CCNF were as expected: CCNF1 and CCNF2 were heterozygous
S621G/S621S (AGT/GGT); The HC1, SOD1, HC2 and SAD lines were all
homozygous S621S (AGT) (Figure 3.10).

3.5.2 Genomic analysis confirms no chromosomal abnormalities
To confirm that no chromosomal abnormalities were induced by the reprogramming
process, iPSC samples were submitted for karyotyping at StemCore. The G-bands
from 15-30 cells per cell line were assessed for copy number variations and
translocations at a resolution of 400 bphs. No chromosomal abnormalities were
detected in any cell lines (Figure 3.11).
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Figure 3.10 Genetic sequencing of CCNF gene
Representative genotyping of the CCNF gene in iPSC derived neural precursor
samples generated from (top) a pre-symptomatic ALS patient with CCNFS621G
mutation (CCNF1), a symptomatic ALS patient CCNFS621G mutation (CCNF2) heterozygous S621G/S621S (AGT/GGT) and (bottom) WT CCNF carriers
originating from a healthy donor (HC1), an ALS patient with a SOD1E101G mutation
(SOD1), an additional healthy donor (HC2) and a sporadic Alzheimer’s disease
patient (SAD) - homozygous S621S (AGT). Nucleotides detection represented in
colours - adenine (A; green), guanine (G; black), thymine (T; red); ALS associated
mutation S621G is represented is denoted by ‘M’ (pink) wherein an overlay of both
adensoine and guanine is present. Samples were collected by Monique Bax, PCR
run by Dr Tracey Berg.
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Figure 3.11 Representative karyograms of the six induced pluripotent stem cell lines.
Karyograms were generated by Stem Cells Limited at 400 bphs from the iPSCs
originating from a healthy donor (HC1), a pre-symptomatic ALS patient with
CCNFS621G mutation (CCNF1), a symptomatic ALS patient with CCNFS621G mutation
(CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an additional healthy
donor (HC2) and a sporadic Alzheimer’s disease male patient (SAD) as a
neurodegenerative control. G-banding from 15-30 cells were investigated per cell
line.
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3.5.1

Stem cell clones differentiated into the three tissue types

For the final confirmation of pluripotency, the clones from the three respective cell
lines, as well as previously established pluripotent control cell lines were
differentiated into cells originating from the three germ layer tissue types: the
endoderm, mesoderm, and ectoderm. All cell lines were able to differentiate into
cells expressing morphology and protein markers consistent with cells from all three
germ layers; also verfiied via q-RT PCR as per Bax et al. (2019) (data not shown).

3.5.1.1 Reprogrammed stem cells were able to differentiate into cells from each of
the three germ layers
To assess that the stem cell lines could differentiate towards an endodermal lineage,
all six cell lines were differentiated using a definitive endoderm protocol. All cell
lines displayed classic endodermal progenitor morphology following differentiation
Cells formed tight clusters in a dense monolayer. Cells from the six cell lines that
were differentiated to endodermal progenitors exhibited expression of FOXA2 via
immunochemistry (Figure 3.13), indicative of definitive endodermal progenitors. To
assess the ability of the cells to differentiate down a mesodermal lineage, cells from
all six cell lines were differentiated according to a myotube differentiation protocol.
Cells from all six cell lines showed typical myoblast morphology: cells elongated
and aligned, and in some cases began to fuse becoming multinuclear (Figure 3.14).
To assess the cells capacity to differentiate to an ectodermal lineage, the cells from
all six cell lines were differentiated to neuronal precursors using a motor neuron
differentiation protocol. All cell lines showed morphology consistent with neural
rosettes, neuronal progenitors and motor neurons (as described further).
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Figure 3.13 Selected pluripotent stem cell lines differentiated into cells expressing
endodermal marker FOXA2
Immunocytochemical analysis of endodermal marker FOXA2 in the iPSC clone lines
differentiated to endodermal progenitor show positive expression of the marker. The
staining indicates the clustering morphology in all cell lines which included from a
healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a
symptomatic CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G
mutation (SOD1), an additional healthy donor (HC2) and a sporadic Alzheimer’s
disease patient (SAD). N=2 Independent differentiations per cell line. Scale bar =
200 μm. Brightfield high magnification images as per Appendices Figure 8.0.
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Figure 3.14 Selected pluripotent stem cell lines differentiated into cells with
mesodermal morphology
Myoblast-like morphology was displayed in cells differentiated in all cell lines which
included from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS donor
(CCNF1), a symptomatic CCNFS621G patient (CCNF2), an ALS patient with a
SOD1E101G mutation (SOD1), an additional healthy donor (HC2) and a sporadic
Alzheimer’s disease patient (SAD). Scale bar = 50 μm.
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3.5.2

Successful differentiation of motor neurons from iPSCs

Once the selected reprogrammed clone lines were confirmed to be pluripotent, and
capable of differentiation to an endodermal and mesodermal lineage, cells were
differentiated through the ectodermal lineage to motor neurons.

Initial

differentiations using the protocol of Dimos et al. (2008) generated low yields
(observations only, data not quantified) and resulted in high cell death in neuronal
development and maturation phases. More recent protocols were trialled, generating
a higher yield of cells with neuronal morphology (based on observations only). The
final protocol used for motor neuron differentiation was an amalgamation of these
protocols, utilising aspects of the protocols by Bilican et al. (2015) and Qu et al.
(2014).

As per Bilican et al. (2015), cells were maintained in hypoxic conditions following
the formation of neural rosettes. Following the differentiation of anterior neural
precursors (aNPCs), the still mitotic cells were plated for the final maturation step.
As per Qu et al. (2014), cultures were grown on laminin, fibronectin and collagen I.
As per all motor neuron protocols that had been published at the time of this study,
cells were caudalised with retinoic acid, and ventralised, to generate spinal motor
neurons.

This study used purmorphamine, as a sonic hedgehog (ventralising

morphogen) agonist, similar to the original Dimos et al. (2014) protocol.

For

maturation, cells were treated with GDNF and BDNF as per previous motor neuron
differentiation protocols, and with cAMP and IGF to increase cell survival as per Qu
et al. (2014). Unlike these published protocols, motor neurons were matured for six
weeks to allow further maturation. Following this maturation period, the neuronal
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cells

were

characterised

based

on

morphology,

protein

expression

and

electrophysiological properties as measured by Dzung Do-Ha.

3.5.3 Differentiated iPSCs formed neural rosettes followed by aNPCs
Following removal of iPSC maintenance media (TeSR E8) Cells were left in
suspension for three days, to form embryoid bodies. When plated down on laminin,
these cells attached and dispersed into rosette structures, radiating from a centre point
(Figure 3.15). All six cell lines were able to successfully generate neural rosettes
with no discernible difference in yield based on general observation. Following
culture in hypoxic conditions, and treatment with bFGF, cells collected from neural
rosettes formed aNPCs (Figure 3.16). Cultures from all six cell lines could be
maintained at this stage for five passages before changes in cellular proliferation.
Cell lines had a varying propensity to change proliferation and eventually
morphology at higher passages.

Below this number of passages there was no

discernible difference in overall morphologies of cells in culture between the six cell
lines. aNPCs from all six cell lines were capable of further differentiated towards a
neuronal phenotype as required with no discernible difference in yield from general
observation.
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Figure 3.15 Neural rosette morphology following differentiation to ectodermal
lineage
Representative inverted microscopy images of neural rosettes formed in cultures
differentiated from iPSC clones derived from a healthy female donor (HC1), a
female ALS patient with CCNFS621G mutation (CCNF1), a male ALS patient with
CCNFS621G mutation (CCNF2), a male ALS patient with a SOD1E101G mutation
(SOD1), a healthy male donor (HC2) and a sporadic Alzheimer’s disease male
patient (SAD). Scale bar =100 µm
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Figure 3.16 Cells exhibited anterior neural precursor morphology following
differentiation towards neural linage
Representative Incucyte Zoom images of anterior neural precursor cells
differentiated from neural rosettes as an intermediate stage of the motor neuron
differentiation. Cells are derived from a healthy donor (HC1), a pre-symptomatic
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), an
ALS patient with a SOD1E101G mutation (SOD1), an additional healthy donor (HC2)
and a sporadic Alzheimer’s disease patient (SAD). Scale bar =100 µm.

154

3.5.1

aNPCs were matured to motor neurons

Following caudalisation and ventralisation of aNPCs, cells developed neuronal
morphology. Cells exhibited outgrowth of neurite structures that appeared to form
networks (Figure 3.17).

Differentiated iPSCs expressed motor neuron-specific

protein markers; To assess the yield of motor neurons generated by the developed
protocol, cells were probed for three neuronal markers, including motor neuron
specific neuronal marker HB9, Islet 1 and neuronal marker neurofilament heavy
(SMI32). The expression of these motor neuron markers were not significantly
different between cell lines (discussed further in this chapter) indicating a similar
propensity in these cells to generate motor neurons using this protocol. Negative
immunocytochemistry controls showed low background fluorescence, and image
settings were adjusted for this.

All cell lines differentiation with this protocol successfully generated cells that
expressed the motor neuron marker HB9 (Bax et al., 2019a). Confocal images of the
neuronal cultures indicated consistently high percentages (ranging from 73-92%) of
this motor neuron marker regardless of the cell line differentiated (Figure 3.19).
Manual cell counts of a minimum of 1,400 cells indicated an average of over 83.9 ±
2.5% HB9 positive cells across the six cell lines (Table 3.3). ANOVA analysis with
Tukey’s multiple comparison post hoc indicated no significant difference in yields
between the different cell lines were detected (F(5,10)=0.99. P=0.47).

All cell lines differentiated with this protocol generated cells that expressed Islet 1.
Confocal images of the neuronal cultures indicated consistently high percentages of
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this motor neuron marker regardless of the cell line differentiated (Figure 3.21.
Manual cell counts using FIJI software indicated an average of over 88.0±1.4% Islet
1 positive cells across the cell lines (Table 3.3). ANOVA analysis with Tukey’s
multiple comparison post hoc indicated no significant difference in yields between
the different cell lines were detected F(5,12)=1.81. P=0.19).

All cell lines differentiation with this protocol generated cells that expressed SMI32.
Confocal images of the neuronal cultures indicated consistently high percentages of
this neuronal marker regardless of the cell line differentiated (Figure 3.22). Manual
cell counts via FIJI software indicated an average of over 90.5±1.4% SMI32 positive
cells across the six cell lines (Table 3.3). ANOVA analysis with Tukey’s multiple
comparison post hoc indicated no significant difference in yields between the
different cell lines were detected F(5,12)=1.81. P=0.19).

Table 3.3. Motor neuron markers detected by immunocytochemistry
Percentage of cells positive for motor neuron markers as indicated by
immunocytochemistry

Cell line

HB9

Islet 1

SMI32

HC1

84.2 ± 2.7% (N=2)

81.4 ± 3.7%

94.3 ± 1.1%

CCNF1

91.5 ± 2.4%

92.8 ± 1.9%

94.0 ± 0.7%

CCNF2

80.7 ± 5.6%

90.2 ± 1.7%

87.5 ± 2.1%

SOD1

84.5 ± 10.5% (N=2)

92.2 ± 1.0%

91.9% (N=1)

HC2

72.6 ± 1.9%

88.2 ± 5.2%

86.3 ± 06.1%

SAD

85.7 ± 6.8%

88.1 ± 2.8%

89.5 ± 3.1%

Average

83.9 ± 2.5%

88.8 ± 1.4%

90.5 ± 1.4%
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Figure 3.17 Motor neuron differentiation produced cell with motor neuron
morphology.
Representative Incucyte Zoom images of motor neurons in culture, which exhibited
long neurite structures and formed intricate networks following the six weeks
maturation. Cells were differentiated from iPSC clones derived from a healthy donor
(HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic
CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD)
Scale bar =100 µm
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Figure 3.18 Motor neuron differentiation produced a high percentage of HB9
positive cells in all cell lines
Representative fluorescent images of motor neurons matured for six weeks,
following staining with mouse anti-HB9 (Alexa Fluor 488), nuclear stain Reddot2.
Overlay image demonstrates the typical nuclear localisation. Cells were
differentiated from iPSC clones derived a healthy donor (HC1), a pre-symptomatic
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), an
ALS patient with a SOD1E101G mutation (SOD1), an additional healthy donor (HC2)
and a sporadic Alzheimer’s disease patient (SAD) (Bax, 2019a). Scale bar = 250 µm.
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Figure 3.19 Quantification of HB9 positive cells in all cell lines
Percentage per image of cells expressing green fluorescence indicative of HB9.An
average of 93.41 cells were manually counted per image of motor neurons matured
for six weeks were quantified using FIJI. Following staining of motor neurons with
mouse anti-HB9 (Alexa Fluor 488) and nuclear stain Reddot2, a minimum of 10
images per cell line were examined for cells with both red and green signal, and red
signal only. No significant difference in HB9 expression in cells differentiated iPSC
clones derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS
patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), an ALS patient with a
SOD1E101G mutation (SOD1), an additional healthy donor (HC2) and a sporadic
Alzheimer’s disease patient (SAD) were detected through ordinary one-way
ANOVA with Tukey’s multiple comparison test post hoc. Averages were determined
from a minimum of two separate differentiations.
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Figure 3.20 Motor neuron differentiation produced a high level of Islet 1 positive
cells in all cell lines
Representative overlay of fluorescent images of motor neurons matured for six
weeks, following staining with Islet 1 (green) and Reddot2 nuclear stain (red). Cells
were differentiated from iPSCs derived from iPSC clones derived from a healthy
donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic
CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD).
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Figure 3.21 Quantification of Islet 1 positive cells in all cell lines
Fluorescent images of motor neurons matured for six weeks were quantified using
FIJI. Following staining of motor neurons with mouse anti-Islet 1 (Alexa Fluor 488)
and nuclear stain Reddot2, a minimum of 10 images per cell line were examined for
cells with both red and green signal, and red signal only. No significant difference
in HB9 expression in cells differentiated iPSC clones derived from a healthy donor
(HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic
CCNFS621G patient (CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD)
were detected through ordinary one-way ANOVA with Tukey’s multiple comparison
test post hoc. Averages were determined from a minimum of two separate
differentiations.
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Figure 3.23 Quantification of SMI32 positive cells in all cell lines
Fluorescent images of motor neurons matured for six weeks were quantified using
FIJI. Following staining of motor neurons with mouse anti-SMI32 (Alexa Fluor 488)
and nuclear stain Reddot2, a minimum of 10 images per cell line were examined for
cells with both red and green signal, and red signal only. No significant difference in
HB9 expression in cells differentiated from iPSCs derived from a from a healthy
female donor (HC1), a female ALS patient with CCNFS621G mutation (CCNF1), a
male ALS patient with CCNFS621G mutation (CCNF2), a male ALS patient with a
SOD1E101G mutation (SOD1), a healthy male donor (HC2) and a sporadic
Alzheimer’s disease male patient (SAD) were detected through ANOVA with
Tukey’s multiple comparison test post hoc. Averages were determined from a
minimum of two separate differentiations.
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Figure 3.24 Quantification of SMI32 positive cells in all cell lines
Representative fluorescent images of motor neurons matured for six weeks,
following staining with SMI32 (green) and DAPI nuclear stain (blue). Cells were
differentiated from iPSCs derived from iPSC clones derived from a healthy donor
(HC1).
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3.6 Discussion
3.6.1 Three fibroblast cell lines were reprogrammed to iPSCs
In this study, three cell lines were successfully reprogrammed using repeated mRNA
transfections of pluripotency factors (Mallanna and Rizzino, 2010; Mandal and
Rossi, 2013). The reprogramming experiments successfully generated multiple
clones, of which three iPSC lines (CCNF1, CCNF2 and HC1) were selected to
represent stem cells derived from a pre-sympotmatic

female donor with

a

CCNFS621G mutation, a male patient with a CCNFS621G mutation and a healthy donor,
respectively. Clones from these reprogramming experiments displayed stem cell like
qualities including a round cellular form, large nuclei, round colony formation, selfrenewal and quick proliferation (Takahashi and Yamanaka, 2013). Clones CCNF110 (CCNF1), CCNF2-1 (CCNF2) and HC1-10 (HC1) all exhibited high levels of
gene expression of POU5F1 (Oct4) and NANOG relative to other clones and
significantly higher than the fibroblasts from which they were derived; Further
evaluation of these cell lines for pluripotency protein expression confirmed
consistent expression of pluripotency factor OCT4, indicating a successful
reprogramming of these fibroblasts to iPSCs (Müller, 2014).

PluriTest scores typical of pluripotent cell lines with no previously known
abnormalities were detected (Müller et al., 2011); karyotyping indicated
chromosomal integrity was maintained; STR profiling, as well as specific PCR of the
CCNF gene failed to reveal any mutations as a result of the reprogramming.
Maintaining the genetic integrity of these cells (I.e. confirming the genetic
background of the donors from which these cells derive matches) is of paramount
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importance, given one of the strengths of engaging iPSCs is that these cells
genetically reflect patients (Ooi et al., 2013). Continuity of the genetic profile is also
of importance for genetic editing which will be undoubtedly critical in future
investigations into the effects of mutations and environmental in ALS (Musunuru,
2013). The final, and most important aspect of establishing pluripotent stem cells
was the confirmation of the capacity to differentiate to the three germ layers
(Takahashi and Yamanaka, 2006).

The reprogrammed cells were capable of

differentiation into cells with characteristics consistent with those from the three
germ layers, including mesodermal, endodermal and ectodermal cell types, as
indicated by morphology and progenitor markers, thereby confirming the successful
generation of iPSCs (Takahashi and Yamanaka, 2013).

3.6.2 iPSC generation unaffected by S621G mutation
The reprogramming of the cells derived from the two ALS patients indicated for the
first time the S621G mutation in the CCNF gene did not inhibit reprogramming or
pluripotency maintenance. The ability to successfully reprogram these cells was not
assured given the involvement of the UPS in stem cell generation and pluripotency
maintenance, and what little was known of the role of cyclin F (Williams et al.,
2016). Some lines of evidence suggest that cells from different donors exhibit
different reprogramming capacity and that not all cell lines are capable of reversion
to a stem cell state (Kyttälä et al., 2016; Liebau et al., 2013). The reprogramming of
the two CCNFS621G cell lines indicated that this mutation did not significantly impact
the ability of these cells to revert to the stem cell state.
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3.6.3 Developed differentiation protocol robustly generated motor neurons
The differentiation protocol developed in this study robustly generated cells with
neuronal morphology, with a high yield of HB9, Islet 1 and HB9 positive cells. This
protocol was developed using features of previously published work, following a
high cell death in cultures generated from the Dimos et al. protocol (data not shown).
The introduction of a more comprehensive extracellular matrix (ECM) cocktail
provided a more biologically relevant extra cellular environment, similar to that
found in vivo. Similar to the importance of the ECM in maintaining pluripotency in
stem cell cultures (Hughes et al., 2010), recent studies indicated that the type of ECM
proteins present directly affect differentiation (Qu et al., 2014). An increased motor
neuron yield is attributed in part to the introduction of collagen I and fibronectin to
this protocol, which was not incorporated in early foundational studies such as that
by Dimos et al. (2008; which used a laminin matrix). Qu et al (2014) found that the
introduction of these two additional ECM proteins to the typically used laminin plate
coating increased the motor neuron yield by over 50 fold. Given over 30 collagen
types have been identified, it would be unsurprising that these ECM proteins would
influence differentiation (Fox, 2008). Indeed, collagen XIII appears to be important
in the formation of neuromuscular junctions (Härönen et al., 2017). Though cells will
secrete their own extracellular proteins (Fox, 2008), further investigation into
supplementing cultures with other collagen subtypes would be an important
undertaking for development of the field.

The introduction of a neural precursor stage in the protocol used by Bilican et al.
(2015) provided a maintenance point within the differentiation. At the neural
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precursor stage, cells maintained a relatively plastic state, still capable of
proliferation and self-renewal for up to five passages, allowing time for expansion, if
required. As per the Bilican et al. (2015) protocol, caudalisation of the neural
precursors would begin the final stages of maturing the cells; these cells would
eventually become post-mitotic and would begin to behave as adult somatic cells.

3.6.4 Motor neuron differentiation unaffected by S621G mutation
Characterisation and subsequent quantification of expression of motor neuron
specific proteins HB9, and Islet 1, as well as neuronal marker SMI32 did not indicate
any significant differences in the propensity of the six cell lines to differentiate to
motor neurons. The S621G mutation of CCNF therefore also appeared to have no
effect on the ability of the cells to differentiate into motor neurons, or other cell
types. Findings by Hogan et al. (2017) indicated that mutant cyclin F impacted
neurodevelopment more than wild type cyclin F in zebrafish. It would therefore be
pertinent to quantify the length of the neurite extensions throughout development in
future studies to examine if these effects are temporal, occurring at a certain through
development, or is perhaps only a phenotype exhibited in zebrafish transfected with
human CCNF.

Motor neuron differentiation protocol development is a fast moving field - at the
commencement of this study the highest reported motor neuron yield was an
impressive claim considering the highest previously reported purity was 50% (Rao
and Malik, 2012). Early into the customisation and development of this protocol, Qu
et al. reported an approximately 70% yield of motor neurons by using a combination
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of compound C, retinoic acid, sonic hedgehog and other neurotrophic factors at new
stages in the differentiation, including the introduction of compound C at day one,
and retinoic acid as early as day three (Qu et al., 2014). The optimisation of the
protocol here has thus yielded significant increases in the motor neuron
differentiation efficiency. Despite this, the protocol described in this study can still
be improved upon. Since this study was completed, advances have been made in
protocol developments.

Motor neuron differentiation protocols are subject to

constant improvement - owing largely due to demand this cell type for motor neuron
research.

Development

of

new

commercial

reagents

and

increases

in

developmental/motor neuron differentiation knowledge are providing constant
opportunities for protocol development. This founding protocol is however, a very
efficient stepping stone for further studies, and serves as an effective protocol to
study the early stages of ALS.

One of the current limitations in the development of these cells is the lack of mature
motor neuron markers. HB9 and Islet 1 expression are currently accepted markers for
motor neurons, however these cannot define the motor neuron subtype, or the
maturity of the cells. Work in the Ooi lab has recently generated motor neurons with
an increased

neuronal

maturation and electrophysiological

activity

using

commercially available products that were not available at the time of this study.
This includes a new basal medium that is now commercially available, which more
closely resemble physiological conditions of the central nervous system (Bardy et al.,
2015). Small molecule inhibitors have become commercially available since the
development of this protocol. In addition to the small molecule purmorphamine
engaged in this study, small molecules including DMH1, an inhibitor of bone
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morphogenetic protein signalling, SB431542, inhibitor of activinnodal signalling and
CHIR99021, a Wnt signal antagonist can be engaged to regulate motor neuron
differentiation and maturation (Du et al., 2015; Huang et al., 2017).

Advances in 3-dimensional (3D) culture systems are providing an additional
approach for generating motor neurons. In order to mimic the in vivo environment,
cells can be cultured in 3D systems. These can range from polymer gels, solid
porous scaffolds, fibrous scaffolds, and acellular scaffolds, to organoidal chip-based
or even microfluidic- based systems (Bhatia and Ingber, 2014; Murphy et al., 2017).
These 3D systems serve to increase the surface area available to the cells, allowing
for greater cellular interactions both the ECM (including available nutrients/growth
factors), and other cells in culture, increasing the potential direct interactions
(Carletti et al., 2011). Though 3D systems present many complex challenges to
experimental designs (for example, how to image cells entrapped in a 3D structures),
the field is increasingly engaging the use of these systems, and will no-doubt
creatively problem solve (such as the use of post mortem techniques and reporter
systems) to engage with these culture systems which better replicate in vivo systems
(Ko and Frampton, 2016).

Motor neuron differentiation research has not only expanded into the 3D, but is also
focussing on the culture of specific cell types, both non-neuronal and motor neuron
subtypes.

It has been long established that co-culturing motor neurons with

myotubes increases cellular survival and maturation in chicks (O’Brien and
Fischbach, 1986; Prives et al., 1976); Logically, the next step in developing human
motor neuron differentiation protocols is to pair these neuronal cells with their
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natural interactors including Schwann cells, astrocytes, and myotubes to generate a
neuromuscular circuit. The field, including the Ooi laboratory, is working towards
these co-culture systems (Bucchia et al., 2018; Sances et al., 2016). Excitingly, the
use of iPSCs means these culture systems can be genetically matched - meaning all
cell types will be of the same origin, replicating even closer the neuromuscular
circuit of a patient.

In additiona to examining the different cell types of the neuromuscular circuit,
research into motor neurons is increasingly moving towards understanding
differentiaitons to specific types of motor neurons. An increased understanding of
Hox genes, a subset of the fundamental development transcription factors, serves to
hone our ability to differentiate motor neuron subtypes (Dasen and Jessell, 2009;
Pearson et al., 2005). For example, the Hox controlled Ret and Gfrα genes have been
identified as key regulators for the development of limbic motor neurons (Catela et
al., 2016). This is a particularly attractive motor neuron subtype to target, as these
are the first motor neurons affected in the majority of ALS aetiology (Vucic et al.,
2007). Generally, motor neuron differentiation protocols have focused on generating
lower (spinal cord) motor neurons, though the early work in upper (corticospinal)
motor neurons will no-doubt serve to drive robust protocols to model these neurons
(Sances et al., 2016). Understanding the differences, and subsequently allowing for
the differentiation of the different motor neuron subtypes will undoubtedly serve to
aid in therapeutic developments for motor neurone diseases (Brockington et al.,
2013).

171

3.7 Summary and future directions

As we increasingly refine our ability to effectively and efficiently generate iPSC
derived motor neuron through improvements to iPSC reprogramming, maintenance,
and subsequent cellular differentiation, we increase the accuracy in which we will be
able replicate disease ‘in a dish’. Improvements to iPSC culture protocols that
promote upscaling (via increased reprogramming efficiencies, and reduced cost in
maintenance, including labour required) allow for the potential to increase in sample
size and number (including the number of cell lines employed).

The successful

reprogramming of iPSCs performed here provides a canvas to create not only cell
types relevant to the study of ALS but also the perfect control cell lines.
Developments in genetic editing with CRISPR have meant that these reprogrammed
cells can be corrected for these ALS causing mutations alone; these cells provide the
exact same genetic background, removing the genetic ‘noise’ from influencing
results. Since the completion of this study, these cells have been used to generate
CRISPR clones. Together, the patient-iPSCs generated from this study, (following
identification of disease phenotypes), and CRISPR clones, generated from these
reprogrammed cells, are powerful tools for therapeutic development. Improved
understanding of motor neuron generation furthers our ability to recapitulate ALS.
Future studies which are able build from this protocol, engaging newly commercial
available small molecules, basal media, 3D systems alongside new protocols to
generate neuromuscular circuits promise the potential to produce in vitro systems to
mimic those in vivo closer than ever before. Employing these holistic systems will
undoubtedly aid furthering our understanding, not only of the effects of the CCNF
mutations, but of ALS as a neurodegenerative disease.
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Chapter Four:

ALS Associated Protein
Expression in Patient Induced
Pluripotent Stem Cell Derived
Motor Neurons
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4 ALS ASSOCIATED PROTEIN EXPRESSION IN PATIENT INDUCED
PLURIPOTENT STEM CELL DERIVED MOTOR NEURONS

4.1 Introduction
4.1.1

Patient iPSC derived motor neurons to model ALS

One of the major strengths of engaging iPSCs in neurodegenerative research is the
ability to examine the endogenous proteins in cell types of interest.

For ALS

research this allows for the investigation of the endogenous cellular mechanisms
affected by the disease, particularly proteostasis dysfunction, in motor neurons. One
of the primary objectives in developing the iPSC derived motor neuron models in
this study was to identify if, and if so, what ALS phenotypes are present, in order to
understand these mechanisms, and to provide potential read-outs for early therapeutic
trials (Faravelli et al., 2014). An invaluable advantage of using these iPSC derived
motor neurons in ALS research, is that overexpression of ALS relevant proteins is
potentially not necessary, as is the case for other motor-neuron model cell lines such
as NSC34 cells (Cashman et al., 1992; Williams et al., 2016). This is particularly
important as the upregulation of proteins can generate artificial effects, which may be
falsely interpreted as disease relevant phenotypes (Hjerpe et al., 2016).

4.1.2

TDP-43 and cyclin F in iPSC derived motor neuron models

As aforementioned, most cases ALS are considered a TDP-43 proteinopathy. TDP43 post-translational modifications are associated with ALS pathology (Mackenzie et
al., 2010); Ubiquitinated and phosphorylated TDP-43 are both found in cellular
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aggregates (Arai et al., 2010). TDP-43 therefore represents a fundamental ALS
protein to examine in ALS models (Ederle and Dormann, 2017). Conversely, cyclin
F represents a relatively novel protein associated with ALS, which will provide new
and important insight into the mechanisms that underlie the disease. While there have
been studies examining TDP-43 in ALS iPSC motor neuron models previously, this
study represents the first to examine TDP-43 in a mutant CCNF model (Bilican et al.,
2012; Burkhardt et al., 2013; Egawa et al., 2012; Nishimura et al., 2014; Serio et al.,
2013; Zhang et al., 2013). To date, no study has examined the endogenous
expression of cyclin F in a motor neuron model.

4.1.3

ALS associated protein localisation and nuclear bodies

Protein localisation is central to ALS aetiology; protein mislocalisation, particularly
the mislocalisation of nuclear proteins to the cytosol is commonly observed in ALS
associated proteins including TDP-43 (Barmada et al., 2010). The inappropriate
localisation of proteins in aggregates is a hallmark of ALS pathology. These protein
bodies, which can be cytosolic and/or nuclear in localisation, can be classified to an
extent by shape, size and number. Cytosolic bodies including JUxta Nuclear Quality
control compartment (JUNQ), Insoluble Protein Deposit (IPOD), RNA interactor
specific compartments/inclusions (RISCI), aggresome-like structures (ALIS), ERassociated degradation-associated vesicles (ERADAV), are vital in modulating
proteostasis in the cytosol. A number of different functional nuclear protein bodies
have been classified to date (Table 4.1; Scotter et al., 2015); the nuclear bodies may
play important roles in mediating transcription and translation processes. In the
cytosol, there are three main types of protein bodies: aggresomes, processing bodies
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(p-bodies) and stress granules. Aggresomes are single irregular bodies up to 10 μm in
size; P bodies are small (0.1 - 1.0 μm large) round bodies that can be far more
abundant reaching up to 30 bodies per cell. P bodies also have overlapping common
features with cytosolic stress granules, which are present in numbers between 5 - 30
per cell, and can be 0.4- 5.0 μm in size. Unlike P bodies, however, stress granules are
irregular in shape (Scotter et al., 2015; Spector, 2006).

Table 4.1. Nuclear protein body (based on Cellular Bodies by Spector (2006))
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4.1.4

Ubiquitome proteasome dysfunction

The presence of aggregates/protein bodies in motor neurons is a hallmark phenotype
of ALS. As aforementioned, it is not clear which and/or to what extent these
aggregate structures are detrimental to motor neurons (Webster et al., 2017).
Nonetheless, the presence of these aggregates is linked to UPS function, and it is
therefore important to investigate aggregation as a potential therapeutic target or
biomarker for disease. Many methods are now available to examine the viability of
the iPSC derived motor neurons, and the efficacy of the UPS. Traditional viability
assays coupled with tools, such as the degron assay (Bett et al., 2009), provide a
powerful platform to investigate cellular populations in bulk cell assays in an
endogenous system. The degron assay provides a functional readout of UPS activity
via expression of florescent proteins. Proteins that are typically destined for
proteasomal degradation are tagged with a degron, a degradation signal. This assay
takes advantage of this degron signalling via expression of a degron tagged GFP (via
plasmid transfection); dysfunction in UPS activity results in an accumulation of GFP,
thereby providing a functional readout.

This study sought to assess abundance and localisation of the above mentioned
proteins, as well as the UPS function in the iPSC derived motor neuron models
generated.

To identify the cellular mechanisms affected by cyclin F, and

subsequently, why mutations to this gene lead to motor neuron death, it is necessary
to first identify the properties of cyclin F in motor neurons. Cellular localisation,
inclusion in aggregates and relative abundance will aid in understanding the role of
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cyclin F in neurons. The successful generation and characterisation of patient-iPSC
derived motor neurons (as described in Chapter Three), including a healthy control,
two CCNFS621G patients, and a SOD1E101G derived cell lines provided dynamic
cellular models with the potential to examine endogenous cyclin F. Together, using
these cells along with two additional iPSC lines (an additional healthy control, and a
sporadic Alzheimer’s disease patient derived cell line, which has been shown to
exhibit a disease phenotype, to act as a neurodegenerative control (Balez et al.,
2016)) it is possible to examine the expression of ALS-relevant phenotypes. Here,
the presence, relative abundance and localisation of endogenous cyclin F and
endogenous TDP-43, along with UPS function have been investigated in these
patient derived motor neurons.

178

4.2 Hypotheses

1. ALS patient iPSC derived motor neurons express endogenous cyclin F at
abundances detectable by western blot.
2. Endogenous cyclin F localises to the nucleus of ALS patient iPSC derived
motor neurons.
3. ALS patient iPSC derived motor neurons will express endogenous TDP-43 at
abundances detectable by western blot, and these abundances will be reduced
in the ALS patient lines.
4. Endogenous TDP-43 localises in the nucleus of ALS patient iPSC derived
motor neurons.
5. Increasing ubiquitin proteasomal system stress will reduce the viability in
ALS patient iPSC derived motor neurons compared to healthy control donor
derived iPSC derived motor neuron.

4.3 Aims

1. To measure cyclin F expression in ALS patient-iPSC derived motor neurons,
and compare to expression in control-iPSC derived motor neurons.
2. To assess the cellular localisation of cyclin F in ALS patient iPSC derived
motor neurons, and compare to control-iPSC derived motor neurons.
3. To measure TDP-43 expression in ALS patient-iPSC derived motor neurons,
and compare to expression in control-iPSC derived motor neurons.
4. To assess the cellular localisation of TDP-43 in ALS patient iPSC derived
motor neurons, and compare to control-iPSC derived motor neurons.
5. To assess ubiquitin proteasome system dysfunction in ALS patient iPSC
derived motor neurons compared to healthy donor derived iPSC derived
motor neurons.
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4.4 Endogenous cyclin F in motor neurons

4.4.1

Expression of cyclin F decreased in CCNFS621G patient iPSC derived motor
neurons

Following the successful generation of CCNFS621G patient iPSC derived motor
neurons, the next crucial task for establishing the iPSC derived motor neurons was to
determine if ALS-associated proteins were detectable at endogenous levels in these
models. Cyclin F, the newly identified ALS-associated protein was first examined:
Endogenous cyclin F was detectable via western blot. Quantification of the protein
in the different iPSC derived motor neuron models (normalising the quantities to
NSE) identified a reduction in cyclin F in the Triton X soluble cell lysate in all three
of the ALS-patient derived lines (Figure 4.1). These reductions were significantly
lower (3.81 - 4.98 fold; F(5,12)=6.771. P=0.0032) compared to one of the two
healthy control lines, though trended to be reduced compared to all other control cell
lines.
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Figure 4.1. Quantification of endogenous cyclin F
Representative image, and dotplot quantification of cyclin F quantified by western
blot analysis of triton X soluble cyclin F in whole cell lysate from iPSC derived
motor neurons. Cell lines were derived from a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative
control. N=3 independent differentiations; Significance determined via ANOVA,
Tukey’s multiple comparison post hoc test**P>0.01
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4.4.2

Endogenous cyclin F localises in the nucleus of motor neurons, as nuclear
bodies.

Confirming cyclin F was detectable at endogenous levels, it was next imperative to
investigate the localisation of cyclin F in these cells. In order to further understand
the role of cyclin F in motor neurons, confocal analysis of cyclin F immunolabelled
motor neurons was performed. Confocal imaging revealed that cyclin F was
expressed in the nucleus in puncta consistent with nuclear bodies across all six cell
lines examined. Imaging at increased magnification of the nuclear bodies indicated
that at least four bodies, irregular in shape were present per nucleus, in all six cell
lines (Figure 4.2). Image analysis via LAS AF software indicated that these nuclear
bodies ranged up to 1.57 μm in diameter.
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Figure 4.2 Representative high magnification confocal images of nuclear cyclin F
positive bodies in motor neurons.
Representative images, of cyclin F in iPSC derived motor neurons Cell lines were
derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient
(CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G ALS
patient (SOD1), and an additional healthy donor (HC2) and a sporadic Alzheimer’s
disease patient (SAD) as a neurodegenerative control. N=3 differentiation repeats
minimum per cell lines; differentiation batches imaged with same confocal settings.
Scale bar = 10 μm.
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Further image analysis was performed to compare the populations of these nuclear
bodies in the different cell lines using Cell Profiler. Comparison of the intensity of
the nuclear bodies (N=3 independent differentiations, normalised to each
differentiation batch) indicated no significant difference in the abundance of cyclin F
present in the nuclear bodies in the different cell lines, as indicated by One-way
ANOVA with Tukey’s post hoc test F (5, 10) = 0.9873. P=0.4715; Figure 4.4A.

A count of the mean number of nuclear bodies per detectable nucleus was also found
to have no significant difference between the cell lines (indicated by One-way
ANOVA with Tukey’s post hoc test F (5, 10) = 0.7602. P=0.5982; Figure 4.4B).
When all replicates were grouped by neurodegenerative motor neurons (cell lines
CCNF1, CCNF2, SOD1 and SAD) or healthy controls (cell lines HC1 and HC2), an
opposite correlation was evident when the average number per nucleus and intensity
of the nuclear bodies were compared (Figure 4.5); Though these correlations were
not significantly non-zero, healthy controls had a trend to have an increased number
of high intensity nuclear bodies (R2= 0.08752. F(1,4)=0.2405. P=0.6496) compared
to the neurodegenerative controls which had a decreasing number of high intensity
nuclear bodies (R2= 0.05671. F(1,8)=0.7673. P=0.4066).
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B

Figure 4.4 Quantification of cyclin F positive nuclear bodies from confocal images of
iPSC derived motor neurons
Dot plots of (A) intensity of nuclear body and (B) number of nuclear bodies per total
number of nuclei from image quantification of cyclin F in iPSC derived motor
neurons calculated using Cell Profiler analysis. Cell lines were derived from a
healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a
symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G ALS patient (SOD1),
and an additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient
(SAD) as a neurodegenerative control. N=3 differentiation repeats; differentiation
batches imaged with same confocal settings. Significance determined via ANOVA,
Tukey’s post hoc (P>0.05).
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Figure 4.5 Correlation of cyclin F positive nuclear body intensity and number per
nuclei
Analysis is from confocal images of motor neurons calculated using Cell Profiler
analysis. Cell lines were derived from a healthy donor (HC1), a pre-symptomatic
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2),
a SOD1E101G ALS patient (SOD1), and an additional healthy donor (HC2) and a
sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control. N=3
differentiation repeats; differentiation batches imaged with same confocal settings.
Significance determined via Linear Regression Analysis (P>0.05).
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4.5 TDP-43 and phosphorylated TDP-43

4.5.1

TDP-43 and phosphorylated TDP-43 expressed in motor neurons

To determine if endogenous TDP-43 was expressed at detectable quantities in these
iPSC derived motor neurons, western blot analysis was performed. Using the
phosphorylated TDP-43 antibody (409/410), both protein bands at both 50 kDa,
(corresponding to phosphorylated TDP-43), and 43 kDa, (the native weight of TDP43), were detectable in all cells lines at endogenous levels (based on previous
antibody use (Foulds et al., 2009; Neumann et al., 2007) (Figure 4.6). Interestingly,
a third band (at approximately 45 kDa) between these two molecular weights was
also detected in the CCNFS621G cell lines in two of the four replicates performed
(lysates collected from independent differentiations). Previous reports of bands at
this weight (45 kDa) have have been detected in ALS patient post mortem tissue
(Sorarú et al., 2009).

To assess if the endogenous TDP-43 was ubiquitinated, a deubiquitinating enzyme
(DUB) inhibitor was either omitted or included at lysate collection. Interestingly, the
different lysates did generate protein bands at different molecular weights in the
presence or absence of the DUB inhibitor, at roughly the same weight as the
previously detected band present in the two CCNFS612G patient derived motor
neurons. Though these changes did not exactly match the change in molecular weight
of ubiquitin (8.5 kDa), the 43 kDa TDP-43 protein band was only present in the
lysates with DUB inhibitor. In lysates without DUB inhibitor bands with higher
molecular weight were detected (Figure 4.6).
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NSE
Figure 4.6. Expression of endogenous TDP-43
Representative image, TDP-43 detected via western blot analysis of triton X soluble
cyclin F in whole cell lysate from iPSC derived motor neurons. Cell lines were
derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient
(CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G ALS
patient (SOD1), and an additional healthy donor (HC2) and a sporadic Alzheimer’s
disease patient (SAD) as a neurodegenerative control. N=4 (N=3 independent
differentiations, and 1 additional replicate). Replicates not shown.

188

Figure 4.6. Endogenous TDP-43 in presence and absence of DUB inhibitor
TDP-43 quantified by western blot analysis of triton X soluble cyclin F collected
with DUB inhibitor (+) and wihtout DUB inhibitor (-) in whole cell lysate from iPSC
derived motor neurons. Cell lines were derived from a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative
control. N=1 independent differentiation.
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4.5.2

Endogenous TDP-43 localises in the nucleus of motor neurons consistent
with nuclear bodies.

Following detection of TDP-43 at endogenous levels, it was pertinent to investigate
the localisation (and potential mislocalisation) of endogenous TDP-43 in these iPSC
derived motor neurons.

Confocal analysis of TDP-43 immunolabelled motor

neurons revealed that TDP-43 was expressed in the nucleus indicative of nuclear
bodies consistently across all six cell lines examined (Figure 4.7). TDP-43 was also
detected in the cytosol in the motor neurons.

Images taken at an increased

magnification indicated diverse bodies of irregular in shape and size were present in
the nucleus, in all six cell lines. Unlike cyclin F, TDP-43 nuclear body analysis was
not possible in the iPSC derived motor neurons due to the inability to discern
individual bodies - being so densely populated in the nucleus. From a general
observation, it appeared that different populations of nuclear bodies existed - some
areas of the nucleus displayed areas of high intensity fluorescence. Further
investigation, using nuclear body specific markers, or actin, is required to allow
quantification to determine what these nuclear bodies are, and if differences are
evident between the different cell lines.
4.5.3

Endogenous TDP-43 can localise in the cytosol in a subset of cells

In all six cell lines examined, TDP-43 was detected to be cytosolic as well as nuclear.
This cytosolic localisation did not appear to be ALS patient derived cell line specific
mislocalisation. The localisation of fluorescence observed is consistent to stress
fibres, as long elongated spindles (Figure 4.8).
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Figure 4.7 Representative high magnification confocal images of nuclear TDP-43
positive bodies in motor neurons
Representative images, of TDP-43 (Abnova, H00023435-M01) in iPSC derived
motor neurons. Cell lines were derived from a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative
control. N=3 differentiations per cell line; differentiation batches imaged with same
confocal settings. Scale bar = 25 μm.
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Figure 4.8 Cytosolic TDP-43 in small population of iPSC derived motor neurons
Representative images, of TDP-43 (Abnova, H00023435-M01) in iPSC derived
motor neurons. Cell lines were derived from a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative
control. N=3 differentiation repeats; differentiation batches imaged with same
confocal settings. Scale bar = 50 μm.
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4.5.4

Endogenous TDP-43 is non significantly decreased in CCNF mutant iPSC
derived motor neurons

Given the propensity of TDP-43 to aggregate in motor neurons, and the presence of
TDP-43 in nuclear bodies observed here, the solubility of the TDP-43 present was
investigated. The solubility of the endogenous TDP-43 was probed via a crude
fractionation process, re-suspending proteins insoluble in RIPA buffer, with a 2%
SDS RIPA solution, and any remaining insoluble proteins in 8M Urea to further
solubilise the remaining TDP-43 (Figure 4.9).

Quantification of the protein

abundance in the three fractions (normalised to the total protein of the triton X
fraction), indicated that soluble TDP-43 at ~50 kDa was present in 2% SDS soluble
fractions, (though less abundant) in the six cell lines examined. In some instances,
there was also 50 kDa TDP-43 present in the least soluble 8M urea fraction (Figure
4.10 A). There was no significant difference between the cell lines when examining
each individual fraction (As indicated by Two-way ANOVA with a Bonferroni post
hoc test; F (10, 30) = 0.7907 P=0.6378. However, the sum of these three solubility
fractions was calculated for the 50 kDa TDP-43 (Figure 4.10 B); in the two
CCNFS621G cell lines (CCNF1 and CCNF2) and trended towards being less abundant
when compared to the other cell lines (though was not significantly different; As
indicated by One-way ANOVA with a Tukey’s post hoc test F (5, 12) = 0.5355.
P=0.7460).

Bands corresponding to the 43 kDa TDP-43 (i.e. TDP-43 with no post-translational
modifications) were also present in all six lines (Figure 4.11 A). No significant
difference was detected between the cell lines when examining each individual
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fraction (As indicated by Two-way ANOVA with a Bonferroni post hoc test; F (10,
36) = 0.4629. P=0.9027). The total abundance of the respective bands at these three
solubilities was then calculated (Figure 4.11 B). There was no significant difference
between the total abundance of 43 kDa TDP-43 between cell lines (as indicated by
One-way ANOVA with a Tukey’s post hoc test (5, 12) = 0.5863. P=0.7107).

Figure 4.9 TDP-43 abundance by solubility, normalised to total protein.
Representative image of western blot of TDP-43 detected at three solubilities, (T)
Triton X, (S) 2% SDS, and (U) Urea soluble in iPSC derived motor neurons. Cell
lines were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS
patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), a SOD1E101G
ALS patient (SOD1), and an additional healthy donor (HC2) and a sporadic
Alzheimer’s disease patient (SAD) as a neurodegenerative control. N=3
differentiation replicates.
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Figure 4.10 TDP-43 ~50kDa band abundance normalised to total protein.
Quantification of TDP-43 50kDa protein in three solubilities detected by western blot
in the (A) Triton X, 2% SDS, and Urea soluble fractions, and (B) sum total in motor
neurons differentiated from the following cell lines: a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS
patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy donor
(HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative
control. Concentrations were normalised to the concentration of total protein. N= 3
biological replicates. Significance determined via ANOVA, Tukey’s post hoc test
(P>0.05).
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Figure 4.11 TDP-43 ~43kDa band abundance normalised to total protein.
Quantification of total TDP-43 43kDa protein detected by western blot in the (A)
Triton X, 2% SDS, and Urea soluble fractions, and (B) total sum in motor neurons
differentiated by following cell lines: a healthy donor (HC1), a pre-symptomatic
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2),
a SOD1E101G ALS patient (SOD1), and an additional healthy donor (HC2) and a
sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control.
Concentrations were normalised to the concentration of total protein. N= 3 biological
replicates, N=2 technical replicates for 2 biological replicates. Significance
determined
via
ANOVA,
Tukey’s
post
hoc
test
(P>0.05).
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4.6 Proteasomal stress affects motor neuron viability
4.6.1

Motor neuron viability decreases following increased proteasomal inhibition

To understand the relationship between cyclin F, ubiquitin proteasome system, and
cellular viability, a proteasomal inhibition assay was performed. Motor neurons
from a healthy donor (HC1), a pre-symptomatic CCNFS621G patient (CCNF1), a
symptomatic CCNFS621G patient (CCNF2), a SOD1E101G (SOD1) patient, an
additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD)
were treated with a range of concentrations of proteasomal inhibitor MG132 (ranging
from 1-250 µM), a vehicle control (DMSO), and untreated. Cell viability was
monitored at three time points (16 h, 48 h, and 72 h). Treatment duration and
MG312 concentrations were based on previously published cellular works (Mazroui
et al., 2007). At each of these three times points, cellular viability was measured
using a PrestoBlue assay as an indication of cellular viability.

Following 16 h of treatment of MG132, there were significant differences in cellular
viability across the cell lines at concentrations between 1-100 µM (normalised to
vehicle control) as indicated by Two-way ANOVA with Tukey’s post hoc test; F (20,
149) = 2.249. P=0.0031 (Figure 4.12). At the lowest concentration of MG132 (1
µM), the SAD patient derived motor neurons exhibited a significantly lower viability
(between 1.43 - 2.34 fold) than other cell lines including the healthy control (HC1;
P=0.003), the CCNFS621G patient (CCNF2; P= 0.0123) and the SOD1E101G (SOD1;
P=0.0011) patient derived motor neurons (Appendices Table 8.2). There was no
significant difference in the viability when comparing within each cell line as the
concentration increased from 1 µM to 2.5 µM MG132, nor between 2.5 µM and 10
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µM MG132 (Appendices Tables 8.3 and 8.4). Following treatment at 100 µM
MG132, viability in motor neurons was significantly lower in HC1 compared to the 1
µM MG132 treated motor neurons and the 2.5 µM MG132, as well as in SOD1
compared to the 1 µM MG132 treated cells (all by approximately 2 fold; P = 0.0372,
0.0006, 0.0026 respectively).

Following treatment at 100 µM MG132, motor

neurons from one of the two CCNFS621G patient (CCNF1) did not exhibit the same
reduction in viability as the other cell lines (Appendices Table 8.6). Treatment of
motor neurons from this same cell line with 250 µM MG132 did not elicit the same
response; this higher dose resulted in a decrease in viability as per the general trend
across these treatments, that an increase in proteasomal inhibition inversely
correlated to cellular viability.

Following 48 h of treatment of MG132, a general decrease in viability was evident
across all cell lines (as indicated by Two-way ANOVA with Tukey’s post hoc test F
(20, 150) = 1.087. P=0.3686). Little difference between cell stages was evident
following this treatment. The only significant difference in viability was between a
CCNFS621G patient (CCNF1) and SOD1E101G patient (SOD1) derived motor neurons:
The SOD1 motor neurons indicated significantly higher viability than the CCNF1
(1.6 fold higher; P = 0.0444; Appendices Tables 8.8 - 8.11). Viability of motor
neurons at this timepoint were repeatedly decreased in inverse correlation with
increased MG132 concentration in all six cell lines examined. Comparison of
viability in motor neurons treated with the lowest concentration of MG132 (1 µM) to
the highest concentration (250 µM) revealed a decrease of between 1.9 fold to 4.4
fold decrease in viability in all cell lines (significance as indicated in Figure 4.13 A,
determined via Two-way ANOVA with Tukey’s post hoc test).
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Following 72 h of treatment of MG132, motor neuron viability was reduced again,
compared to the other time points, and cells morphology (or lack of) indicated high
levels of cell death. At lower concentrations (1- 10 µM) MG132, some differences
were evident between cell lines as indicated by Two-way ANOVA with Tukey’s post
hoc test; F (20, 139) = 2.901. P=0.0001 (Figure 4.13 B; Appendices Tables 8.12 8.16). At higher concentrations, cell death was consistently observed.

Figure 4.12 Motor neuron mitochondrial viability following 16 h proteasomal
inhibition
A PrestoBlue assay was performed to assess the reducing ability of iPSC derived
motor neurons from a healthy donor (HC1), a pre-symptomatic CCNFS621G patient
(CCNF1), a symptomatic CCNFS621G patient (CCNF2), a SOD1E101G patient (SOD1),
an additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD)
as a neurodegenerative control, following treatment with a range of concentrations of
proteasomal inhibitor MG132. Fluorescence was detected at 590 nm. Significance
determined from Two-way ANOVA with Tukey’s post hoc test, denoted as
*P<0.0332,
**P<0.0021, ***P<0.0002, ****P<0.0001. N=5 independent
differentiations.
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Figure 4.13 Motor neuron mitochondrial viability following 48 h and 72 h
proteasomal inhibition
A PrestoBlue assay was performed to assess the reducing ability of iPSC derived
motor neurons from a healthy donor (HC1), a pre-symptomatic CCNFS621G patient
(CCNF1), a symptomatic CCNFS621G patient (CCNF2), a SOD1E101G patient (SOD1),
an additional healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD)
as a neurodegenerative control, following treatment with a range of concentrations of
proteasomal inhibitor MG132 for (A) 48 h and (B) 72 h. Fluorescence was detected
at 590nm. Fluorescence was detected at 590nm. Significance determined from Twoway ANOVA with Tukey’s post hoc test, denoted as *P<0.0332, **P<0.0021,
***P<0.0002,
****P<0.0001.
N=5
independent
differentiations.
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4.7 Ubiquitin system function decreased in CCNFS621G motor
neurons
Following assessment of proteasomal stress on cellular viability and the relative
exclusion of nitrosative stress in the cells (Appendices Figure 8.2), this study sought
to assess the functionality of the UPS. Using a degron assay, which engages a
protein degradation (degron) signal fused to a GFP as an indicator of cellular UPS
efficacy - cells are unable to degrade the GFP as efficiently when under UPS stress.
The degron plasmid was co-transfected with a mCherry plasmid (to account for the
transfection efficacy of the cells), and motor neuron precursors were monitored using
live cell imaging for proteasomal activity.

A significant increase in fluorescence,

indicating a decreased capacity to degrade cellular proteins, was found in the
symptomatic CCNFS621G (CCNF2) derived iPSC-motor neuron precursors (Figure
4.14).
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Figure 4.14 Degron Assay in motor neurons following proteasomal inhibition
GFP fluorescence detected by Incucyte Zoom analysis normalised to co-transfected
mCherry plasmid expression in iPSC derived motor neurons a healthy donor (HC1),
a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G
ALS patient (CCNF2), a SOD1E101G ALS patient (SOD1), and an additional healthy
donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a
neurodegenerative control. Significance determined via One-way ANOVA, Tukey’s
post hoc test * P>0.05, **P>0.01, ***P>0.001. N=3.
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4.8 Discussion
4.8.1

Endogenous ALS proteins TDP-43 and cyclin F expressed ALS patient
derived motor neurons

The ability to study endogenous protein is of great value to ALS research wherein
protein overexpression systems can result in confounding, potentially misleading
effects. As hypothesized, the two ALS proteins examined, TDP-43 and cyclin F,
were both detectable at endogenous concentrations in the iPSC derived motor neuron
models generated in this study. The detection of endogenous TDP-43 is inline with
previous iPSC-ALS studies (Bilican et al., 2012; Burkhardt et al., 2013; Egawa et al.,
2012; Nishimura et al., 2014; Serio et al., 2013; Zhang et al., 2013), which have
detected endogenous TDP-43 in iPSC derived motor neurons.

The detectable

expression of endogenous cyclin F was not guaranteed based on the literature; Cyclin
F is known to play different roles in different cell types (and is therefore likely to
vary in expression) (Tetzlaff et al., 2004). Though endogenous cyclin F has been
detected in mouse iPSCs (Buganim et al., 2012), proteasomal inhibition via MG132
treatment has been previously required to detect endogenous levels of cyclin F in
some models (D’Angiolella et al., 2013).

It is therefore greatly beneficial that

detection of endogenous cyclin F was possible given the need for an ALS relevant
model with detectable endogenous cyclin F. Particularly as the endogenous cyclin F
in the existing zebrafish model varies from the human form of cyclin F and therefore
requires transfection of the human form to study it in the context of ALS (Hogan et
al., 2017).
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A limitation of the few previous studies examining cyclin F in the context of ALS
(Williams et al (2016), Hogan et al (2017), and Lee et al (2017; 2018), is the
investigation of a cyclin in mitotic cells such as the mouse neuroblastoma line, which
remains mitotic in culture. It would be unsurprising that the role of cyclin F change
in different cell types - particularly in post-mitotic cells. Indeed, these findings
represent the first reporting of cyclin F expression and localisation in a noncancerous derived-human cell line, an important step in considering the function of
cyclin F in post-mitotic motor neurons.

4.8.2

Cyclin F may be decreased in iPSC derived motor neurons

Cyclin F was decreased across all three of the ALS cell lines (CCNF1, CCNF2 and
SOD1) compared to the three other controls (including significant differences
between HC1, as well as a decrease compared to HC2 and SAD). This suggests that
either Triton X soluble NSE is increased in ALS, or that Triton X soluble cyclin F
was decreased (or reduced in solubility), or a combination of both. The relative
intensity and number of these aggregates did not decrease as per protein
quantification (via western blots), and examination of correlation of these two
features did not yield significantly distinct partitioning. Though this technique is not
necessarily definitive, it may suggest that the decrease in cyclin F detected via
western blot is due to an increased retention of NSE, which can occur as a result of
UPS dysfunction, and has been reported to occur in ALS (Jain et al., 2008), despite
being a commonly used normalising protein (Li et al., 2015). Conversely, it may be
speculated that cyclin F is self-regulating, and mutations to this protein may cause an
increased propensity for either aggregation (thereby sequestering the soluble protein
into undetectable aggregates) or degradation. The limited number of previous studies
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into cyclin F expression have not detected differences in the expression of cyclin F
compared to control, (Hogan et al., 2017; Lee et al., 2018; Y.-C. Lee et al., 2017;
Williams et al., 2016), however, this study is the first study to examine the
endogenous levels of cyclin F. Further examination into the regulation of cyclin F
would be warranted to better evaluate if cyclin F is decreased.

4.8.3

iPSC derived motor neurons express cyclin F in structures consistent with
nuclear bodies

The expression of cyclin F in these motor neurons was further analysed via
immunocytochemistry. Motor neurons expressed nuclear cyclin F, localising
predominantly in structures consistent with nuclear bodies. There was no significant
difference in the intensity or number of these structures amongst the different cell
lines. There was, however, a trend for a decrease in a high number of high intensity
cyclin F positive aggregates in the neurodegenerative cell lines, when compared to
the two healthy controls. It could be speculated that this trend suggests a changing
role of cyclin F in the nucleus (potentially a change in nuclear protein targets), or that
there is a shift towards larger nuclear bodies in the neurodegenerative cell lines
which may suggest sequestering of proteins, as would be seen in cells under UPS
stress. Assessing the size and number of these aggregate structures via a technique
such as FloIT, a flow cytometric aggregate analysis would provide further high
throughput quantification of these structures that may elucidate this potential shift in
cyclin F positive nuclear bodies (Whiten et al., 2016). This would be very useful in
ascertaining the heterogeneity of the nuclear body-like structures, which would give
a direction for assessing the type of nuclear bodies present.
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As an early study of the expression of cyclin F in these patient derived motor
neurons, the ALS causing mechanism of a cyclin F mutation was also considered.
Given the role of nuclear bodies in transcription and translation (Table 4.1), the
expression of cyclin F in nuclear bodies suggests the cyclin F has a role in
transcription or post - translational modifications. It may be that cyclin F is included
in multiple nuclear body functions, or may simply be involved in a limited number of
processes. Should this be the case, cyclin F positive bodies would likely be (which
were present in at least four irregular bodies in each nucleus) nuclear speckle/granule
clusters, nuclear stress bodies, or polycomb bodies (Table 4.6). The co-expression of
specific nuclear body antibodies, examining expression of SC35 SF2/ASF (nuclear
speckles), HSF1 (nuclear stress bodies) BMI1, and PC2 (polycomb) shoud be
performed to determine if these nuclear body species are present (Spector, 2006).

Table 4.6 Nuclear protein body characteristics corresponding to cyclin F nuclear
bodies in iPSC motor neurons

4.8.4

TDP-43 decreased in CCNFS621G patient derived motor neurons

Western blot quantification of TDP-43 indicated a decrease in total endogenous
TDP-43 in the two CCNFS621G patient derived lines compared to the other cell lines.
This is in opposition with a majority of iPSC-ALS studies which have found
increases in TDP-43 in ALS-iPSC derived motor neurons compared to healthy
controls (Bilican et al., 2012; Burkhardt et al., 2013; Egawa et al., 2012; Nishimura
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et al., 2014; Serio et al., 2013; Zhang et al., 2013). The detected decrease in TDP-43
and particularly phosphorylated TDP-43 in this study corroborates with the findings
by Lee et al (2017), which proposed that mutant CCNFS621G caused an increase in
degradation-associated ubiquitination in neuronal-like cell models (Neuro-2as and
Sh-SY5Ys).

Expression of TDP-43 in two of the four samples indicated additional banding at ~40
kDa in both pre-symptomatic and symptomatic CCNFS621G patient derived motor
neurons samples (CCNF1 and CCNF2). TDP-43 is known to be ubiquitinated, and
given the role of cyclin F as an E3 ubiquitin ligase, this line of investigation was
probed further. iPSC derived motor neuron samples were divided upon collection
and treated with either a deubiquitinating inhibitor, or a vehicle control. A change in
the detected weight of TDP-43 following exclusion of DUB inhibitor suggests that
this band is likely the ubiquitinated from of TDP-43. This is in agreement with
findings that indicate CCNFS621G transfected neuronal models experience an increase
in ubiquitinated (Lys48) substrates (Lee et al., 2018). The variability (band was
present in only two of the four replicates) would be interesting to investigate to
determine what slight variations in experimental conditions lead to this variability.
This band has been previously detected in ALS tissue. This previously detected band
was removed by λ-phosphatase, which may indicate that this is in fact an alternate
phosphorylated TDP-43 species, which should be considered for future analysis
(Sorarú et al., 2009). The presence of the Triton X insoluble TDP-43 in all cell lines
suggests that careful buffer selection is required for future studies of the protein.
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These preliminary findings in TDP-43 expression justify further studies to examine
the less-soluble TDP-43 species to determine if, and what abnormal cellular
aggregates are present in the ALS cell lines.

Previous studies have examined

endogenous TDP-43 in iPSC derived motor neurons, and found a distinction in
expression of TDP-43 and phosphorylated TDP-43 in the nucleus; TDP-43 showed a
lower intensity overlap with the nuclear stain DAPI and was positive in only
concentrated high intensity structures consistent with nuclear bodes, while co-stained
phosphorylated TDP-43 was only expressed in these concentrated high intensity
structures (Burkhardt et al., 2013). An antibody for this same epitope (409/410
phosphorylated TDP-43) was used in this study, however western blot results
strongly suggest that this antibody was also able to detect other TDP-43 forms.
Further studies using selective antibodies (including one specific for the 45 kDa
fragment) would be advantageous in discerning what TDP-43 species are present in
these abundant nuclear structures, and to accurately quantify if there are differences
between ALS patient derived motor neurons and controls, or if this is an artifact of
non specific binding. The study by Burkhardt et al (2013) assumed that these nuclear
structures were aggregates related to disease pathology, as these were only detected
in the SALS patient derived motor neurons, compared to healthy control motor
neurons, though interestingly were not observed in the FALS patient derived motor
neurons, highlighting the need for further investigation into the purpose of these
structures. Alternate methods of investigating these structures would also be
valuable; similar to cyclin F, co-staining motor neurons with TDP-43 and nuclear
body specific markers would work towards quantifying the potentially heterogeneous
population. Again, using a technique such as FloIT would be useful in discerning the
population of these nuclear structures in a bulk study. TDP-43 positive aggregates,
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which did not show visual distinction to the extent at which they could be quantified
in the motor neurons, could be further investigated using this technique (Whiten et
al., 2016). It would also be of value to further investigate these nuclear structures via
increase biological sample size to determine if this is a true trend, or artefact of
smaller biological sample size.

4.8.5

An additional role for TDP-43 in iPSC motor neuron cultures

TDP-43 was not only detected in the nucleus, but was also found in the cytosol,
associating in a spindle - stress fibre-like pattern in select cells (Tojkander et al.,
2012). This phenotype was observed in select cells across every cell line, suggesting
it is not an ALS phenotype. As the cultures are not pure motor neurons, it is possible
that this cytosolic TDP-43 indicates the presence of a different cell type in the
cultures (Ederle and Dormann, 2017; Sephton et al., 2010). Further investigation
into the identity of these select cells would be of great value in understanding this
variability in TDP-43 expression in these cultures, and further our understanding of
the role of TDP-43 in ALS.

Cell specific protein markers expression and

electrophysiology, which could discern specific cell types, would be of benefit to
further examine any differences in TDP-43 distribution between cell types. It would
be important to examine co-expression of a motor neuron marker with both TDP-43
and cyclin F in the future, potentially engaging a reporter vector, or simply costaining via immunocytochemistry.
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4.8.6

UPS function decreased in CCNFS621G motor neurons

UPS dysfunction was detected in one of the two CCNFS621G carrier derived motor
neurons as indicated via the degron assay. The reporter protein destined for
ubiquitination and degradation were retained at a greater concentration in the CCNF2
line motor neuron precursors, derived from a symptomatic patient. This finding is
validated by the findings that previously examined the effects of cyclin F
overexpression in neuronal-like models, including NSC-34s, Neuro-2A and SHSY5Y cells (Lee et al., 2018; Lee et al., 2017; Williams et al., 2016). NSC-34 cells
overexpressing cyclin F with different ALS causing mutations were found to have an
increased retention of the UPS reporter protein compared to controls. A proteasomal
assay indicated mutation to cyclin F had no effect on proteasomal activity, thereby
implicating the ubiquitination machinery of the UPS (Williams et al., 2016).
Interestingly, the motor neuron precursors from the pre-symptomatic donor with the
CCNFS621G mutation (CCNF1) did not show this level of UPS dysfunction. This
discrepancy suggests that there may be alternate cellular influences that are either
neuroprotective in the CCNF1 cells, or cause additional cellular stress in the
symptomatic CCNFS621G (CCNF2) cell line.

4.8.7

CCNFS621G likely increases degradation of substrates including TDP-43

The decrease in TDP-43 further supports the previous findings that cyclin F
associates with TDP-43. Williams et al (2016) found that an increased abundance of
TDP-43 pulled down with ubiquitin, indicating that TDP-43 is a possible substrate of
cyclin F in its capacity as a substrate recognition subunit of an E3 ubiquitin ligase.
Lee et al

(2017) indicated that the CCNFS621G resulted in an inability to be

deactivated by phosphorylation, thereby leading to an increase in ubiquitination
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activity. Together with the results of this study, which indicate a reduction of
endogenous TDP-43, and a likely increase in the ubiquitinated form of TDP-43,
would strongly suggest that TDP-43 is reduced as a consequence of increased TDP43 ubiquitination by cyclin F (as further discussed in Chapter 6).

4.8.8

Motor neuron viability was inversely correlative to proteasomal inhibition

Across all cell lines examined, motor neurons exhibited a decrease in viability as
proteasomal inhibitor increased (from 1 µM to 250 µM MG132). Overall, viability
decreased over time (at the three time points examined: 16 h, 48 h, 72 h). These
findings did not show a clear difference in the viability of motor neurons from ALS
patients and controls. The sporadic Alzheimer’s disease (SAD) derived cells showed
the most consistent sensitivity to the proteasomal inhibition; this is consistent with
the previously reported SAD phenotype (Balez et al., 2016). It was hypothesized
that the ALS patient derived motor neurons would show a similar decrease in
viability, being more affected by the UPS stressed caused by the proteasomal
inhibition than healthy controls. At the time points measured, there was not a
consistent pattern of the ALS derived motor neurons having a significantly reduced
viability compared to both healthy controls. Despite the lack of distinction between
the healthy motor neurons and the ALS derived motor neurons in viability
measurements, there was a significant difference in the function of the UPS in one of
the two CCNFS621G derived motor neurons, following UPS stress. The symptomatic
CCNFS621G patient (CCNF2) derived motor neurons exhibited a retention of reporter
protein following proteasomal inhibition for 16 h, (10 µM MG132) at a increased
level compared to the five other cell lines, consistent with UPS stress being an
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upstream mechanism in motor neurons, prior to a loss of viability (and therefore a
potential contributing factor).

4.9 Summary and future directions

Due to the very recent discovery of mutations in the CCNF gene as a cause of ALS,
very limited information was available at the commencement of this study into the
role of cyclin F in motor neurons. Here, it was identified that endogenous levels of
both cyclin F and TDP-43 were detectable in iPSC derived motor neurons, in both
healthy donor- and patient derived motor neurons.

The detectability of the

endogenous TDP-43 and cyclin F are of great importance for these models, which
represent a dynamic system to examine the underlying mechanisms of ALS. The
ability to detect these endogenous proteins provided the means to quantify and
further examine the localisation of these ALS associated proteins. Cyclin F was
found to decrease, via western blot though not by immunocytochemistry, requiring
more analysis to determine if the decrease was an artefact of normalising to neuronal
marker NSE.

Given the role of cyclin F as an E3 ubiquitin ligase substrate

recognition subunit, which likely recognises a range of protein substrates, a non-bias
investigatory approach would serve to bring great insight to why mutations in this
protein cause ALS.

TDP-43 was detected at a weight of 50 kDa (consistent with phosphorylated TDP43), 43 kDa (no post translational modifications), as well as a 45 kDa TDP-43
(potentially a phosphorylated or ubiquitinated TDP-43) in only the CCNFS621G motor
neurons. As only four studies to date have examined the role of cyclin F, and its
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interaction with TDP-43 in the context of ALS (Hogan et al., 2017; Lee et al., 2018;
Lee et al., 2017; Williams et al., 2016), we can only draw comparisons to these
studies. This data supports the proposition that TDP-43 abundance is reduced in
mutant CCNFS621G ; this reduction is likely the result of the inability to phosphorylate
cyclin F, which results in abnormal activity of the cyclin F (Lee et al., 2017).
However, together these studies serve to raise many questions. Future investigations
are needed to establish the fundamental role of cyclin F in motor neurons, which
would no longer serve the same purpose as it would in a mitotic cell. A colocalisation study with TDP-43 and cyclin F would be the next logical step in
establishing if, and if so, how these two proteins interact, which has been previously
alluded to in overexpression systems (Williams et al., 2016). It is critical to establish
what type (or types) of cyclin F positive and TDP-43 positive nuclear structures are
present in these motor neurons, which could be performed via co-expression with
nuclear body specific antibodies, and flow cytometry techniques such as FloIT. In
addition, assays to further exacerbate UPS stress, such as proteasomal inhibitor
treatments would likely accelerate this aggregation, and potentially other ALS
pathology.

This study also endeavoured to examine the relationship between mutations affecting
the proteasome, the UPS and cellular viability.

Though there was not a clear

difference in the susceptibility of motor neurons derived from ALS patients to UPS
stress in terms of viability (compared to healthy controls), one of the two CCNFS621G
patient derived motor neurons did exhibit an increased propensity to retain the UPS
reporter protein compared to the other cell lines, suggesting this is upstream of a
reduced viability in ALS motor neurons. Overall, this study overcomes the first
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hurdle in establishing viable models for probing ALS mechanisms, establishing
measurable parameters, and identifying potential phenotypes from which future
studies may measure improvements to disease pathogenesis; Identifying a testable
phenotype is critical for trialling potential therapeutics.
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Chapter Five:

Ubiquitomes of iPSC Derived
Motor Neurons and Related Cell
Types
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5 UBIQUITOMES OF IPSC DERIVED MOTOR NEURONS AND RELATED
CELL TYPES

5.1 Introduction
Ubiquitin is required as an essential protein for healthy motor neuron function, and
survival (Park and Ryu, 2014). Deficits in the ubiquitin system are detrimental to
multiple facets of neuronal function (Tai and Schuman, 2008).

Many proteins

associated with essential motor neuron functions have been shown to be modulated
by ubiquitin, including proteins associated with the synapse (including vesicles), the
spliceosome, and the UPS itself. Despite the now widespread use of iPSC derived
motor neurons in ALS research, our understanding of the role of the UPS in these
models remains limited.

No study to date has collectively examined the global

ubiquitinated proteome (ubiquitome) of human iPSCs, nor any human iPSC derived
cells. As aforementioned, deficits in the UPS are suggested to contribute to the
susceptibility of motor neurons in ALS. This susceptibility has been highlighted in a
comparison between ocular and spinal motor neurons, wherein an upregulation of
UPS component proteins correlated with neuroprotection (Brockington et al., 2013).
The importance of this system in ALS has also been highlighted through the
identification of ALS-causing mutation in UPS genes (Deng et al., 2011).

Advances in mass spectrometry techniques now allow for specific qualification and
subsequent quantification of ubiquitinated proteins via ubiquitinomics. Examination
of the ubiquitinated proteome (termed the ubiquitome) can be used to identify
changes that occur in different cellular stages – for example through the different
cellular stages in cellular modelling of neurons. Despite the exponential increase in
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iPSC disease modelling, little is known about the iPSC ubiquitome. Buckley et al.
(2012) have previously investigated the mouse iPSC ubiquitome in a comparison of
these cells in cultures containing both embryonic stem cells and mouse embryonic
fibroblasts (Buckley et al., 2012). No studies have yet identified the ubiquitome of
human iPSC-motor neuron or their derivative cells for comparison. Such a study
would be valuable in furthering our understanding of cellular differentiation, as well
as motor neuron diseases.

Differences in the pathways ubiquitin regulates can be elucidated using pathway
analysis tools, such as Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING). Changes in protein-protein interactions can be grouped using a number
of features including similar Molecular Functions, Cellular Components, Biological
Process, and via the Kyoto Encyclopedia of Genes and Genomes (KEGG). Once
target pathways, and proteins of interest are identified through this technique,
methods such as colourimeteric viability assays are effective probing techniques to
ascertain the functional consequence of altering these pathways.

Here, following the successful generation of iPSC derived motor neurons at a
relatively high yield, and identification of an ALS relevant phenotype, we have
employed high-throughput mass spectrometry to map the global ubiquitome of
human donor derived fibroblasts, iPSCs and iPSC derived motor neurons.
Quantitative mass spectrometry allowed for the evaluation of dynamic changes in the
ubiquitome across these three cellular stages and four cell lines (Figure 5.1). This
comparison examines the ubiquitomes from a pre-symptomatic CCNFS621G patient
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(CCNF1), a symptomatic CCNFS621G patient (CCNF2), a healthy donor (HC2), and a
sporadic Alzheimer’s disease patient. This data is available upon request.

Figure 5.1 Schematic of ubiquitinomics workflow
Lysate from fibroblasts, iPSCs and motor neurons were purified via affinity column,
and detected via an LC-MS/MS for analysis.
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5.2 Hypotheses
1. Different cell types throughout the reprogramming and differentiation of
fibroblasts, iPSCs and motor neurons will exhibit different ubiquitinated proteomes.

2. Drug treatments affecting pathways identified in Aim 1 as being signficantly
regulated will affect neuronal development and viability.

3. iPSC derived motor neuron ubiquitomes will vary between individual cell lines.

5.3 Aims
1. To perform ubiquitinomic analysis on the cell types throughout the
reprogramming and differentiation (fibroblasts, iPSCs and motor neurons).

2. To use drug treatments to test whether significant pathways identified to be
regulated by ubiquitin in Aim 1 affect neuronal development and viability.

3. To compare ubiquitomes of iPSC derived motor neurons derived from different
donors.
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5.4 Ubiquitome changes through fibroblast-iPSC reprogramming
5.4.1

Total ubiquitomes of samples correlated strongly between replicates and
partitioned between cell types.

To identify and quantify the ubiquitome during cellular reprogramming and
differentiation, fibroblasts, iPSCs, and iPSC derived motor neuron lysates from ALS
patient- and healthy control- derived cell lines were immunoprecipitated by ubiquitin
affinity beads. Following overnight digestion with trypsin, samples were analysed
using quantitative liquid chromatography tandem mass spectrometry (LC-MS/MS).
Replicate data was first evaluated for robustness via visualisation using heatmaps of
both the filtered MaxQuant output, as well as the imputed data normalized using a zscore scale (Appendices Figure 8.4). Heatmaps of the Pearson’s Correlation values
indicated similarity in replicates and distinct partitioning of datasets within cell lines
by cell stage (Figure 5.2; Appendices Figures 8.5). Multiscatter plots of the total data
sets of each cell line assured there was consistency in replicates (Figure 5.3,
Appendices Supplementary 8.7 - 8.8).

Similarity of samples was assessed via a Principal component analysis (PCA). This
analysis, which uses a singular value decomposition to provide a scaled projection of
the total data (please see Appendices Figure 8.9 for further explanation; Kassambara,
2017) indicated distinct partitioning of samples by cell type (Figure 5.4).
Interestingly, within this total grouping of all replicates analysed, the motor neuron
samples from derived from a CCNFS621G patient (CCNF2), and from a sporadic
Alzheimer’s disease patient (SAD) grouped closely to all the iPSC samples (which
tightly clustered together regardless of sample). A PCA was performed for each of
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the separate cell lines examined, to compare the ubiquitomes of fibroblasts, iPSCs
and motor neurons derived from the same donors. These analyses also consistently
indicated separate clustering of these cell types within each cell line; For example in
comparing the cells from a CCNFS621G patient (CCNF1), the fibroblasts grouped
separately from the iPSCs, and these grouped separately again from the motor
neurons (Appendices Figures 8.10 - 8.11).

The ubiquitinomics data was also grouped by cell type, to compare the similarity of
the cell lines within a given cell type. These PCA consistently revealed clustering of
all cell lines closely together, with the exception of one of the CCNFS621G patient
derived cell lines (CCNF2) in the fibroblasts (Figure 5.5), iPSCs (Figure 5.6), and
motor neurons (Figure 5.7), suggesting there is a consistent difference in the
ubiquitomes of these cells, regardless of the effects of reprogramming or
differentiation.
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Figure 5.2 Representative heatmap of Pearson’s correlation values
Pearson’s correlation values were calculated from the comparison of samples from
pre-symptomatic CCNFS621G patient derived cell lines (CCNF1). Heatmaps were
generated for each cell line to compare between replicates and between cell stages
(See Appendices Figure 8.5).
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Figure 5.3 Representative multiscatter correlation plots
Multiscatter values were calculated from pre-symptomatic CCNFS621G patient derived ubiquitomes (CCNF1) as an additional measure for
correlation of data within sample replicates and between cell types. Multiscatter plots were generated for each cell line to compare between
replicates
and
between
cell
stages
(See
Appendices
Figures
8.6
8.7).
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Figure 5.4 Principle components analysis of all samples measured between cell lines
Plot was generated from comparison of filtered ubiquitinomics data from fibroblasts, iPSCs and motor neurons from the different cell lines
examined.
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Fibroblasts

Figure 5.5 Principle components analysis of all fibroblast samples
Plot was generated from comparison of filtered ubiquitinomics data from cells harvested from a whole cell lysate from fibroblasts. Cell lines
were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient
(CCNF2), and a sporadic Alzheimer’s disease patient (SAD).
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iPSCs

Figure 5.6 Principle components analysis of iPSC samples
Plot was generated from comparison of filtered ubiquitinomics data from cells harvested from a whole cell lysate from iPSCs. Cell lines were
derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2),
and a healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control.
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Motor Neurons

Figure 5.7 Principle components analysis of iPSC derived motor neuron samples
Plot was generated from comparison of filtered ubiquitinomics data from cells harvested from a whole cell lysate from iPSC derived motor
neurons. Cell lines were derived from a pre-symptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2),
and a healthy donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control.
.
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5.4.2

Symptomatic CCNFS621G patient derived ubiquitome exhibits large abundance
of ubiquitinated proteins

The ubiquitomes from each cell line were quantified and compared at each of the
three cell stages. As would be expected, many of the cell lines expressed uniquely
ubiquitinated proteins. The comparison of cell lines at the fibroblast stage indicated
that over half of all the ubiquitinated proteins were common to all samples.
Interestingly, in these fibroblasts, the ubiquitome of the CCNF2 cell line (originating
from a patient with a symptomatic CCNFS621G mutation expressed three fold more
ubiquitinated proteins compared to the other cell lines (Figure 5.8). This pattern
continued in the other cell types examined. In all iPSC samples, over half of the
proteins ubiquitinated were common amongst the five cell lines; total ubiquitinated
proteins were increased (1.30 - 1.36 fold) compared to the other cell lines examined.
There was a large increase of ubiquitinated proteins present only in the CCNF2
sample and not in any of the others (Figure 5.9). In the iPSC derived motor neurons
the uniquely ubiquitinated proteins were also more abundant in CCNF2 with a 65
fold increase compared to healthy control (Figure 5.10). Between 64% - 78% of all
proteins examined in the iPSC derived motor neurons (collectively) were commonly
ubiquitinated in all cell lines.
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Fibroblasts

Figure 5.8 Venn analysis of ubiquitinated protein expression in fibroblasts
Lysates were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G
ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), and a
sporadic Alzheimer’s disease patient (SAD) as a neurodegenerative control.
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iPSCs

Figure 5.9 Venn analysis of ubiquitinated protein expression in iPSCs
Lysates were derived from a healthy donor (HC1), a pre-symptomatic CCNFS621G
ALS patient (CCNF1), a symptomatic CCNFS621G patient (CCNF2), and a healthy
donor (HC2) and a sporadic Alzheimer’s disease patient (SAD) as a
neurodegenerative
control.
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Motor Neurons

Figure 5.10 Venn analysis of ubiquitinated protein expression in iPSC derived motor
neurons
Lysates were derived from a pre-symptomatic CCNFS621G ALS patient (CCNF1), a
symptomatic CCNFS621G patient (CCNF2), and a healthy donor (HC2) and a sporadic
Alzheimer’s disease patient (SAD) as a neurodegenerative control.
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5.4.3

Comparison

of

the

ubiquitinomic

changes

that

occur

following

reprogramming fibroblasts to iPSCs in multiple cell lines
Following the identification of ubiquitinated proteins, it was possible to quantify the
changes in the ubiquitinated proteins identified between cell types (as well as cell
lines). To examine the changes through the reprogramming and differentiation of
iPSC derived motor neurons, the ubiquitinated proteins increased in abundance in
each of these cell stages was compared via student T-test, and visualised via volcano
plot (Appendices Figures 8.14 - 8.15). Proteins commonly increased amongst the cell
lines were analysed via STRING, and the pathways that were significantly expressed
(categorised Molecular Functions, Cellular Components, Biological Process, and
KEGG as determined by STRING when set to Highest Confidence 0.900 Interaction
Score) were examined. First, the significantly more abundant proteins from each cell
type (I.e. 1. The ubiquitinated proteins increased in fibroblasts; and 2. Ubiquitinated
proteins increased in iPSCs), were examined for a focused analysis of pathways
common to the proteins in these cell types via STRING. Second, the network
generated from all the proteins that were increased in abudance in the comparison
(I.e. in fibroblasts and iPSCs), were exported to examine the changes to pathways
involved in these processes (reprogramming and differentiation) via Cytoscape.

STRING analysis of the significantly increased ubiquitinated proteins indicated the
pathways that were commonly increasingly regulated by ubiquitin in all four of the
cell lines examined in fibroblasts, when compared to iPSCs. The relative abundance
of only 15 ubiquitinated proteins was commonly increased in abundance in all
fibroblast four cell lines examined compared to iPSCs. An additional 14 proteins
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were also commonly significantly more abundant in fibroblasts compared to iPSCs in
all cell lines except fibroblasts from the symptomatic CCNFS61G patient (CCNF2).
Together, these 29 proteins were combined for analysis. STRING analysis of the
protein interactions by Biological Process indicated the enrichment of 62 biological
processes. This included a significantly higher abundance in ECM and cytoskeletal
associated proteins. For example a number of heat-shock associated proteins were
also more abundantly ubiquitinated in fibroblasts compared to iPSCs, including heat
shock protein 27, coded by HSPB1, which was significantly increased in the
fibroblast samples, and annexin 2 (ANXA2), a calcium-regulated membrane-binding
protein that has also been associated with heat-stress response were increased in
abundance.

Figure 5.11 Representative volcano plot analysis comparing iPSCs to fibroblasts
Data represents ubiquitinated protein expression in CCNFS621G patient derived iPSCs
compared to fibroblasts. Proteins significantly increased in abundance (P<0.01) in
fibroblasts and iPSCs indicated in red.
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A small number of ubiquitinated proteins were increased in iPSCs (totalling 12
proteins common amongst all four cell lines) compared to fibroblasts. An additional
21 proteins were significantly increased in all cell lines excluding CCNF2. When
combined with the proteins commonly increased in all five cell lines, these 33
proteins, when analysed using STRING showed no KEGG pathway enrichments,
however had strong enrichment for spliceosomal biological processes. One third of
the proteins increased in iPSCs compared to fibroblasts were associated with the
pathways RNA stabilization, processing and splicing.

Cytoscape analysis of the collection of increased proteins in the comparison of
fibroblasts and iPSCs (as visualised by volcano plot; Figure 5.11) indicated changes
to the abundance of ubiquitinated ECM associated proteins (Figure 5.12). Two
collagen-associated proteins, collagen-6A1 (COL6A1) and -1A2 (COL1A2), along
with CD44, Ras GTPase-activating-like protein (IQGAP1) and Lamin A/C (LMNA)
were significantly more abundant in fibroblasts compared to iPSCs. Conversely,
ubiquitinated Lamin B1 (LMNB1) was significantly more abundantly ubiquitinated
in iPSCs (P>0.01). These changes are consistent with a changed requirement for
ECM proteins in the reprogrammed iPSCs (Figure 5.12).

The comparison of

fibroblasts and iPSCs indicated a significant increase in the abundance of
ubiquitinated poly(A) RNA binding proteins (12) in iPSCs, as well as base excision
proteins (3), suggesting a significant shift in the role of ubiquitin in regulating these
pathways in iPSCs. Additionally, there was an increase in ubiquitinated proteins
associated with immune response (4), and lysosomal proteins (3) in fibroblasts.
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Figure 5.12 STRING map of ubiquitinated proteins commonly significantly different
in fibroblasts compared to iPSCs in lysates examined
Lysates compared were derived from a healthy donor (HC1), a CCNFS621G ALS
patient (CCNF1), a CCNFS621G ALS patient (CCNF2), and a healthy donor (HC2)
and a sporadic Alzheimer’s disease male (SAD) as a neurodegenerative control.
Higher protein abundance in iPSCs indicated in magenta, fibroblasts in blue.
Significance determined by Student T-test (Threshold cut-off setting P>0.01).
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5.4.4

The ubiquitome of iPSC derived motor neurons is significantly different from
their originating iPSCs

A comparison of the ubiquitinated proteins of significantly higher abundance in
iPSCs and iPSC derived motor neurons indicated significant changes to the
ubiquitome following differentiation (as visualised by volcano plot; Figure 5.13).
Eight proteins were commonly increased in iPSCs compared to iPSC derived motor
neurons in all four cell lines compared. An additional 13 proteins were commonly
increased in iPSCs compared to motor neurons in three of the four cell lines
(excluding the symptomatic CCNFS621G patient line, CCNF2). Combined, the
analysis of 21 proteins revealed the pathways that were significantly increased in
iPSCs compared to motor neurons:

Biological Process analysis revealed 24

pathways were signficantly more present, including RNA processing (including
splicing). Cellular Component analysis of the protein interactions shared between
these proteins indicated that in addition to an increase of DNA replication
minichromosome maintenance (MCM) proteins -4, -5 and -7 (MCM4, MCM5 and
MCM7) which are associated with DNA helicase (as classified by Molecular
Function analysis), DNA replication and cell cycle (as classified via KEGG).
Additionally nuclear speckle proteins were also increased in their ubiquitinated form,
as well as spliceosomal proteins which were increasingly abundant in iPSCs
compared to motor neurons, included serine/arginine-rich splicing factor (SRSF) -1, 3, -6 (SRSF1, SRSF3, SRSF6) transformer 2 -alpha homolog (TRA2A), and -beta
homolog (TRA2B), and apoptotic chromatin condensation inducer 1 (ACIN1).

236

Twenty ubiquitinated proteins were commonly significantly increased in motor
neurons compared to iPSCs. Comparison of these protein interactions as classified
by Biological Process indicated that half (10) of these ubiquitinated proteins were
associated with nervous system development, and these included roles in
neurogenesis and regulation of axogenesis.

An additional 47 proteins were

increased in abundance commonly in three of the four cell line iPSC derived motor
neurons (excluding the symptomatic CCNFS621G patient line, CCNF2). Combined,
these 67 proteins were also analysed for protein interactions via STRING. Biological
Process analysis indicated that an additional 8 protein (totalling 18) were associated
with nervous system development. Almost two thirds (43) of the proteins increased
in motor neurons were associated with vesicles, as classified by Cellular Component
analysis.

Examining Cellular Component interactions revealed ECM and

cytoskeletal proteins were increased in iPSC derived motor neurons compared to
iPSCs; this included microtubule associated protein -2, -4, -1B, and -RE1 (MAP2,
MAP4, MAP1B, MAPRE1) and annexin 1 and 6 (ANAX1, ANXA6).

Three

proteins associated with the positive regulation of the endoplasmic reticulum
(ubiquitin-dependent) protein catabolism, ubiquilin -1 (UBQLN1), -2 (UBQLN2)
and ubiquitin-like 4A (UBL4A), were also increased in motor neurons.
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Figure 5.13 Representative volcano plot comparing iPSCs to motor neurons
Data represents ubiquitinated protein expression in CCNFS621G patient derived iPSCs
compared to motor neurons. Proteins significantly increased (P<0.01) in fibroblasts
and iPSCs indicated in red.

All increased ubiquitinated proteins from the comparison of iPSCs and iPSC derived
motor neurons were analysed for network changes using Cytoscape (Figure 5.14).
Examination of the collection of significantly different proteins reiterated the
findings of the individual analyses performed via STRING, including the increased
abundance of ubiquitinated spliceosomal proteins (6) and DNA replication proteins
(3) in iPSCs. This second analysis also highlighted the increased abundance of
ubiquitinated proteins associated with axogenesis pathways (4), as well as and
cytoplasmic transport proteins (5). Interestingly there was an increased abundance in
ten ubiquitinated mitochondrial associated proteins in motor neurons, and one
ubiquitinated mitochondrial associated protein (ATP Citrate Lyase; ACLY) in iPSCs,
suggesting a change in mitochondrial activity in iPSC derived motor neurons.
238

Figure 5.14 STRING map of ubiquitinated protein significantly different in iPSCs
compared to motor neurons in lysates examined
Lysates compared were derived from a healthy donor (HC1), a pre-symptomatic
CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2),
and a healthy donor (HC2) and a sporadic Alzheimer’s disease male (SAD) as a
neurodegenerative control. Higher protein abundance in iPSCs indicated in magenta,
motor neurons in cyan. Significance determined by Student T-test (Threshold
P<0.01).
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A qualitative analysis of the proteins expressed in motor neurons was also performed
to further validate the successful differentiation of motor neurons from iPSCs via
expression of motor neuron specific proteins. Expression of ALS relevant proteins
(as indicated by comparison to the ALS bioinformatics database ALSoD) including
proteins such as profilin-1, ubiquilin-2, dynactin subunit 1 and tubulin proteins -β, β3, -β4, -β4A and -4B, in these iPSC derived motor neurons further supported the
engagement of these cellular models in ALS research (Table 5.1; Abel et al., 2012).

Table 5.1 ALS relevant ubiquitinated proteins detectable by ubiquitinomics in
motor neuron lysates as listed in ALSoD bioinformatics database
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Ubiquitinated ALS mutation proteins encoded by genes of which mutants
are known to cause ALS
Protein

Gene

UnitProt Protein Name

DCTN1
MATR3
PROF1
SQSTM
TADBP

DCTN1
MATR3
PFN1
SQSTM1
TARDBP

Q14203
P43243
P07737
Q13501
Q13148

TERA

VCP

P55072

UBQL2

UBQLN2

Q9UHD9

Dynactin subunit 1
Matrin-3
Profilin-1
Sequestosome-1
TAR DNA-binding protein 43
Transitional endoplasmic reticulum ATPase (valosincontaining protein)
Ubiquilin-2

Ubiquitinated proteins associated with ALS and/or proteostasis related
Protein

Gene

UnitProt Protein Name

ATX10
CAND1*
CLUS
CUL3
NED4L
PSD12*
SAE2
SRS10
SUMO1
SUMO2
TBB3
TBB4A
TUBB
TUBB4B
UBA1
UBA52
UBE2N
UBE3A
UBP2L
UBP5
UBP7
UBQL1*
UBR5
UBXN1
USP9X*

ATXN10
CAND1
CLU
CUL3
NEDD4L
PSMD12
UBA2
SRSF10
SUMO1
SUMO2
TUBB3
TUBB4A
TUBB
TUBB4B
UBA1
UBA52
UBE2N
UBE3A
UBAP2L
USP5
USP7
UBQLN1
UBR5
UBXN1
USP9X

Q9UBB4
Q86VP6
P10909
Q13618
Q96PU5
O00232
Q9UBT2
O75494
P63165
P61956
Q13509
P04350
P07437
P68371
P22314
P62987
P61088
Q05086
Q14157
P45974
Q93009
Q9UMX0
O95071
Q04323
Q93008

Ataxin-10
Cullin-associated NEDD8-dissociated protein 1
Clusterin
Cullin-3
E3 ubiquitin-protein ligase NEDD4-like
26S proteasome non-ATPase regulatory subunit 12
SUMO-activating enzyme subunit 2
Serine/arginine-rich splicing factor 10
Small ubiquitin-related modifier 1
Small ubiquitin-related modifier 2
Tubulin beta-3 chain
Tubulin beta-4A chain
Tubulin beta chain
Tubulin beta-4B chain
Ubiquitin-like modifier-activating enzyme 1
Ubiquitin-60S ribosomal protein L40
Ubiquitin-conjugating enzyme E2 N
Ubiquitin-protein ligase E3A
Ubiquitin-associated protein 2-like
Ubiquitin carboxyl-terminal hydrolase 5
Ubiquitin carboxyl-terminal hydrolase 7
Ubiquilin-1
E3 ubiquitin-protein ligase UBR5
UBX domain-containing protein 1
Probable ubiquitin carboxyl-terminal hydrolase FAF-X
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5.4.5

The ubiquitinomics profile of the two terminally differentiated cell stages in
multiple cell lines are significantly different

A comparison of the ubiquitinated proteins of significantly higher abundance in
fibroblasts and iPSC derived motor neurons further highlighted the cell type
dependent regulation governed by the ubiquitome (as visualised by volcano plot;
Figure 5.15). STRING analysis indicated only eight ubiquitinated proteins were
commonly increased in fibroblasts compared to motor neurons in all cell lines. Of
these proteins, seven were extracellular exosomal proteins.

An additional 25

ubiquitinated proteins were commonly increased in fibroblasts all lines except the
CCNF2 line. Combined, these 33 proteins were associated with a range of proteininteraction pathways. Eight ubiquitinated spliceosomal proteins were significantly
more abundant in fibroblasts.

Interestingly, four cytoskeleton proteins were

increased in fibroblasts - tenascin C (TNC), CD44, fibronectin 1 (FN1), and
thrombospondin 1, (THBS1), and 20 proteins were associated with the extracellular
exosome/extracellular region cellular component. By comparison, only 20 proteins
were increased in all cell lines examined in motor neurons compared to fibroblasts
The only commonality between these proteins was the Cellular Component in which
they were increased - the cytosol. No Biological Component or KEGG protein
interactions were shared in these commonly increased ubiquitinated proteins.
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Figure 5.15 Representative volcano plot comparing fibroblasts to motor neurons
Data represents ubiquitinated protein expression in CCNFS621G patient derived in
fibroblasts compared to motor neurons. Proteins significantly increased in abundance
(P<0.01) indicated in red.

Sharing the same trend as other cell stage comparisons, the common proteins
significantly increased in all cell lines except the symptomatic CCNFS621G patient
(CCNF2) were far more numerous: 79 proteins were commonly increased in motor
neurons compared to fibroblasts. Combined, these 99 proteins were examined for
interactions.

When grouping the protein interactions by Biological Process (46

pathways were identified), 16 of these ubiquitinated proteins increased in motor
neurons compared to fibroblasts were associated with RNA processing, including
splicing, and stabilisation. Five proteasomal proteins were also increased as
ubiquitinated proteins in motor neurons including small ubiquitin-related modifier 2
(SUMO2), ubiquitin-like protein-4A (UBL4A), clusterin (CLU), ubiquilin-1
(UBQLN1) and ubiquilin-2 (UBQLN2). Examination of the protein interactions by
Molecular Function protein interactions revealed approximately one third of the 99
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proteins were associated with poly(A) RNA binding. As mentioned, many of these
proteins were also classified as neuron specific components such as neuronal cell
body (10), neuron projection (13), myelin sheath (12), dendrite (8), microtubule (8),
and vesicles (52) components. Mitochondrial proteins (12) were also increased in
this classification (Molecular Function) in motor neurons compared to fibroblasts.

All increased ubiquitinated proteins from the comparison of fibroblasts and iPSC
derived motor neurons were analysed for network changes using Cytoscape (Figure
5.16). Similar to the comparison between fibroblasts and iPSCs, ECM associated
proteins changed, with an increased abundance in two proteins in motor neurons and
three proteins in fibroblasts. Exosomal proteins also exhibited changes within this
pathway comparison: 15 exosomal proteins increased abundance in motor neurons,
and two exosomal proteins increased in fibroblasts, suggesting a change in the
regulation required in the motor neurons comparatively. As would be expected
axogenesis proteins (3) again increased in ubiquitination abundance in the motor
neurons compared to fibroblasts, similar to the comparison with iPSCs and motor
neurons. Most pronounced, however were again changes to the spliceosome, which
accounted for approximately one third of the significantly different ubiquitinated
proteins in this comparison. Interestingly, there were significant differences in the
abundance of spliceosomal proteins in both cell types, highlighting the cell specific
role of the spliceosome; this strongly suggests that ubiquitin is an important regulator
of this cellular mechanism.
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Figure 5.16 STRING map of ubiquitinated protein significantly different in
fibroblasts compared to motor neurons in lysates examined
Lysates compared were derived from a pre-symptomatic CCNFS621G ALS patient
(CCNF1), a symptomatic CCNFS621G ALS patient (CCNF2), and a healthy donor
(HC2) and a sporadic Alzheimer’s disease male (SAD) as a neurodegenerative
control. Higher protein abundance in fibroblasts indicated in blue, motor neurons in
cyan. Significance determined by Student T-test (Threshold P>0.01).
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5.4.6

Proteasomal inhibition has greatest effect on iPSCs, followed by motor
neurons, compared to fibroblasts

Following the identification of the widespread involvement of the UPS in such a
variety of cellular pathways at each of the three cell stages investigated, we sought to
determine the effects of inhibition of the UPS on the maintenance of these cell stages
and the course of differentiation. We compared the viability of the cells from each
cell stage (fibroblasts, iPSCs and motor neurons) to those treated with proteasome
inhibitor MG132, treated concurrently, in six biological replicates (from the six
individuals examined in this study) (Figure 5.17).

Cells from all biological samples, from all cell stages showed a dose dependent
decrease in viability, inversely correlating to MG132 concentration which ranged
from 1 μM – 250 μM. Fibroblasts showed the lowest rate of change in viability, with
a TC50 calculated at 149.8 μM MG132. The iPSC derived motor neurons were more
susceptible to MG132 compared to fibroblasts. A mean TC50 was calculated at 43.3
μM MG132. Intriguingly, the highest susceptibility to proteasomal stress was
exhibited in iPSCs. MG132 treatment was lethal to 100% of iPSC colonies at all
concentrations tested. Vehicle controls and no treatment control exhibited normal
proliferation, increasing confluence by ~140% over 16 hours (Figure 2A). The iPSC
colonies detached in as little as three hours at 1 μM MG132, the lowest concentration
tested. This cell death was consistent amongst all of the six biological replicates, in
100% of cells as measured by Trypan Blue following 16 hours of incubation. By
comparison, neither fibroblasts nor motor neurons showed this level of toxicity to
MG132.
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A

TC50 = 43.3 μM

B

C

TC50 = 149.8 μM

Figure 5.17 Cellular viability decrease was inversely correlated to increasing MG132
concentration
MG132 was incubation for 16 hour treatment in firboblasts, iPSCs and motor
neurons, compared to vehicle control. iPSC viability was severely affected by
MG132 treatment at the same concentrations as fibroblast and motor neuron
treatments. Following 16 hour treatment, no iPSCs remained attached to culture dish;
detached
cells
were
determined
dead
by
Trypan
Blue.
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5.4.7

E1 inhibition detrimental to motor neuron viability

To further investigate the importance of the ubiquitin system in the development of
motor neurons we inhibited E1 ubiquitin binding protein UBA1 during motor neuron
differentiation. UBA1 is a central regulator of the UPS, and mutations in UBA1 have
previously been identified to cause the motor neurone disease spinal muscular
atrophy (Groen and Gillingwater, 2015; Ramser et al., 2008). Neurite outgrowth was
monitored 24 h following treatment with the UBA1-specific inhibitor PYR41 during
motor neuron differentiation (Figure 5.18). Neurite analysis revealed a decrease in
neurite length in motor neuron precursor cells in all six biological replicates when
treated with 10 µM PYR41. Neurite length was significantly decreased in three of
these cell lines compared to vehicle control (0 µM PYR41) treated motor neuron
precursors (from both ALS derived and healthy control derived cells) with one donor
cell line exhibiting an approximately two-fold decrease in neurite length.

To determine the long-term effects of UBA1 inhibition, and thus ubiquitin system
stress on motor neuron development, we treated motor neuron precursors with a low
dose (1 µM PYR41) and a higher dose of UBA1 inhibitor (10 µM PYR41) over the
course of differentiation (Figure 7.19; Appendices Figures 8.17 - 8.19). Motor
neuron precursors were dosed and imaged on alternative days. Over the course of
three doses of 10 µM PYR41, motor neuron precursors showed decreased neurite
outgrowth and decreased cellular integrity. Cell death was evident by day 6 of the
differentiation in all motor neuron precursors. Precursors treated with 1 µM PYR41
exhibited no significant difference in neurite outgrowth following four weeks of
treatment compared to the vehicle control.
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Despite no morphological differences, there was a clear decrease in viability of cells
following four weeks of treatment with 1 µM PYR41 (Figure 5.20). Cell viability
assay of the motor neurons at the end stage of the treatment revealed a significant
decrease in the viability of the cells in the five biological replicates (As indicated by
Student T-test, t=2.642, 5. P= 0.0459).

Figure 5.18 Neurite outgrowth of motor neuron precursors following 24 hour
treatment with UBA1 inhibitor PYR41
Concentrations ranging from 1 µM – 10 µM PYR41 elicited a dose dependent
response across six biological replicates, derived from a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G ALS
patient (CCNF2), and a healthy donor (HC2) and a sporadic Alzheimer’s disease
male (SAD). Significant difference determined by ANOVA *P<0.05, ***P<0.001.
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Figure 5.19 Representative graph of neurite outgrowth in motor neurons precursors
Neurite outgrowth was monitored for 4 weeks of culture with UBA1 inhibitor
PYR41 at high (10 µM) and low (1 µM) concentrations in the six biological
replicates. Neurite outgrowth was unaffected by long-term low dose PYR41
treatment, high dose PYR41 (10 µM) treatment resulted in cell death. Data shown
from the CCNF1 cell line, derived from a pre-symptomatic CCNFS621G ALS donor.
Significant difference tested via ANOVA P>0.05.
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Figure 5.20 Motor neuron viability following low concentration UBA1 inhibition
Cellular viability of PrestoBlue assay in motor neurons following alternate day
treatment with UBA inhibitor PYR41 (1 µM) during the maturation of motor neurons
measured by fluorescence emission at 590 nm compared to vehicle control across six
biological replicates, derived from a healthy donor (1; HC1), a CCNFS621G ALS
patient (2; CCNF1), a CCNFS621G ALS patient (3; CCNF2), a SOD1E101G ALS patient
(4; SOD1), and a healthy donor (5; HC2). Significant difference assessed via Student
T-Test *P<0.05.
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5.5 Comparison of motor neuron ubiquitomes

To further investigate if there were significant differences in the ubiquitination of
protein pathways in motor neurons derived from individuals (inlcuding ALS
patients), analysis of the different motor neuron cell lines was performed.

An

ANOVA analysis was performed comparing the quantified ubiquitinated proteins
expressed in each cell line. STRING analysis for protein interactions was then
performed for the significantly different proteins expressed in the CCNF2 line, which
had repeatedly exhibited differences in UPS activity. A group of 423 ubiquitinated
proteins were significantly different in the CCNF2 cell line. These results could be
further sub-grouped into ubiquitinated proteins that were significantly different only
between the HC2 (22), proteins that were only significantly different between
CCNF2 and all other cell line proteins only (92), significant differences between
HC2 and all other cell lines only (50) and all other assorted combinations wherein
CCNF2 are significantly different (259) (Table 5.2).
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Table 5.2 Summary of analysis of all proteins significantly different between
CCNF2 and HC2
Significantly
different
between:

Total

HC2 vs
CCNF2

CCNF2 vs all
cell lines
exclusively

Assorted
CCNF2

HC2 vs
all cell
lines

Significant difference present (ANOVA comparisons)
HC2 vs. CCNF2

Yes

Yes

Yes

Yes

Yes

HC2 vs. CCNF1

Yes/No

No

No

Yes/No

Yes

HC2 vs. SAD

Yes/No

No

No

Yes/No

Yes

CCNF1 vs. CCNF2

Yes/No

No

Yes

Yes/No

No

CCNF1 vs. SAD

Yes/No

No

No

Yes/No

No

CCNF2 vs. SAD

Yes/No

No

Yes

Yes/No

No

92

259

50

Proteins significantly different (ANOVA)

Number of proteins

423

22

Pathways with Significant Interactions (indicated by STRING)
KEGG

20

0

0

7

0

Biological Process

372

0

29

232

14

Cellular Component

134

4

34

84

11

Molecular Function

55

0

7

45

1

Analysis of the interactions of the 432 ubiquitinated proteins significantly different
between lysates via KEGG analysis indicated 20 pathways were increasingly
represented - this included 12 spliceosomal proteins, 5 proteasome proteins, 11
phagosomal proteins, 4 TCA proteins, 9 tight junctions, 11 focal adhesion, and
interestingly, 9 proteins previously associated with Parkinson’s disease (which are
predominantly mitochondrial proteins, when classified by Cellular Component) were
significantly different between motor neurons from the CCNFS621G derived motor
neurons (CCNF2) and the healthy donor derived cell lines (HC2). Of the nine
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significantly different proteins identified as belonging to this network, six of these
were mitochondrial proteins. Two of these proteins were subunits of mitochondrial
ATP Synthase; the abundance of these proteins was varied between the healthy
control motor neurons and the symptomatic CCNFS621G (CCNF2) line. Three proteins
were NADH dehydrogenase subunit proteins; all of these proteins were significantly
decreased in CCNF2 compared to the healthy control. The ubiquitinated cytochrome
C oxidase subunit protein was significantly more abundant in the CCNF2 line
compared to the healthy control.

Examining the protein interactions via STRING, revealed over 370 different
Biological Processes were differently ubiquitinated in the symptomatic CCNFS621G
(CCNF2) cell line compared to the healthy control line. The top ten processes
included a number of processes that have already been associated with ALS including cellular transport, cellular stress and gene expression processes, as well as
neuronal differentiation (Table 5.3).
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Table 5.3 Significantly different Biological Processes between the healthy control
(HC2) and symptomatic CCNF2S621G (CCNF2) motor neurons

Ten most abundant Biological Processes significantly different
between the healthy donor-derived (HC2) and a CCNFS621G ALS
patient-derived (CCNF2) motor neurons
Biological Process

Number of
proteins

False Discovery
Rates

Organelle organization
Transport
Response to stress
Cell differentiation
Gene expression
Protein localization
Intracellular transport
Neurogenesis/generation of neurons
Cellular response to stress
Vesicle-mediated transport

105
102
102
100
99
72
66
54
54
50

1.78E-09
3.93E-05
4.45E-0.5
2.73E-06
0.0379
1.79E-08
2.08E-10
4.58E-05
0.00167
5.72E-06

Pathways previously associated with dysfunction in ALS were highlighted in this
analysis - processes such as proteostasis associated processes, endoplasmic reticulum
localization (15), RNA splicing (22), as well as synaptic processes (via synaptic
vesicle associated; 19), and microtubule organization (39) were significantly
different (Figures 5.22 - 5.29).

When examining the Cellular Component protein interactions (grouped localisation
of these signficantly increased ubiqutiinated proteins), proteins localised (not
necessarily exclusively) in vesicles (46%), the nucleus (44.4%), in the
endomembrane (25%), cytoskeleton (17.5%), and mitochondria (14%). There were
22 ubiquitinated proteins only significantly different in between only CCNF2 and the
healthy control - these were enriched for four cellular components - 13 were
associated with extracellular exosomes and the extracellular region (the same 13
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proteins), and 20 were associated with membrane/membrane-bounded organelle
components of the cell. Additionally, 11 membrane proteins were also classified as
the extracellular component associated proteins.

An ANOVA analysis revealed close to a quarter of the total ubiquitinated proteins
were significantly different between CCNF2 and all other cell lines (exclusively).
Examining only these proteins via STRING indicated 29 Biological Processes,
including organelle organization (26 proteins), regulation of ER-associated ubiquitindependent protein catabolic process including ubiquitin like protein 4A (UBL4A)
ubiquilin 2 (UBQLN2), and ubiquitin-specific protease 14 (USP14), proteasomal
ubiquitin-independent protein catabolic process including proteasome subunit -A1, A6 and B5 (PSMA1 PSMA6, PSMB5). Interestingly, two mitochondrial proteins
mitochondrial ATP-dependent protease lon (LONP1), and stomatin-like protein 2
(STOML2) registered as the Biological Process of regulation of mitochondrial DNA
replication.

Together, these proteins were associated with over 30 Cellular

Compartments, and belonged to 7 molecular function-enriched groupings.
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Figure 5.21 STRING map of ubiquitinated protein significantly different in iPSC
derived motor neurons
Comparison was between CCNFS621G ALS patient (CCNF2) and a healthy donor
(HC2) and other cell lines. iPSC derived motor neuron lysates from motor neurons
from a CCNFS621G ALS patient (CCNF1) and a sporadic Alzheimer’s disease male
(SAD) as a neurodegenerative control were also compared. Significance determined
via ANOVA minimum of P<0.05.
257

****

2

*

***

*

SG
TA

«
n
u
l

N
P1

***

****

HC2
CCNF1
CCNF2
SAD

1

1
TS
G
10

1
TC
EB

LO

7
IA
A

19
6

5
K

H

SP
A

1
90
B
H
SP

B
P4
G
TP

C

A
PN
C

LU

0
2

Relative abundance of ubiquitinated protein

3

Proteostasis Associated Proteins

Figure 5.22 Dotplot of proteostasis associated proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared to
pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.
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Figure 5.23 Dotplot of proteasomal proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared to
pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.

259

«
n
u
l

4

HC2
CCNF1
CCNF2
SAD

****
3

*
****

2

****

**

1

W
E1
U
H

TD
1
H

EC

R
5
U

B

A
1
B
U

4
SP
1
U

XN
1
B
U

LN
2
U

B
Q

LN
1
U

B
Q

L4
U

B

U
C

A

0
L3

Relative abundance of ubiquitinated protein

5

Ubiquitin Associated Proteins

Figure 5.24 Dotplot of ubiquitin associated proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.
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Figure 5.25 Dotplot of spliceosomal proteins expressed in motor neurons significantly different in abundance.
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.
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Figure 5.26 Dotplot of glycoxylate/dicarbocylate metabolism proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.
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Figure 5.27 Dotplot of focal adhesion proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.
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Figure 5.28 Dotplot of synaptic vesicle associated proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also compared
to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were classified via
STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via ANOVA with
post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference between HC2 and
CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002, ****P<0.0001.
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Figure 5.29 Dotplot of synaptic vesicle associated proteins expressed in motor neurons significantly different in abundance
Proteins were compared between a in a symptomatic CCNFS621G ALS patient (CCNF2), compared to a healthy donor (HC2), and also
compared to pre-symptomatic CCNFS621G ALS patient (CCNF1), and a sporadic Alzheimer’s disease patient (SAD). Proteins groups were
classified via STRING analysis (High Confidence setting). N = 3 differentiation replicates minimum. All data shown significantly different via
ANOVA with post hoc multiple comparisons corrections (Benjamini, Kreiger and Yekutieli method of correction); significant difference
between HC2 and CCNF2 minimum P<0.05, Tukey’s post hoc test indicated by asterisks; *P<0.0332, **P<0.0021, ***P<0.0002,
****P<0.0001.
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5.6 Discussion

Despite the increasing use of both iPSCs and iPSC derived motor neurons in medical
research no study has yet examined the changes to the human ubiquitome following
cellular reprogramming of primary cells to iPSCs, or the effects of differentiation to
motor neurons on this landscape.

By engaging ubiquitin-filtering techniques

combined with tandem mass spectrometry this study has, for the first time, mapped
the global ubiquitinated proteome of iPSC derived motor neurons and derivative cell
types (iPSCs and fibroblasts). Comparison of lysates from fibroblasts, iPSCs, and
motor neurons following (I) reprogramming, and (II) differentiation, indicated
significant changes in the ubiquitome in a broad range of pathways including heat
shock, cytoskeletal, and the spliceosome system, which are undoubtedly important to
the intrinsic properties of these cell types (Chen and Moore, 2015; Fan, 2012; Kim et
al., 2017; Omori et al., 2014; Tai and Schuman, 2008). Further probing of the
importance of the UPS in these cellular stages indicated significant decreases in
viability following UPS inhibition. This study also importantly, for the first time,
detects significant differences between ubiquitomes of motor neurons derived from
ALS patients and those derived from healthy individuals.

Comparison of the

collective ubiquitomes at the three fundamental stages of iPSC-motor neuron
modelling indicated significant cell stage specific differences in the pathways
regulated by ubiquitin. Changes in abundance of ubiquitinated proteins essential to
both pluripotency maintenance, as well as motor neuron differentiation reiterated the
dynamic and central role of the ubiquitin proteasome system, in regulating a wide
spanning network of systems (Hershko and Ciechanover, 1998).
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5.6.1

The dynamic landscape of the ubiquitome changes following iPSCreprogramming

Comparisons of iPSCs and the derivative fibroblast cell stage revealed numerous
changes in the ubiquitinated protein landscape.

Reprogramming of fibroblasts to

iPSCs led to changes in the abundance of ubiquitinated heat shock associated
proteins, as well as a significant lowering in the abundance of ubiquitinated ECM
proteins. Conversely, increases in the ubiquitinated spliceosomal and poly(A) RNA
binding proteins were evident in iPSCs. Together these highlight the changing role
of these pathways in the generation of these pluripotent cells, and the likely changing
requirement of the ubiquitome in regulating these systems.

5.6.1.1 Regulation of heat shock protein changes upon reprogramming
The ubiquitinated forms of Hsp27 (encoded by HSPB1), and Annexin 2 were
significantly changed following reprogramming.

Regulation of the heat shock

protein network by the UPS via HSF1 ubiquitination has been previously reported in
human cell lines including neuroblastoma cells (Kim, 2017; San Gil et al., 2017),
however little is known regarding the regulation of the heat shock proteins by
ubiquitination in pluripotency. It is believed that many heat shock proteins have been
associated with maintenance of pluripotency. Increased expression of the heat shock
protein Hsp90 has been shown to decrease the ability of ESCs to differentiate to
other cell types (Bradley et al., 2012; Cheng et al., 2016). Similarly, Hsp70 has been
shown to regulate pluripotency by facilitating OCT4 binding to DNA in human
embryonic carcinoma cells (Geng et al., 2015). Moreover, a previous study indicated
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proteasomal inhibition in ESCs correlated with a reduction in HSP70 and
pluripotency factors - including OCT4 and nanog (Park et al., 2012). The increased
levels of the ubiquitinated form of these heat shock proteins in iPSCs could therefore
indicate that ubiquitin is not necessarily acting as a degradation signal in these cells,
but as a conformational alteration, to change the function of the heat shock proteins.
Following these results, it would be of value to better understand the role of
ubiquitination of the heat shock proteins in the maintenance of iPSCs, and during
neuronal differentiation.

5.6.1.2 Cytoskeletal and ECM proteins decreased in iPSC ubiquitome
The rapid detachment of the iPSCs following UPS inhibition was particularly
noteworthy given the changes in abundance of ubiquitinated proteins associated with
focal adhesion/ECM interactions. Ubiquitinated forms of both a fibrillar (type 1) and
non-fibrillar collagen (type 6) were downregulated in iPSCs. A reduction in these
collagen levels may also be due to an overall decrease in the presence of these
proteins, which has been previously reported in a comparison of mouse fibroblast
and mouse iPSCs and ESCs (Hao et al., 2013). This previous work indicated mouse
pluripotent stem cells had a lower abundance of cell adhesion and cytoskeletal
proteins, compared to tail tip fibroblasts, from which the mouse iPSCs were derived
(Hao et al., 2013). Total proteomic analysis of the mouse lines also indicated that
ANXA1, ILK, collagens 1 (A1) and 6 (A1 and A2), LGALS1 and LGALS3 were
significantly decreased in mouse iPSCs compared to the fibroblasts from which they
derived. This is also corroborated by findings that mouse ESCs (2i) expressed a
decrease in nine cell adhesion proteins and seven cytoskeletal proteins compared to
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the mouse ESC being differentiated in serum (Taleahmad et al., 2016). Collectively,
the decrease observed suggests that the decreased levels of ubiquitination could be
due to the ubiquitin mediated degradation of these proteins following
reprogramming, or a that these proteins are decreased in iPSCs, regardless of
ubiquitination. It is not clear why these pathways are decreased in pluripotency. It is
important to consider that ECM proteins are added to iPSC cultures; Matrigel, which
has been analysed to be 30% collagen IV, as indicated by the analysis performed in
1982 (Kleinman et al., 1982). More recent analysis by LC-MS identified collagen I,
3A1, 6A1 and 6A2 were present in Matrigel composition (Hughes et al., 2010).
Further understanding of how iPSCs regulate ECM associated proteins will
undoubtedly prove valuable given that ECM proteins remain one of the major costs
of stem cell maintenance, and remain a source of variability in cultures (Hughes et
al., 2011).

5.6.1.3 Ubiquitinated

spliceosomal

proteins

increased

in

iPSCs

upon

reprogramming
The ubiquitination of ten spliceosomal proteins were commonly significantly
increased in iPSCs compared to both fibroblasts and motor neurons. Two of the
proteins identified as more abundant in iPSCs, TRA2A, TRA2B have been
previously reported as being increased in iPSCs (Munoz et al., 2014). Whether this
higher abundance in iPSCs indicates regulation of abundance via ubiquitin signalled
degradation, or is the result ubiquitin-mediated of spliceosomal regulation is unclear.
Spliceosomal proteins, by their very nature, are modulators of cellular identity
(Matera and Wang, 2014). The depletion of specific spliceosomal proteins have been
known to cause a loss of pluripotency (Kim et al., 2017), and are altered in the event
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of differentiation. The ubiquitination of spliceosomal factors is under-explored in
the context of pluripotency and differentiation, compared to other post-translational
modifications, despite the importance of the spliceosome in both these processes
(Graveley, 2011; Tsuiji et al., 2013). Mutant ubiquitin has been shown to inhibit
splicing events (Bellare et al., 2008). Collectively, these findings present a strong
argument for further investigation of the ubiquitin regulation of spliceosomal events
in differentiation given the potential importance of spliceosomal pathways in
managing cellular fate.

Ubiquitinated poly(A) RNA binding proteins were also identified as also being
increased in iPSCs following reprogramming from fibroblasts.

Poly(A) RNA

binding proteins are responsible for the additional of adenosine stretches to RNA
transcripts, referred to as RNA polyadenylation. This polyadenylation of RNA has
been linked to transcript stability, localization, and subsequent translation (Ye and
Blelloch, 2014). This adenylation may occur at more than one poly(A) site on a
transcript (in a process known as alternate polyadenylation) (Elkon et al., 2013).
Poly(A) tail length affects mRNA abundance thereby regulating cellular protein
levels. Short tails are thought to result in transcript degradation (Sach, 1970), while
longer tails are associated with cellular proliferation (Ye and Blelloch, 2014). Given
the increase in proteins associated with this process following reprogramming,
further investigation into this protein regulating mechanism would be of great value specifically, examining the poly(A) tail lengths of proteins, and the regulation of
pluripotency by the UPS.
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5.6.1.4 No ubiquitin modification detected in OSKM factors
Only one other study to date has investigated the global changes to ubiquitin during
iPSC reprogramming - Buckley et al. compared mouse embryonic fibroblasts
(MEFs), mouse iPSCs, and mouse ESCs (Buckley et al., 2012). This study found
some similarities in the proteins ubiquitinated in human iPSCs with the combined
MEF-iPSC ubiquitome reported.

Species differences, as well as varying data

filtering techniques may contribute to differences between the datasets. In addition,
as stem cells in this study were cultured under feeder-free conditions, there is no
contribution of the MEF ubiquitome to our human iPSC dataset. This was not
possible for Buckley et al. as their datasets could not distinguish the ubiquitomes of
iPSCs and MEFs, due to the requirement of co-culturing stem cells on MEFs.

Buckley et al. (2012) identified novel ubiquitinated pluripotency regulating proteins,
including the reprogramming transcription factors, Oct4 and Nanog, which were
reported in mouse iPSCs-MEF dataset (Buckley et al., 2012). Ubiquitinated Oct4 and
Nanog were not detected in human iPSCs in this study, despite confirmation of the
expression of these proteins via immunocytochemistry and/or qRT-PCR.

The

absence of these proteins in the ubiquitome suggests that the ubiquitination of
pluripotency factors is not required to maintain pluripotency in human iPSCs.
Instead, it may be that ubiquitination causes a downregulation of these proteins,
required for differentiation. This was indeed reported in mice, whereby inhibiting
polyubiquitination of N-myc and c-myc inhibited neural differentiation of mESC
(Zhao et al., 2008). The ubiquitination in this scenario is thus potentially promoting
degradation of these pluripotency factors by the proteasome to permit differentiation.
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5.6.2

Fundamental motor neuron pathways ubiquitinated in iPSC derived motor
neurons

Comparison of the collective ubiquitomes from iPSCs and motor neurons suggested
a shift in the role of ubiquitin. Differentiation of the stem cells resulted in a decrease
in ubiquitinated cell cycle proteins, and an increase in the presence of ubiquitinated
spliceosomal, cytoskeletal, and synaptic proteins. Qualitative analysis confirmed the
presence of motor neuron proteins and ALS relevant proteins further validating the
usefulness of these models.

5.6.2.1 Ubiquitinated cell cycle proteins decreased in iPSC-motor neuron
differentiation
Ubiquitinated

MCM

proteins

were

significantly

decreased

following

the

differentiation of iPSCs to motor neurons. These MCM proteins combine to form a
DNA helicase. Accordingly, these proteins are associated with cell cycling, and
activity is known to decrease upon differentiation (Matson et al., 2017). This is not
the first reporting of regulation of MCM proteins via ubiquitin. Ubiquitination of
MCM proteins has been indicated to influence the activity of these proteins, for
example ubiquitination of MCM10 alters the binding affinity of this protein to DNA
polymerase (Gilberto and Peter, 2017). MCM7 ubiquitination has been found to be
restrictive for replication forks (Maculins et al., 2015). Ubiquitin is therefore likely to
play an important role in the regulation of DNA replication. Further studies will be
required to indicate to what extent the ubiquitination of these MCM proteins is
homogenous, and what to verify what purpose it serves in these cells. Given that the
ubiquitination is a known requirement for the regulation of MCM proteins, the
absence of these ubiquitinated proteins in the motor neurons is consistent with the
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expectation that DNA replication processes are no longer occurring in motor
neurons, and suggests this is a decrease in this pathway as a whole (GarcíaRodríguez et al., 2016).

5.6.2.2 Microtubule and synaptic proteins increased upon differentiation
Microtubule-associated proteins and tubulin proteins were detected at significantly
higher abundances in the ubiquitome following differentiation, reiterating previous
findings that ubiquitin is an important modulator of cytoskeletal structures (Hamilton
and Zito, 2013). This is also likely a reflection of the general increase of these
proteins in the differentiating cells.

Unsurprisingly, synaptic proteins were

increasingly found in the motor neurons. This regulation of synaptic proteins is
particularly interesting as previous findings suggest that even small alterations to the
ubiquitination of synaptic proteins can lead to motor neuron death (Liu, Y et al.,
2015). The iPSC derived motor neurons therefore present a suitable model system
for probing these pathways, which are fundamental to motor neuron function, and are
affected in motor neurone diseases.

5.6.2.3 Mitochondrial ubiquitination increases following differentiation
When considering the comparison between cellular states, mitochondrial proteins
were significantly more abundant in motor neurons than in iPSCs. This is consistent
with an overall increase in mitochondrial count following differentiation from a stem
cell state; two previous reports examining the number of mitochondria in hESC
compared to differentiated cell indicated an increase in the mitochondrial mass and
mtDNA in differentiated cells (Lonergan et al., 2007).
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This reflects the changing

demand of the cells - stem cells are maintained in a glycolytic state, whereas motor
neurons rely on oxidative phosphorylation for the generation of ATP (Zhang et al.,
2018).

5.6.2.4 Ubiquitinated spliceosomal protein profile shifts in motor neurons
Comparison of ubiquitinated spliceosomal proteins in motor neurons with both other
cell types indicated changes to this cellular process. A decrease in the number of
ubiquitinated proteins following reprogramming, as well as a shift in the
spliceosomal proteins ubiquitinated in fibroblasts is, again, a likely reflection of the
cell stage specific activity of the spliceosomal system. Changes to spliceosomal
proteins and RNA splicing/processing/stabilising proteins were evident when
comparing the terminally fated cell lines, motor neurons and fibroblasts. A variety of
proteins were found to be increased in fibroblasts and motor neurons alike, indicating
a shift in the RNA processing proteins required to maintain these cellular states. As
aforementioned, spliceosomal and RNA processing proteins are crucial regulators of
cellular fate (Papasaikas and Valcárcel, 2016); that this distinct shift is evident in
these different cell types is a testament to the importance of the UPS in regulating
cell fate.

5.6.3

iPSCs and motor neurons more susceptible to UPS stress compared to
fibroblasts

Following previous reports of an increased sensitivity in motor neurons to UPS
stress, and the known vulnerability of motor neurons ALS to proteostasis dysfunction
(Tai and Schuman, 2008; Yerbury et al., 2016), in combination with the extensive
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differences in the ubiquitome of the different cell stages examined in this study, we
sought to investigate the effects of UPS stress in motor neurons and derivate cell
stages. The UPS is important in maintaining pluripotent stem cells in even the
lowest doses. It was clear that the UPS is vital to iPSCs maintenance, as indicated by
the fatal response in iPSCs to inhibition of the UPS. All six human iPSC lines
examined in this study exhibited an extreme sensitivity to proteasomal inhibition via
MG132 treatment, compared to simultaneously treated fibroblasts and iPSC derived
motor neurons. While fibroblast and motor neuron viability was inversely correlated
to MG132 concentrations, indicating a dose dependent response, iPSCs showed a
rapid deterioration following MG132 treatment, even at the lowest concentrations
tested. MG132 at 1 µM was sufficient to cause cell death of iPSCs in five biological
replicates within 16 hours. Monitoring via live cell imaging indicated that cellular
detachment was evident at concentrations of 1 µM in only three hours.

Further

preliminary testing by others in the Ooi laboratory identified that iPSCs were
sensitive at concentrations as low as 10 nM MG132, leading to 80% cell death within
16 hours (data not shown). Interestingly, UPS inhibition has previously been reported
to have this effect in mouse ESCs, with doses higher than 0.2 μM MG132 causing
cytotoxic effects (Geis et al., 2017), together these findings highlight the importance
of the UPS in stem cell survival.

Previous reports have suggested that proteasomal activity is increased in stem cells
compared to fibroblasts (Vilchez et al., 2012), which may suggest an increased
reliance of iPSCs on the proteasomal system. Again, it would be interesting to
identify the type of ubiquitination occurring in these cells, whether the ubiquitination
of the subunits is a conformation/activity modifier, or if the ubiquitin modification is
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a degradation signal due to an over-production of these proteins. Vilchez et al.
(2012) identified a lower level of polyubiquitin chains and an increase in protease
activity when normalised to total protein in iPSCs compared to other cell types. An
increase in polyubiquitination is not necessarily indicative of decreased proteasomal
function, and the polyubiquitin signal may provide a range of complex functions,
including regulating cellular signalling (Alfano et al., 2016). The ratio of
proteasomes to total protein is also an interesting consideration when comparing
different cell types. The ratio of total protein to proteasome is crucially important,
since total protein changes within cell types (Pontén et al., 2009); This changes the
ratio of protein required to be degraded by the proteasome, and thus the required
number of proteasomes per cell to maintain the same level percentage of protein
degradation.

5.6.3.1 Ubiquitinated proteasomal proteins most abundant in motor neurons
In three of the four cell lines examined, five proteasomal proteins were significantly
more abundant in motor neurons compared to fibroblasts; interestingly, some of
these same proteins were also more abundant in motor neurons when compared to
iPSCs. This increase in proteasomal proteins may suggest a total increase in these
proteins in motor neurons (not just the ubiquitinated form).

The increase in

ubiquitinated proteasomal proteins did not correlate with the susceptibility to
proteasomal stress as seen in iPSCs compared to the other two cell types.

To further investigate the importance of the ubiquitin system in the development of
motor neurons UBA1, an E1 ubiquitin binding protein, was inhibited during motor
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neuron differentiation. UBA1 is a central regulator of the UPS, and mutations in
UBA1 have previously been identified to cause the motor neurone disease spinal
muscular atrophy (Groen and Gillingwater, 2015; Ramser et al., 2008). Image
analysis of neurite outgrowth following UBA1 inhibition revealed a decrease in
neurite outgrowth in motor neuron precursor cells in all six biological replicates
when treated with 10 µM PYR41; Neurite length was significantly decreased in three
of these cell lines compared to vehicle control treated motor neuron precursors, with
one donor cell line exhibiting an approximately two fold decrease in neurite length.
Early characterisation via cell stage specific markers (pluripotency markers and
motor neuron markers) did not indicate a difference in these cell stages suggesting
this was not due to the capacity to differentiate. Admittedly however, it is
increasingly evident in the field that high expression of cell type specific
mRNA/protein expression may not fully indicate the ultimate state of these cells.
Accordingly, further research is required to investigate the effects of these mutations
on the cell lines, through dynamic physiological means such as electrophysiology.
Combined, these data may inform an underlying cause of dysfunction to the UPS
seen in these cells, and the potentially compensatory mechanisms.

As the UPS is a two-part system it was also important to investigate the ubiquitin
system specifically, by treating differentiating cells with an ubiquitin system
inhibitor.

Neurite outgrowth following inhibition of apex E1 ubiquitin-binding

enzyme UBA1 via 24 h monitoring following treatment with a concentration curve
of PYR41 revealed a non-linear response in neurite outgrowth in neural precursors.
Treatments ranging from 0 µM - 5 µM PYR41 showed no signficant difference in
outgrowth, while 10 µM PYR41 significantly reduced the outgrowth. This was likely
277

due to the redundancies of the ubiquitin proteasome system, allowing the cell to
compensate for the inhibition at low doses (Tai and Schuman, 2008). Long-term
treatment options (selected from this short term study) followed this non-linear
pattern. The total cell death in motor neuron precursors occurred following three
treatments of 10 µM PYR41; low dose treatment of motor neuron precursors had no
effect on neurite outgrowth viability.

This may suggest that the UPS system

redundancies were overwhelmed at higher concentrations of the UBA1 inhibitor,
which proved toxic to the cells. This would be unsurprising given the vast array of
pathways we identified as being regulated by the ubiquitin system in motor neurons.
Interestingly, though neurite length remained unaffected over a four-week low dose
PYR41 treatment, this low level UBA1 inhibition by 1 µM PYR41 caused a decrease
in cellular viability. This significant decrease in viability following 1 µM PYR41
treatment coupled with an absence of difference in the neurite extension could
indicate that a relatively normal development process is possible in the presence of
mild UPS stress, though may still be detrimental to the long-term health of motor
neurons. This sensitivity to UBA1 inhibition may also be exacerbated in ALSderived motor neurons – further investigation into this would be of great value.

5.6.4

Symptomatic CCNFS621G ALS patient derived motor neurons exhibit unique
ubiquitome profile

As a preliminary investigation into the ALS ubiquitome, the motor neuron lysates
derived from a selection of the cell lines, including the motor neurons dervied from
the two CCNFS621G patients, a healthy donor derived line, and a sporadic Alzheimer’s
disease line were compared with two control lines (one healthy, one
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neurodegenerative).

While the PCA of all samples examined indicated cellular

lysates grouped primarily by cell stage, examination within cell stages indicated
differences within the cell stages by cell type: in all three cell stages examined, the
CCNF2 cell line, derived from a CCNFS621G ALS patient, grouped separate from the
cell lines examined. The CCNF2 cell line showed a greater variety of ubiquitinated
proteins than the other cell lines in all three of the cell stages, and exhibited a
distinctly different ubiquitome. Commonalities between all cell lines examined were
less numerous than expected, however when the CCNF2 cell line was excluded the
number of commonly increased ubiquitinated proteins increased dramatically. This
could reflect differences in the capacity of the CCNF2 cells to reprogram and
differentiate and in the future this should be probed by dynamic physiological
methods. This may also suggest that this cell line exhbits detectable differences in
the ubiquitome of the fibroblasts, suggesting examination the ubiquitome in patients
may present as a potential detection method for diagnosis, as previously suggested
(Yang et al., 2015). Increasing sample sizes, and additional clones originating from
these same patient derived cells will be citical in further assessing this possibility.

5.6.4.1 Mitochondrial differences in the symptomatic CCNFS621G patient derived
cell line
As the unique phenotype exhibited in CCNF2 was present in all three cell types, this
may indicate a limited capacity of the mitochondria within these cells, which are
retained following reprogramming.

In addition to changes in the abundance of

ubiquitinated mitochondrial proteins in different cell stages, significant differences
were also detected between the cell lines in motor neurons: Parkinson’s diseases
associated proteins were identified by KEGG classification as being significantly
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different in the symptomatic CCNFS621G patient derived cell line (CCNF2). Two
thirds of these Parkinson’s disease associated proteins were mitochondrial proteins.
Ubiquitination of mitochondria signals autophagy (mitophagy) which can be the
result of damage via reactive oxygen species (Harper et al., 2018). Mitochondrial
dysfunction can be retained through reprograming as unlike other organelles, which
are simply degraded via cellular degradation pathways, mitochondria have a unique
transmission process. While mitochondria are turned over via autophagy, they are
more often renewed via mitochondrial fusion and fission (Terman et al., 2010). This
process provides the opportunity for daughter cells (and reprogrammed cells) to
inherit defective mitochondria. Normally, defective mitochondria are signalled for
degradation via parkin-induced ubiquitination of mitochondrial outer membrane
proteins (that are yet to be fully defined in the field) (Narendra et al., 2008). There is
the potential that these mitochondrial proteins identified in this study may be
involved in this process; Further verification in the ubiqitination of these
mitochondrial proteins would therefore be pertinent. Together the dysfunction in the
ALS line (regardless of cell stage) could indicate mitochondrial dysfunction is an
early downstream pathways affected by UPS dysfunction.

A dysfunction in

mitophagy is well documented in ALS (Desai et al., 2018), and linked to the
accumulation of aberrant mitochondria seen in early ALS pathology (Smith et al.,
2017); unsurprisingly reduced ATP production is common in ALS. Mitochondrial
dysfunction pathology has not been restricted to detection only in motor neurons fibroblasts have been detected to have altered ATP production compared to healthy
controls, and have been shown to have fragmentation in the mitochondrial network in
C9ORF72 patient cells (Kirk et al., 2014; Onesto et al., 2016). It is premature to
claim that the consistent differences in the UPS of the symptomatic CCNFS621G
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patient derived cell line (CCNF2) throughout the cellular stages is linked with
mitochondria. However, considering the inheritance of mitochondria through cellular
stages due to transmission via mitochondrial fusion/fission (Scott and Youle, 2010),
and the importance of ubiquitin in mitochondrial maintenance (Lavie et al., 2018), it
would be greatly relevant to examine the mitochondrial network in these cells.
Importantly, samples have been recently made available to the Ooi lab which were
collected following symptom onset from the pre-symptomatic CCNFS621G patient
(CCNF1), as well as CRISPR corrected clones, which for future investigations will
be incredibly valuable in ascertaining the role of mitochondria in the CCNFS621G
phenotype (Musunuru, 2013).

5.6.4.2 Self-regulation of UPS differs in the symptomatic CCNFS621G patient
derived cell line
The ubiquitination of both ubiquitin and proteasomal proteins significantly differed
in the symptomatic CCNFS621G patient (CCNF2) iPSC derived motor neurons. Four
of the five proteasomal proteins identified as being significantly different were
decreased; this may suggest a decrease in total proteasomal proteins, and/or a
decrease capacity to regulate the proteasome in the symptomatic CCNFS621G patient
derived cell line (CCNF2). A decrease in proteasomal function has been previously
associated with ALS. In a comparison of spinal motor neurons collected at autopsy
from ALS patients to both healthy controls and cerebral tissue (matched from the
same patients), a decrease in activity in proteasomes, as well as a decrease in
particular subunits (20SB5 and 19S5a) were detected (Kabashi et al., 2012). This
decrease in the abundance of proteasomal proteins can broadly be labelled as a result
of UPS dysfunction. It is however possible to speculate that the inappropriate
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ubiquitination of these subunits leads to a decrease in the overall abundance of these
units.

5.6.4.3 Decreased abundance of ubiquitinated spliceosomal proteins in the
symptomatic CCNFS621G patient derived cell line
A decrease in eight of the nine spliceosomal proteins was evident in symptomatic
CCNFS621G patient derived motor neurons (CCNF2) compared to the healthy control
(HC2) motor neurons. A loss of spliceosomal system integrity has previously been
associated with ALS. Previous reports into the loss of spliceosomal system integrity
in ALS found an increase in spliceosomal proteins - contrary to this study; these
previous findings were however immunochemical findings in post mortem tissue,
and therefore included proteins with a reduced solubility, which were not possible to
detect through this ubiquitinomics method (Tsuiji et al., 2013). Given the difference
in the symptomatic CCNFS621G patient cell line (CCNF2), it will be important to
further probe these differences using different detection techniques. Nonetheless,
these findings further implicate a dysfunction in the spliceosomal system in motor
neurons derived from a CCNFS621G patient.

The ninth protein identified to be significantly different in its ubiquitinated form
compared to the healthy control was heat shock protein 8 (HSPA8), which was
significantly more abundant in the symptomatic CCNFS621G patient derived motor
neurons (CCNF2), as well as the sporadic Alzheimer’s disease patient derived motor
neurons (SAD), compared to the healthy donor derived (HC2) motor neurons.
Though, again, detection of this protein would need to be validated via alternate
methods of protein quantification, this elevation does correlate with ALS patient
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serum studies. HSP70 levels have been detected to be elevated in serum derived
from ALS patients compared to healthy control, warranting further investigation of
this protein (Miyazaki et al., 2016).

5.7 Summary and future directions

This study provided the first step in identifying the much-needed characterisation of
cell type specific ubiquitin modifications, which will be essential in identifying and
understanding the role of the dynamic human ubiquitome. This is the first reported
human iPSC ubiquitome, and subsequently, the first comparison of fibroblasts,
iPSCs, and iPSC derived motor neurons (the majority of which are derived from the
same genetic pool). The relative quantification of these ubiquitinated proteomes
revealed significant shifts in the requirements of the ubiquitin system contingent of
cellular stage.

Identification of a plethora of pathways further confirms the

widespread reliance of cells on the UPS. Fundamental pathways including RNA
splicing, heat shock, and ECM and cytoskeletal proteins, along with the ubiquitin
proteasome itself were all detected to be regulated by ubiquitin., as well as a range of
ALS associated proteins. Further investigation into the role of ubiquitin in regulating
these pathways may represent potential areas for improving reprogramming and
differentiation protocols. Importantly, these pathways may highlight potential
weaknesses for cells under UPS stress. Understanding the pathways that are most
affected under conditions of cellular stress, and why, may provide invaluable insight
into potential therapies from devastating neurodegenerative disease. Motor neurons
examined in this study were shown to be more sensitive to UPS stress compared to
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their terminally matured fibroblast counterparts. Interestingly, this study highlighted
the incredible sensitivity of iPSCs to proteasomal stress. iPSCs may represent a
strong candidate for modelling the effects of therapeutics on the UPS so desperately
required for neurodegenerative diseases such as ALS. The investigation into the
differences in individual motor neurons also provided the opportunity for a
preliminary comparison of ALS motor neuron samples to controls. Differences were
evident motor neurons derived from a symptomatic CCNFS621G patient. Differences
in the ubiquitination of pathways known to be dysfunctional in ALS further implicate
the UPS as a central player in ALS pathology.
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Chapter Six:

The Ubiquitin Proteasome System
in Patient iPSC Derived Motor
Neurons and Derivative Cell
Types
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6 THE UBIQUITIN PROTEASOME SYTEM IN PATIENT IPSC DERIVED
MOTOR NEURONS AND DERIVATIVE CELL TYPES

6.1 Generating patient derived models to study ALS
Here, for the first time, two CCNFS621G ALS patient derived motor neuron models,
and an additional healthy control line have been generated using viral-free
reprogramming. These cells were characterised via conventional means including
via the expression of pluripotent mRNA via qRT-PCR as well as the PluriTest, and
via pluripotency factor expression detected via immunocytochemistry (Engel et al.,
2018; Muñoz et al., 2018). Additionally, as an ancillary benefit of the ubiquitinomics
analysis performed later in this study, the lines were further validated by the
detection of cell type specific pathways. For iPSCs this included pathways such as
the cell cycle and cellular proliferation, which were significantly increased. The
characterisation of these three lines, along with a SOD1E101G iPSC line
(reprogrammed by Rachelle Balez), indicate the successful generation of four novel
cell lines which can be used to help understand the underlying mechanisms that
cause ALS, as well as for drug screening for therapeutic development (Dimos et al.,
2008).

Successful generation of motor neurons was characterised by motor neuron markers
Hb9, Islet 1, and neurofilament heavy, via immunocytochemistry (Zeineddine et al.,
2015) and, similar to the iPSCs, via ubiquitinomics. For the study of proteostasis,
the novel patient iPSC derived motor neurons generated by this study provide an
important tool; these iPSC derived motor neurons allow for the study for endogenous
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proteins in a patient derived motor neuron model. The dynamic nature of the models
allow for responsive studies, for example monitoring of cellular phenotypes
following the inhibition of the UPS (Dimos et al., 2008). As previously indicated,
the ability to study endogenous proteins is particularly valuable when investigating
the UPS, as protein overexpression systems are susceptible to results which may not
be indicative of the true disease phenotype (Seminary et al., 2018). This has been
reported to occur in numerous disease associated proteins, with a variety of side
effects (Hjerpe et al., 2016). These range from arresting the cell cycle to causing cell
death (Matiuhin et al., 2008). Of particular importance when studying the UPS, is
that overexpressing UBL-UBA domain proteins, such as ubiquitin domaincontaining protein DSK2, UV excision repair protein RAD23 homolog A, can have
qualities of a proteasome inhibitor, preventing general degradation mechanisms
(Chen and Madura, 2002; Funakoshi et al., 2002; Ortolan et al., 2000). Given the
broad effect of proteasomal inhibition, it is difficult to discern native interactions of
these proteins (which is of partcicular importance in reviewing the ubiquitome) under
normal or disease conditions, in an overexpression model. For examining cyclin F,
the ability to monitor endogenous cyclin F is of great value to accompany models
such as the zebrafish, which share only 61.4% nucleotide sequence similarity
between

the

fish

and

human

cyclin
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F

(Hogan

et

al.,

2017).

6.2

A UPS dysfunction phenotype is present in symptomatic
CCNFS621G

A crucial undertaking for establishing these patient derived models was to identify
phenotypes from which to measure therapeutic outcomes, and to investigate the
underlying ALS mechanisms. The iPSC derived motor neuron models expressed
detectable levels of relevant endogenous proteins - including cyclin F, as well as the
hallmark ALS protein TDP-43. The quantification of these proteins indicated that a
measurable disease phenotype was present, even at low levels of stress (cell culture
conditions alone) (Table 6.1). Comparison of the ALS affected iPSC derived motor
neurons saw a relative reduction in total TDP-43, and the increased presence of an
additional TDP-43 species in both the CCNFS621G cell lines motor neurons suggesting
the CCNFS621G mutation may cause an altered post-translational modification to
TDP-43, consistent with a TDP-43 proteinopathy. These results, combined with the
functional assays investigating the UPS dysfunction, and the ubiquitome of
fibroblasts, iPSCs and motor neurons derived from a symptomatic CCNFS621G patient
(CCNF2) indicate that the S621G mutation affects the global distribution
ubiquitination of proteins (including TDP-43, as discussed in this section).
Collectively, the findings of this study corroborate the proposition that this mutation
to CCNF causes a toxic gain of function (Galper et al., 2017), further supported by
the non-lethal effects of cyclin F knock out in mice (Tetzlaff et al., 2004). It cannot
be ruled out, however, that there may be a toxic loss of function, as the change in the
substrate recognition detected in symptomatic CCNFS621G cells may also render
cyclin

F

unable

to

bind
288

to

normal

substrates.

Table 6.1 Comparative summary of phenotypes observed in cell lines analysed in
this study

Cell lines
Assay

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

Endogenous Cyclin F
Expression

+

+

+

+

+

+

Soluble expression

-







-

-

Localisation

Nuclear

Nuclear

Nuclear

Nuclear

Nuclear

Nuclear

Nuclear body-like
structures
Number and
intensity of nuclear
bodies

+

+

+

+

+

+

-

-

-

-

-

-

-

-

-

-

-

-

Correlation

Endogenous TDP-43
Expression 43 kDa

+

+

+

+

+

+

Quantification of 43
kDa

-

-

-

-

-

-

Expression 45 kDa

-

+

+





-

-

-

Quantification of 50
kDa

-





-

-

-

Localisation

Nuclear

Nuclear

Nuclear

Nuclear

Nuclear

Nuclear

Expression 50 kDa

UPS Function
Proteasomal Stress

NS pattern

NS pattern

NS pattern

NS pattern

NS pattern

NS pattern

Protein retention

-

-

+

-

-

-

Ubiquitome

-

-

Increased
number of
substrates

-

-

-

- No significant difference, + Present  Decreased abundance
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6.2.1

Increased ubiquitination of proteins including TDP-43 was evident in
CCNFS621G motor neurons

The data from the ubiquitinomics comparison of the symptomatic CCNFS621G motor
neurons (CCNF2), compared to the healthy control (HC2), combined with the UPS
dysfunction exhibited in the UPS reporter ‘degron’ assay in this same cell line
(CCNF2), are consistent with the CCNFS621G mutation causing UPS dysfunction.
This proposal is further supported by reduction in total endogenous TDP-43, and the
presence of a likely ubiquitinated TDP-43 species in both CCNFS621G iPSC derived
motor neurons cell lines (CCNF1 and CCNF2).

Ubiquitinated TDP-43 has

previously been shown to be increased in abundance in cells expressed mutatnt
cyclin F (Williams et al 2016), and cells expressing the CCNFS621G mutation have
been shown to have an increased population of (Lys48) ubiquitinated protein species
in neuronal-like models (Lee et al., 2018). It could therefore be postulated that the
inability to inactivate cyclin F, due to a reduced ability of phosphorylation at S621G
(Lee et al., 2018), leads to an increased ubiquitination of cyclin F substrates and the
subsequent degradation of these substrates until the UPS is overwhelmed, causing
the accumulation of ubiquitinated protein (Figure 6.1). This increased ubiquitination
would decrease the available free ubiquitin pool, stressing the UPS (Farrawell et al.,
2017). Additionally, decreasing the level of cyclin F would potentially have serious
implications for cellular homeostasis. The ubiquitinomics comparison performed in
this study indicate that pathways including mitochondrial, spliceosomal, and
ribosomal pathways, vesicle and ECM associated pathways, and the UPS itself were
differently ubiquitinated in the symptomatic CCNFS621G motor neurons (Figure 6.1).
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Figure 6.1 Proposed suggested mechanism of toxic gain of function caused by
CCNFS621G
The phosphorylation of wild type (WT), represented by the asterisks (*), cyclin F is
believed to prevent ubiquitination and regulating the E3 ubiquitin ligase activity of
cyclin F to maintain homeostasis. Mutant cyclin F reduces phosphorylation, and
therefore degradation of cyclin F; this increases the ubiquitination of substrates, and
may alter the substrate recognition, resulting in a decreased specificity, leading to the
dysfunction of a number of pathways. *Pathways previously identified by Lee et al.,
(2018).
6.2.2

Protection against a UPS phenotype

Interestingly, the lines derived from the pre-symptomatic and symptomatic
CCNFS621G carriers did not have identical phenotypes. It is admittedly possible,
though unlikely, that this phenotype is anomalous, having only one symptomatic
replicate available at the time of this study. As discussed later in this chapter, the
development of CRISPR CCNFS621G corrected motor neurons will be essential in
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confirming these phenotypes (Musunuru, 2013). The findings of this study, do
however corroborate with the few mechanistic studies of cyclin F in ALS performed
to date, and are in agreement with the general theme of UPS dysfunction reported in
ALS research.

It is more likely that the fibroblasts collected from the pre-

symptomatic sibling were subject to a protective element that the patient with ALS
symptoms at the time of collection (CCNF2; the UPS dysfunction phenotype) did not
have, or had lost. There are two lines of inquiry that should be pursued to better
understand the ALS causing mechanisms at play: Firstly, the possibility that
reprogrammed iPSCs were able to retain a protective element from the presymptomatic fibroblasts, or retain a detrimental element in the symptomatic (or
both). For example mitochondria are retained throughout the reprogramming process
owing to the fusion/fission process unique to this organelle, or the epigenetic profile
of these cells is retained. Both of these features have been previously documented to
be issues affected in iPSCs (Hayden, 2011; Wahlestedt et al., 2014). Secondly, that
there is a protective genetic component in the pre-symptomatic donor cells - or
secondary detrimental factor in the non symptomatic (or both). Specific genotypes
of APOE, for example, are neuroprotective, neutral, or promote neurodegeneration in
Alzheimer’s disease - ε2, ε3, ε4, respectively (Saunders et al., 1993; Huang 2017).
Interestingly, the symptomatic CCNFS621G line (CCNF2) is APOE ε3/4, carrying the
neurodegenerative-associated allele. The pre-symptomatic CCNFS621G line (CCNF1)
line is APOE ε3/3, and therefore does not have a neurodegenerative allele for APOE.
Further research into these neuroprotective/neurodegenerative-enhancing agents
would be of great benefit for therapeutic development, or even risk management.
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If there is an element or genetic feature in the pre-symptomatic CCNFS621G patient
derived cells that is neuroprotective in these motor neurons, it would be interesting to
examine the differences in phenotypes of these cells. The pre-symptomatic
CCNFS621G patient derived cells did not show the same level of UPS stress or the
same level of changes to the ubiquitome as the symptomatic CCNFS621G patient
derived cells. A trend of decreased TDP-43 and the presence of an additional TDP43 band were common to both these patient derived cells. Together, this may suggest
that there is a compensatory element protecting the UPS, which is renown for
redundancies (Nagarajan et al., 2017), which may serve as a therapeutic target.
Additional research into this disease mechanism is therefore critical to determine
appropriate therapeutic interventions.

Excitingly, as aforemnetioned, the Ooi

laboratory has recently been provided access to fibroblasts from multiple timepoints
over the course of the patient’s diagnosis - including pre-symptomatic fibroblasts
used in this study, early symptomatic and later stage symptomatic. Further
investigation into these cells will no doubt provide important information for
discerning the protective effects at play in these cells, which could prove incredibly
useful for therapeutic development.

6.2.3

Cyclin F may regulate the motor neuron spliceosome

A recurring trend that arose through this investigation of the CCNFS621G phenotype
was an association with the spliceosome. Based on the localisation of cyclin F in
nuclear bodies, commonly associated with spliceosomal function, as well as the
significant differences in abundance of eight ubiquitinated spliceosomal proteins in
symptomatic CCNFS621G motor neurons, it could be speculated that cyclin F has an
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additional role in modulating the motor neuron spliceosome. This transcriptional
regulation may be an indirect regulation by cyclin F. Known substrates of cyclin F
range in function (as indicated in Table 3.1). Notably, transcription factor B-Myb is a
cyclin F substrate (Klein et al., 2015).

It would therefore be unsurprising that

spliceosomal factors are regulated via cyclin F as well. TDP-43, which has been
shown to be altered in abundance in cyclin F in overexpression systems, (Williams et
al., 2016) is also known to be associated with mRNA splicing. Alterations to the
abundance of TDP-43, such as that seen in this study, could induce changes to the
spliceosomal landscape. (Ederle and Dormann, 2017). The spliceosome was also a
pathway subject to changed ubiquitination following reporgramming and
differentiation, indicating a changing reliance on this cellular mechanism in motor
neurons. Increasing evidence has implicated spliceosomal dysfunction as a
mechanism that contributes to ALS.

Spliceosomal dysfunction, including

dysfunction of TDP43 (and another ALS associated protein FUS) is believed to
cause abnormal splicing, as seen in motor neuron post mortem tissue (Tsuiji et al.,
2013). A study of 12 sporadic ALS post mortem motor neurons, collected by laser
capture microdissection, indicated 411 proteins were abnormally spliced.
Interestingly, these aberrantly spliced proteins showed a significant number of ECM
proteins; further emphasising the great need to focus on these mechanisms identified
in iPSC derived motor neuron models. Further studies will be required to investigate
this relationship between the cyclin F and spliceosomal mechanisms.
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6.3 Ubiquitin in maintaining pluripotency and differentiation

In addition to establishing novel ALS models, this study also represents the first
reported human iPSC ubiquitome, as well as the first comparison of fibroblasts and
differentiated iPSC derived motor neurons from the same genetic origin.

The

relative quantification of these ubiquitinated proteomes revealed significant shifts in
the requirements of the ubiquitin system contingent on cellular stage.

Further

investigation into the role of ubiquitin in regulating these pathways, including ECM
associated pathways may represent potential areas for improving reprogramming and
differentiation protocols.

Importantly, these pathways may highlight potential vulnerable mechanisms for cells
under UPS stress. Understanding which pathways are most affected under conditions
of cellular stress, and why, may provide invaluable insight into potential therapies for
devastating neurodegenerative disease. We have shown that motor neurons are more
sensitive to UPS stress compared to their terminally matured fibroblast counterparts.
This vulnerability of motor neurons to UPS stress has been suggested throughout
motor neuron disease research (Brockington et al., 2013; Ferrari et al., 2016; Tam et
al., 2019), though perhaps not yet addressed so directly as in this study wherein we
have been able to compare multiple different cell types derived from the same
donors. Interestingly, this study highlighted the incredible sensitivity of iPSCs to
proteasomal stress. iPSCs may represent a strong candidate for modelling the effects
of therapeutics, especially those targeting the UPS, so desperately required for
neurodegenerative

diseases

such
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as

ALS.

6.4 Limitations

As with all ALS-iPSC studies, and cell model studies, these studies are limited by the
number of cell lines able to be examined at a given time; this limitation is due to the
costly nature of using these cells, and the limited availability of donors. To date, only
four studies have examined the prevalence of mutations in the CCNF gene in ALS
patient populations - these studies have found the frequency of cyclin F mutations
ranged from 0.6% - 3.3%, meaning there is a limited pool of donors available (Lee et
al., 2017; Pan et al., 2017; Tian et al., 2018; Williams et al., 2016). Engagement of
control lines, including healthy controls and a neurodegenerative control engaged in
this study provide a limited reference from which we can begin to draw insight on
disease aetiology.

As suggested earlier in this chapter, it is still not clear to what extent these cells are
influences by epigenetic and mitochondrial inheritance. The “age” of these motor
neurons is thought to be reset during reprogramming to an extent. It was initially
thought that the reprogramming process cleared the epigenetic memory of the cells,
however more recent evidence indicated that cells with multiple rounds of passaging
were more epigenetically similar to ESCs compared to cells newly reprogrammed
(Nishizawa et al., 2016). Whether this similarity in epigenetic profile was due to
culture time, or passage round was unclear. In the studies presented here, cells were
cultured for at least 20 passages prior to differentiation, reducing the likelihood of
retaining an unwanted epigenetic state (Mallon et al., 2014).
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In addition to the epigenetic influence retained during reprogramming, the
mitochondria

(thus

the

mitochondrial

DNA)

remains

unchanged

during

reprogramming (Wahlestedt et al., 2014). This may actually prove a strength for the
model in regards to modelling ALS. Mitochondrial dysfunction has been linked to
ALS (Bannwarth et al., 2014). The retention of these fundamental organelles may
therefore provide valuable insight in ALS mechanisms. Mitochondrial inheritance by
the iPSCs would therefore be an interesting avenue to pursue in understanding this
relationship and the consequences for ALS pathogenesis.

Not only is the reprogramming ‘age’ an ongoing issue in the field, but the maturation
of motor neurons is also still a highly contentious. Motor neuron differentiations vary
in duration, and induction of neuronal development stages (Lee and Huang, 2017).
The protein markers commonly used for motor neuron characterisation are HB9 and
Islet 1, however HB9 is an early motor neuron marker. Electrophysiology can be
used to evaluate the functional properties of the cells, as a strong indicator of the
maturation the cells (Bardy et al., 2016). Whole cell patch clamping as well as
simpler techniques, such as calcium imaging, and multielectrode arrays would be of
great benefit in further elucidating the level of maturity of these cells (Bianchi et al.,
2018; Tang et al., 2016). In order to best mimic the in vivo motor neurons, it would
be advantageous to mature motor neurons alongside myoblasts and other cell types
including astrocytes to provide a neuromuscular circuit that will even further
replicate the in vivo system. Previous co-culture studies of primary motor neuron
precursors with myoblasts have indicated that the pairing of these cell types advances
the maturation of the motor neurons (O’Brien and Fischbach, 1986; Prives et al.,
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1976). Nonetheless, less mature motor neurons may provide critical information in
the aetiology of ALS as shown in this study and others, as phenotypes can be
detected at this ‘early age’. Indeed, these early phenotypes may represent early stage
biomarkers and therefore good indicators of therapeutic intervention (Yoshida et al.,
2015).

One such strategy for examining biomarkers could be via ubiquitinomics. As
highlighted earlier, PCA indicated that cells derived from the CCNFS621G expressed a
distinct ubiquitome to other cell lines in fibroblasts, iPSCs, and motor neurons.
Defining a ‘normal’ ubiquitome would therefore be of great diagnostic value.
Moreover, a recurring question raised in these ubiquitinomics studies is what are the
types of ubiquitination post-translational modification amongst the redistributed
proteins? Specific linkages of ubiquitin chains dictate the protein signalling
properties of a ubiquitin modification (Xu and Jaffrey, 2011). Understanding which
ubiqiutin linkages are involved, and potentially dysregulated will aid in determining
the signalling and functional consequences of alterations. Establishing the type, or
types, of ubiquitination occurring on TDP-43 and other substrates of cyclin F will be
important for establishing the disease mechanisms (and therefore therapeutics).
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6.5 Future directions
6.5.1.1 ALS causing mutations can be corrected in iPSCs
Boulting et al. were the second group to ever describe iPSC-ALS motor neuron
differentiation. This group made an astute observation that removal of an ALS
mutation (A4V SOD1) would be the optimal method to determine the effects of the
mutation. At the time of publication, technologies limited their ability to validate
this proposed idea (Boulting et al., 2011). Tools now exist to edit the genome to
correct or introduce disease-causing mutations, using a technique now referred to as
genome editing. Genetic sequences can be altered using tools such as the clustered
regularly interspaced short palindromic repeats system (CRISPR), the transcription
activator-like effector nuclease system (TALENS) and Zinc finger nucleases, which
act a ‘molecular scissors’ cutting specific sites of DNA to allow the removal or
insertion of DNA sequences. These tools allow even single base pair changes,
making it possible to determine the effects of small changes to a genome (Musunuru,
2013).

Multiple iPSC motor neuron studies have corrected mutations using genome editing
to induce a reversal of disease phenotype in the same patient derived cell lines,
creating isogenic controls. Using such techniques, SOD1 corrections have become a
reality, and have been successful in eliminating mutant SOD1 cellular phenotypes
(Chen et al., 2014; Kiskinis et al., 2014; Wainger et al., 2014). For example,
SOD1D90A patient iPSC derived motor neurons displayed neurofibrillary tangles,
protein aggregates and cellular degeneration (Chen et al., 2014). Upon correction of
this mutation using TALENS, the aggregate formation and cellular stress was
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alleviated in an isogenic control (same genome maintained however with the D90A
mutation was reverted to D). Interestingly, the insertion of the D90A mutation into
ESCs was also sufficient to cause cells to exhibit a similar disease phenotype as the
D90A iPSC line.

The ability to correct the known mutations provides a Koch's Principle-like method
of assessing how mutations cause disease, linking mutant genotypes to disease
phenotypes. The method of genome correction has three strengths in ALS research:
First, these corrected mutations confirm the expression of an ALS specific phenotype
in the iPSC motor neurons. Corrections to ALS causing mutations in disease affected
cells and the introduction of these same mutations into healthy patient derived cells,
further confirm the validity of these ALS-iPSC motor neuron models, for example in
research by Chen et al. (2014) and Waigner et al. (2014).

Second, genetic

engineering can identify and verify the effects of novel mutations. For disease
causing mutations, and perhaps genetic risk factors, this will be crucial in confirming
true causation. Third, the ability to remove and replace mutations enables us to
elucidate the other genetic factors of ALS. In many cases of neurodegeneration more
than one genetic anomaly is required for disease presentation to occur. This ‘dual hit’
hypothesis would be easily validated using genetic engineering to remove or
introduce one of the two mutations from a cell line, and determine if there is a
phenotype change. Genetic engineering in ALS-iPSC lines is therefore a useful
method to explore the additional effects of genetics in ALS, as it provides the ability
to examine small changes to genotypes and their effects on disease phenotypes in a
way that was not previously possible before (Musunuru, 2013).
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6.5.1.2 Driving the latest model
As is the fast paced nature of neuroscience, many new methods of research have
been developed over the duration of this study, of which these cellular models can be
applied. The use of hydrogels and polymer scaffolds hold exciting new opportunities
and challenges to ALS modelling, providing the ability to better model in vivo cells
with 3D applications. Similar to co-culture systems, it is possible that the use of 3D
systems would change the motor neuron differentiation - potentially changing the
maturity of the cells (Kawada et al., 2017). Better systems are now commercially
available to mimic multicellular systems, including co-culture systems such as
microfluidic chamber co-cultures with myoblasts, and potentially, following
improved protocols and characterisations, motor neuron subtypes. These systems,
combined with gene editing such as CRISPR will undoubtedly provide powerful
models to replicate “ALS in a dish”.
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6.6 Conclusions

In this study, iPSCs, and iPSC derived motor neurons have been generated from ALS
patients and healthy donors to serve as viable models for ALS research.
Characterisation of the cell types has laid the foundations for these cells to serve as
tools to study the underlying mechanisms of ALS. In examining the expression of
ALS-associated proteins and vulnerable pathways in iPSC derived motor neurons, a
number of measurable phenotypes were detected. These included expression of
cyclin F and TDP-43 in the nucleus in aggregates consistent with nuclear bodies, a
relative decrease in TDP-43 and cyclin F, UPS dysfunction measured via UPS
reporter assay, as well as differences in the ubiquitome of a symptomatic CCNFS621G
patient derived motor neurons, iPSCs, and fibroblasts. A range of ubiquitinated ALS
associated proteins were detected at endogenous levels in the iPSC derived motor
neurons were generated from the cells. Importantly, this means the models generated
from this study can be employed in ALS research, including in mechanistic studies,
as well as translating to drug screening trials, to be used alongside traditional models.
Additionally, this research has provided important information in the generation of
patient derived motor neurons in both protocol development as well as defining the
ubiquitinomic landscapes of the iPSC derived motor neurons and their derivative cell
types, furthering our understanding of the UPS. Together these studies provide
valuable information, which further our collective knowledge on the role of the UPS
in iPSC maintenance, iPSC derived motor neuron differentiation, and the role of the
UPS in the context of ALS.
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8 APPENDICES

8.1 Additional materials
Table 8.1 Consumables utilised
Product
Consumable

Brand

Source
Number

Aerosol barrier pipette tips 10 µL

Interpath Services

Interpath

24300

Aerosol barrier pipette tips 20 µL

Interpath Services

Interpath

24500

Aerosol barrier pipette tips 100 µL

Interpath Services

Interpath

24600

Aerosol barrier pipette tips 200 µL

Interpath Services

Interpath

24700

Aerosol barrier pipette tips 1000 µL

Interpath Services

Interpath

24800

Serological pipette tips 1 mL

Greiner bio-one

Interpath

604181

Serological pipette tips 5mL

Greiner bio-one

Interpath

606180

Serological pipette tips 10 mL

Greiner bio-one

Interpath

607180

Serological pipette tips 25 mL

Greiner bio-one

Interpath

760180

Serological pipette tips 50 mL

Greiner bio-one

Interpath

768180

Cell scrapers

Greiner bio-one

Interpath

541070

60 mm tissue culture dishes

Greiner bio-one

Interpath

628160

60 mm petri dishes

Interpath Services

Interpath

628103

6 well tissue culture plates

Greiner bio-one

Interpath

657160X

12 well tissue culture plates

Greiner bio-one

Interpath

665180

24 well tissue culture plates

Greiner bio-one

Interpath

662160X

96 well tissue culture plates

Greiner bio-one

Interpath

655101

96 well optical bottom black plates

NUNC

Thermo Fisher

160376

96 well plates

Greiner bio-one

Interpath

655180X

Cryovials

Greiner bio-one

Interpath

122263

15 mL tubes

Greiner bio-one

Interpath

188271S

50 mL tubes

Greiner bio-one

Interpath

227261S

T25 tissue culture flasks

Greiner bio-one

Interpath

690175V

T75 tissue culture flasks

Greiner bio-one

Interpath

658175V

T175 tissue culture flasks

Greiner bio-one

Interpath

660175V

Pipette tips (200 µL no filter)

Greiner bio-one

Interpath

739290

Pipette tips (1000 µL no filter)

Greiner bio-one

740290

Reagent reservoirs

Corning

Microtubes (1.5 mL, low binding)

Eppendorf

Microtube (1.5 mL)

Greiner bio-one

Microtube (2 mL, low binding)

Eppendorf

Interpath
In
Vitro
Technologies
Point of Care
Diagnostics
Interpath
Point of Care
Diagnostics
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cor4870
30120086
616201X
30120094

Microtube (.5 mL)

Eppendorf

PCR plate

Roche

Point of Care
Diagnostics
Roche

PCR plate seal

Roche

Roche

4729757001

Coverslips (13 mm)

KNITTTEL

ProSciTech

Microscope slides

Livingstone

Thermo Fisher

Aluminium foil

Glad Foil

OfficeMax

Latex Gloves

Skin Shield

Livingstone

Glass bottle (250 mL)

SIMAX

Livingstone

G400-13
FN7101GRN
-A
2549123
GLVLPF100
M-T
DB0250SB

Inoculation loops

Sarstedt

Sarstedt

86.1562.010

Petridish

Interpath Services

Interpath

S9014S20

Cell strainer (40 µm)

Greiner BioOne

Greiner

542040

Cell strainer (70 µm)

Greiner BioOne

Greiner

542070

Syringe

Terumo Syringe

Livingstone

TSS50LZ

Filter

Millipore Merck
Leica
Microsystems

SLGP033RS

85.1562.010
DN23GX1.0
LV
DN21GX1.0
LV

Ethanol (70% v/v)

POCD Healthcare

Spreader

Sarstedt

Interpath
Leica
Microsystems
Point of Care
Diagnostics
Sarstedt

Inoculation loop

Sarstedt

Sarstedt

23 G needle

Livingstone

Thermo Fisher

21 G needle

Livingstone

Thermo Fisher

18 G needle

BD

Criterion blot filter paper

Biorad

Objective Oil

Bacto
laboratories
Biorad
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30121023
4729692001

5682
ETHABS701
PUW
83.1830

302032
1704085

Figure 8.0 Representative brightfield images of endodermal progenitors
Images of iPSC clone lines differentiated to endodermal progenitors which exhbited
typical clustering morphology (indicatd by arrows) in a healthy donor (HC1), a presymptomatic CCNFS621G ALS patient (CCNF1), a symptomatic CCNFS621G patient
(CCNF2), an ALS patient with a SOD1E101G mutation (SOD1), an additional healthy
donor (HC2) and a sporadic Alzheimer’s disease patient (SAD). N=2 Independent
differentiations per cell line. Scale bar = 200 μm.
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8.2 TDP-43 - Western blots

A

B

Figure 8.1 Full western blots immunolabelled with TDP-43
Demonstrate no TDP-43 fragmentation at low molecular weight was present in motor
neuron samples in blots of (A) Triton X only soluble motor neuron samples and (B)
Triton X, 2% SDS, and 8M Urea soluble motor neuron samples.
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8.3 Nitrosative stress assay (Griess)

Following the evaluation of proteasomal stress in the motor neurons, we sought to
determine if nitrosative stress was also exhibited. To investigate cellular nitrosative
stress in the motor neurons under normal culturing conditions, a Griess assay was
first performed to determine the concentration of nitrosative stress product (nitrite)
following normalisation to the total triton X soluble proteins of the culture, to
account for any differences in cellular abundance-. While no significant difference
was detected in the endogenous levels of supernatant, some interesting trends were
observed: The mean level of nitrite detected in the supernatant of the CCNF2 and
SOD1 motor neurons were lower than the four cell lines examined, including the
SAD line.

Following the evaluation of the levels of nitrosative stress under normal culture
conditions, we sought to examine the effects of proteasomal stress; the supernatant of
MG132 treated motor neurons were compared to DMSO control treated cells.
Again, no significant difference was observed between the motor neuron
supernatants. Interestingly, the proteasomal stress of induced by MG132 appeared to
have no effect on the supernatant nitrite levels, compared to the DMSO control.
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[Nitrite] (mM) normalised to
total Triton X soluble protein (mg/mL)

20

15

10

5

0

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

Figure 8.2 Nitrogenous stress in motor neurons
Concentrations of released nitrite from motor neurons cultured under normal
conditions in supernatant reacted with Griess reagent as detected at absorbance 548
nm taken from the following cell lines: healthy female (HC1), a CCNFS621G female
(CCNF1), a CCNFS621G male (CCNF2), a SOD1E101G male (SOD1), a healthy male
(HC2) and a sporadic Alzheimer’s disease male (SAD) as a neurodegenerative
control. Concentrations were normalised to the concentration of total protein.

337

The Griess assay harnesses the Griess diazotization reaction to colourimetrically
determine the concentration of NO2 species against a standard curve.

First

established by Griess in 1879, the assay selectively assesses the NO2 levels, however
cannot account for other nitrosative stress species. The over two fold difference in
the mean concentration of NO2 species in the supernatant from the motor neurons
derived from the positive ALS control SOD1E101G male donor, strongly suggests that
NO2 may be further catalysed to ONOO-, in the supernatant. The similarities in the
motor neuron supernatant derived from the CCNFS21G male donor, and the reduced
levels in the other CCNF mutant cell line, derived from the CCNFS21G female, and
the neurodegenerative control SAD male donor derived motor neurons.

Nitrosative stress following proteasomal stress was next monitored. As may be
expected, no significant differences between DMSO treated motor neurons and
MG132 treated motor neuron. Suggests that proteasomal stress is an early disease
even compared to nitrosative stress exhibited in ALS pathology. Comparison of the
non-treated cells and the DMSO/MG132 treatments indicated a difference between
the comparative levels of SOD1, indicated that the vehicle, DMSO, may yield an
increase in nitrosative stress.
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[Nitrite] (mM) in
motor neuron supernatant

1.5

1.0

0.5

HC1

CCNF1

CCNF2

SOD1

HC1

MG132

DMSO

MG132

DMSO

MG132

DMSO

MG132

DMSO

MG132

DMSO

MG132

DMSO

0.0

SAD

Figure 8.3 Nitrogenous stress in motor neurons following proteasomal inhibition.
Concentrations of released nitrite from motor neurons cultured following
proteasomal inhibition (16 h treatment with 10 mM MG132) in supernatant reacted
with Griess reagent as detected at absorbance 548 nm taken from the following cell
lines: healthy female (HC1), a CCNFS621G female (CCNF1), a CCNFS621G male
(CCNF2), a SOD1E101G male (SOD1), a healthy male (HC2) and a sporadic
Alzheimer’s disease male (SAD) as a neurodegenerative control. Concentrations
were normalised to paired vehicle (DMSO) treated motor neuron concentrations.
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8.4 Motor neuron response to proteasomal inhibition

Table 8.2 Fold change of mitochondrial viability following 16 h proteasomal
inhibition at 1 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.74

0.97

0.61

0.83

1.43*

1.00

1.31

0.82

1.12

1.93

1.00

0.63

0.86

1.48*

1.00

1.36

2.34**

1.00

1.72

CCNF1
CCNF2
SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared
to
cell
line
indicated
on
Y
axis.
Significant difference denoted as *P<0.0332, **P<0.0021.

Table 8.3 Fold change of mitochondrial viability following 16 h proteasomal
inhibition at 2.5 µM.

HC1
CCNF1
CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.79*

0.82

0.89**

0.88**

0.97

1.00

1.03

1.13

1.11

1.23

1.00

1.09

1.08

1.19**

1.00

0.98

1.09

1.00

1.10

SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference denoted as * P<0.0332, ** P<0.0021.
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Table 8.4 Fold change of mitochondrial viability following 16 h proteasomal
inhibition at 10 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.20

0.83

1.58

2.13*

1.62

1.00

0.69

1.31

1.77

1.35

1.00

1.91

2.58

1.96

1.00

1.35

1.25

1.00

0.76

CCNF1
CCNF2
SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference denoted as * P<0.0332.

Table 8.5 Fold change of mitochondrial viability following 16 h proteasomal
inhibition at 100 µM.

HC1
CCNF1
CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.06**

1.11

2.39

2.91

5.54

1.00

1.05

2.27**

2.76***

5.25****

1.00

2.15

2.61

4.98****

1.00

1.22

2.31

1.00

1.90

SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant difference
determined from Two-way ANOVA with Tukey’s Post Hoc Test,
denoted as **P<0.0021, ***P<0.0002, ****P<0.0001
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Table 8.6 Fold change of mitochondrial viability following 16 h proteasomal
inhibition at 250 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.50

1.07

1.52

2.50

3.65

1.00

0.71

1.01

1.66

2.43

1.00

1.42

2.34

3.43

1.00

1.65

2.41

1.00

1.46

CCNF1
CCNF2
SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant difference
determined from Two-way ANOVA with Tukey’s Post Hoc Test.

Table 8.7 Fold change of mitochondrial viability following 48 h proteasomal
inhibition at 1 µM.
HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.47

1.12

1.43

1.59

1.19

1.00

0.76

0.98

1.08

0.81

1.00

1.28

1.42

1.06

1.00

1.11

0.83

1.00

0.75

HC1
1.00
CCNF1
CCNF2
SOD1
HC2
SAD
1.00
Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant difference
determined from Two-way ANOVA with Tukey’s Post Hoc Test.
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Table 8.8 Fold change of mitochondrial viability following 48 h proteasomal
inhibition at 2.5 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.30

1.14

0.81

1.22

1.16

1.00

0.87

0.62*

0.94

0.89

1.00

0.71

1.08

1.02

1.00

1.51

1.43

1.00

0.95

CCNF1
CCNF2
SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test denoted as *P<0.0332.

Table 8.9 Fold change of mitochondrial viability following 48 h proteasomal
inhibition at 10 µM.

HC1

CCNF1
CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.32

0.91

0.97

1.27

1.14

1.00

0.69

0.74

0.97

0.87

1.00

1.07

1.40

1.25

1.00

1.31

1.17

1.00

0.89

SOD1

HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test.
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Table 8.10 Fold change of mitochondrial viability following 48 H proteasomal
inhibition at 100 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.80

0.71

0.48

0.72

1.05

1.00

0.88

0.60

0.90

1.31

1.00

0.67

1.02

1.48

1.00

1.51

2.19

1.00

1.45

CCNF1

CCNF2

SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test.

Table 8.11 Fold change of mitochondrial viability following 48 H proteasomal
inhibition at 250 µM.

HC1
CCNF1
CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.90

0.91

0.62

0.79

0.90

1.00

1.00

0.69

0.87

0.99

1.00

0.69

0.87

0.99

1.00

1.27

1.45

1.00

1.14

SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test.

344

Table 8.12 Fold change of mitochondrial viability following 72 H proteasomal
inhibition at 1 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.78***

1.22

1.19

1.47*

0.90

1.00

0.68

0.67

0.83

0.51****

1.00

0.98

1.21

0.74

1.00

1.24

0.76

1.00

0.61***

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant difference
determined from Two-way ANOVA with Tukey’s Post Hoc Test,
denoted as *P<0.0332, ***P<0.0002, ****P<0.0001.

Table 8.13 Fold change of mitochondrial viability following 72 H proteasomal
inhibition at 2.5µM.

HC1
CCNF1
CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

1.29

1.87

0.70

1.19

0.80

1.00

1.45

0.54

0.93

0.62

1.00

0.37*

0.64

0.43*

1.00

1.71

1.15

1.00

0.67

SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant difference
determined from Two-way ANOVA with Tukey’s Post Hoc
Test, denoted as *P<0.0332.
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Table 8.14 Fold change of mitochondrial viability following 72 H proteasomal
inhibition at 10 µM.

HC1

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.94

1.54

0.45*

1.29

1.22

1.00

1.64

0.48

1.37

1.30

1.00

0.29**

0.83

0.79

1.00

2.83**

2.68**

1.00

0.95

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test, denoted as *P<0.0332, ***P<0.0002.

Table 8.15 Fold change of mitochondrial viability following 72 H proteasomal
inhibition at 100 µM.

HC1
CCNF1
CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.46

0.62

0.32*

0.64

1.01

1.00

1.33

0.70

1.39

2.18

1.00

0.52

1.04

1.63

1.00

2.00

3.12*

1.00

1.56

SOD1
HC2
SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test, denoted as *P<0.0332.
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Table 8.16 Fold change of mitochondrial viability following 72 H proteasomal
inhibition at 250 µM.

HC1

CCNF1

CCNF2

HC1

CCNF1

CCNF2

SOD1

HC2

SAD

1.00

0.77

1.12

0.61

0.97

1.20

1.00

1.46

0.80

1.26

1.56

1.00

0.55

0.86

1.07

1.00

1.58

1.96

1.00

1.24

SOD1

HC2

SAD

1.00

Red indicates decrease, blue indicates increased viability
compared to cell line indicated on Y axis. Significant
difference determined from Two-way ANOVA with Tukey’s
Post Hoc Test.
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Figure 8.4 Heat maps of total filtered ubiquitinomics
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8.5 Heatmap of ubiquitinomes examined
Motor Neurons

24

22

20

18

16

8.6 Pearson’s correlation heatmaps

A

B

C

Figure 8.5 Heatmaps of Pearson’s correlation values
Pearson’s correlation values calculated from the comparison of samples from (A)
symptomatic CCNFS621G patient derived cell lines (CCNF2), (B) healthy control
(HC2), and (C) sporadic Alzheimer’s disease (SAD). Heatmaps were generated for
each cell line to compare between replicates and between cell stages.
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8.7 Multiscatter

Figure 8.6 Multiscatter correlation plot of pre-symptomatic CCNFS621G patient derived ubiquitomes (CCNF1).
Multiscatter plot was calculated as an additional measure for correlation of data within sample replicates and between cell types. Multiscatter
plots
were
generated
for
each
cell
line
to
compare
between
replicates
and
between
cell
stages.
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Figure 8.7 Multiscatter correlation plot of healthy donor derived ubiquitomes (HC2)
Multiscatter plot was calculated as an additional measure for correlation of data within sample replicates and between cell types. Multiscatter
plots were generated for each cell line to compare between replicates and between cell stages.
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8.8

Principal component analyses

Figure 8.9 Visualisation of principal component analysis (PCA).
The PCA uses a singular value decomposition to provide a scaled projection of the
total data. The axis generated from the data two principal components are used to replot data. Principal Component 1 (PC1) is plotted from the largest variation of the
total data. Principal Component 2 (PC2) is plotted perpendicular to PC1. Figure is
from Kassambara (2017).

Figure 8.10 Principle components analysis of samples from pre-symptomatic
CCNFS621G patient derived ubiquitomes (CCNF1).
PCA generated from comparison of filtered ubiquitinomic data from fibroblasts,
iPSCs and motor neurons. Numbers indicate replicates.
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A

B

Figure 8.11 Principle components analysis of cell types.
Data is from (A) symptomatic CCNFS621G patient-derived ubiquitomes (CCNF2) and
(B) sporadic Alzheimer’s disease patient-derived ubiquitomes. Principle components
analysis generated from comparison of filtered ubiquitinomic data from fibroblasts,
iPSCs and motor neurons. Numbers indicate replicates.
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8.9

Qualitative ubiquitome venn analyses

A

B

C

Figure 8.12 Venn analysis of ubiquitinated proteins in fibroblasts, iPSCs, and motor
neurons
Comparisons are within cell lines from samples from (A) a pre-symptomatic
CCNFS621G (CCNF1), (B) a symptomatic CCNFS621G (CCNF2) and (C) sporadic
Alzheimer’s disease (SAD).
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8.10 Volcano plots
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Figure 8.14 Volcano plot comparisons of ubiquitomes derived from symptomatic
CCNFS621G patient (CCNF2). Plots compare (A) fibroblast v iPSC, (B) iPSC v motor
neurons, and (C) fibroblasts v motor neurons.
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Figure 8.15 Volcano plot comparison of ubiquitomes derived from a healthy donors
Volcano plots compare (A) fibroblast v iPSC (HC1) (B) iPSC v motor neurons
(HC2).
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Figure 8.16 Volcano plot comparison of ubiquitomes derived from a sporadic
Alzheimer’s disease donor (SAD)
Volcano plots compare (A) fibroblast v iPSC, (B) iPSC v motor neurons, and (C)
fibroblasts v motor neurons.
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Figure 8.17 Neurite outgrowth following longitudinal UBA1 inhibition
Neurite outgrowth was monitored for 4 weeks of culture with PYR41 at high (10
µM) and low (1 µM) concentrations in five biological replicates. Neurite outgrowth
was unaffected by long-term low dose PYR41 treatment in healthy control iPSCderived motor neurons (A) HC1 and (B) a symptomatic CCNFS621G (CCNF2).
Significant difference tested via ANOVA P>0.05.
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Figure 8.18 Neurite outgrowth following longitudinal UBA1 inhibition
Neurite outgrowth was monitored for 4 weeks of culture with PYR41 at high (10
µM) and low (1 µM) concentrations in five biological replicates. Neurite outgrowth
was unaffected by long term low dose PYR41 treatment in healthy control iPSCderived motor neurons from (A) SOD1 and a (B) healthy control (HC2) patient
iPSC-derived motor neurons. Significant difference tested via ANOVA P>0.05.
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Figure 8.19 Neurite outgrowth following longitudinal UBA1 inhibition.
Neurite outgrowth was monitored for 4 weeks of culture with PYR41 at high (10
µM) and low (1 µM) concentrations in five biological replicates. Neurite outgrowth
was unaffected by long term low dose PYR41 treatment in healthy control iPSCderived motor neurons from a sporadic Alzheimer’s disease patient iPSC-derived
motor neurons. Significant difference tested via ANOVA P>0.05.
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